

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S1	1698	(514/374).CCLS.	US-PGPUB; USPAT; EPO; DERWENT	OR	OFF	2006/11/29 12:34

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	AUG 09	INSPEC enhanced with 1898-1968 archive
NEWS	4	AUG 28	ADISCTI Reloaded and Enhanced
NEWS	5	AUG 30	CA(SM)/Capius(SM) Austrian patent law changes
NEWS	6	SEP 11	CA/Capius enhanced with more pre-1907 records
NEWS	7	SEP 21	CA/Capius fields enhanced with simultaneous left and right truncation
NEWS	8	SEP 25	CA(SM)/Capius(SM) display of CA Lexicon enhanced
NEWS	9	SEP 25	CAS REGISTRY(SM) no longer includes Concord 3D coordinates
NEWS	10	SEP 25	CAS REGISTRY(SM) updated with amino acid codes for pyrrolysine
NEWS	11	SEP 28	CEABA-VTB classification code fields reloaded with new classification scheme
NEWS	12	OCT 19	LOGOFF HOLD duration extended to 120 minutes
NEWS	13	OCT 19	E-mail format enhanced
NEWS	14	OCT 23	Option to turn off MARPAT highlighting enhancements available
NEWS	15	OCT 23	CAS Registry Number crossover limit increased to 300,000 in multiple databases
NEWS	16	OCT 23	The Derwent World Patents Index suite of databases on STN has been enhanced and reloaded
NEWS	17	OCT 30	CHEMLIST enhanced with new search and display field
NEWS	18	NOV 03	JAPIO enhanced with IPC 8 features and functionality
NEWS	19	NOV 10	CA/Capius F-Term thesaurus enhanced
NEWS	20	NOV 10	STN Express with Discover! free maintenance release Version 8.01c now available
NEWS	21	NOV 13	CA/Capius pre-1967 chemical substance index entries enhanced with preparation role
NEWS	22	NOV 20	CAS Registry Number crossover limit increased to 300,000 in additional databases
NEWS	23	NOV 20	CA/Capius to MARPAT accession number crossover limit increased to 50,000
NEWS	24	NOV 20	CA/Capius patent kind codes will be updated
NEWS EXPRESS		NOVEMBER 10	CURRENT WINDOWS VERSION IS V8.01c, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 25 SEPTEMBER 2006.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items
NEWS IPC8			For general information regarding STN implementation of IPC 8
NEWS X25			X.25 communication option no longer available

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may

result in loss of user privileges and other penalties.

***** STN Columbus *****

FILE 'HOME' ENTERED AT 12:40:21 ON 29 NOV 2006

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.42

0.42

FILE 'REGISTRY' ENTERED AT 12:41:38 ON 29 NOV 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 27 NOV 2006 HIGHEST RN 914071-04-8

DICTIONARY FILE UPDATES: 27 NOV 2006 HIGHEST RN 914071-04-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=>

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10089993a.str



chain nodes :

14 15 16

ring nodes :

1 2 3 4 5 7 8 9 10 11 12

chain bonds :

14-15 15-16

ring bonds :

1-2 1-5 2-3 3-4 4-5 7-8 7-12 8-9 9-10 10-11 11-12

exact/norm bonds :

1-2 1-5 2-3 3-4 4-5 14-15 15-16

normalized bonds :

7-8 7-12 8-9 9-10 10-11 11-12

isolated ring systems :

containing 1 : 7 :

Match level :


1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:Atom
12:Atom 13:Atom 14:CLASS 15:CLASS 16:CLASS 17:Atom

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 12:42:08 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 12344 TO ITERATE

16.2% PROCESSED 2000 ITERATIONS

50 ANSWERS

INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 240223 TO 253537

PROJECTED ANSWERS: 22462 TO 26666

L2 50 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 12:42:12 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 250059 TO ITERATE

100.0% PROCESSED 250059 ITERATIONS

25297 ANSWERS

SEARCH TIME: 00.00.01

L3 25297 SEA SSS FUL L1

=> fil caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

166.94

167.36

FILE 'CAPLUS' ENTERED AT 12:42:16 ON 29 NOV 2006

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the

American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 29 Nov 2006 VOL 145 ISS 23
FILE LAST UPDATED: 27 Nov 2006 (20061127/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> s l3

L4 5162 L3

=> s l4 and Parkinson

21548 PARKINSON

1164 PARKINSONS

21629 PARKINSON

(PARKINSON OR PARKINSONS)

L5 50 L4 AND PARKINSON

=> s l4 and Parkinson's

MISMATCHED QUOTE 'PARKINSON'S'

Quotation marks (or apostrophes) must be used in pairs, one before and one after the expression you are setting off or masking.


=> d ibib abs hitstr l5 1-50

L5 ANSWER 1 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:1147258 CAPLUS
 TITLE: Preparation of multicyclic peptide derivatives as dipeptidyl peptidase-IV inhibitors
 Kiroth, Heiko; Feuerstein, Tim; Richter, Frank; Boer, Jurgen; Essers, Michael; Nolte, Bert; Schneider, Matthias; Hochguertel, Matthias; Frickel, Fritz-Frieder; Taveras, Arthur
 INVENTOR(S): Alantoss Pharmaceuticals, Inc., USA
 PATENT ASSIGNEE(S): PCT Int. Appl., 542pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006116157	A2	20061102	WO 2006-US15200	20060421
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2005-674151P P 20050422

GI




AB The invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitory compds. A-B-CO-D (A is a bicyclic or tricyclic ring system attached to B at carbon or nitrogen; B is a linking group such as an amino acid residue or fragment; D is a pyrrolidine or thiazolidine residue or derivative), including isomers and pharmaceutically-acceptable salts, for treatment of DPP-IV mediated diseases, in particular, type-2 diabetes. Thus, pyrrolidinecarbonitrile derivative I was prepared by reaction of 5-[(S)-2-aminopropyl]-10,11-dihydro-5H-dibenzo[a,d]cycloheptene-5-carboxamide with N-glyoxyloxy-L-prolinecarbonitrile (preps. given) and showed $K_i < 6$ nM for inhibition of DPP-IV.

L5 ANSWER 1 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


L5 ANSWER 1 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 IT 213411-83-7, Edaglitazone 331741-94-7, Muraglitazar
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (Preparation of multicyclic peptide derivs. as dipeptidyl peptidase-IV inhibitors)
 RN 213411-83-7 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)benzo[b]thien-7-yl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 331741-94-7 CAPLUS
 CN Glycine, N-[[4-methoxyphenoxy]carbonyl]-N-[[4-(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy)phenyl]methyl]- (9CI) (CA INDEX NAME)





L5 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2006:1033644 CAPLUS
 DOCUMENT NUMBER: 145:397503
 TITLE: Preparation of oxazole and thiazole derivatives as H3-receptor ligands with numerous therapeutic uses
 Celanire, Sylvain; Denonne, Frederic
 INVENTOR(S): Ucb S.A., Belg.
 PATENT ASSIGNEE(S): PCT Int. Appl., 200pp.
 SOURCE: CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006103045	A1	20061005	WO 2006-EP2806	20060328
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: EP 2005-6971 A 20050331


OTHER SOURCE(S): MARPAT 145:397503

GI




AB The present invention relates to compds. comprising an oxazole or thiazole moiety (shown as I; variables defined below: e.g. 1-[3-[4-[(2-methylpyrrolidin-1-yl)methyl]-1,3-oxazol-2-yl]phenoxy]propyl]piperidine (I)), processes for preparing them (synthetic intermediates but no methods of preparation are claimed), pharmaceutical compds. comprising said compds. and their uses (no data) as H3-receptor ligands. For I: A1 is CH, C(alkyl), C-halogen or N; R1 is H, halogen, C1-6 alkyl or alkoxy; R2 is H, A3 is O or S; R3 is H, halogen, C1-6 alkyl or alkoxy; R4 is H, halogen, C1-6 alkyl, alkoxy or -O-L; R5 is H or -O-L, wherein L is an aminoalkyl group and at least one of R4 and R5 should be -O-L; R10 and R11 = H, sulfonyl, amino, et al.; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, preps. and/or characterization data for >100 examples of I are included. For example,

L5 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 was prepd. (42 %) at room temp. by mixing 4-(chloromethyl)-2-[4-(3-chloropropoxy)phenyl]-1,3-oxazole (prepn. given), NaI, K₂CO₃, and 2-methylpyrrolidine in MeCN for 72 h, after which piperidine was added and the mixt. stirred at 80° overnight. In an [35S]GTPγS-binding assay using human histamine H₃-receptor, compds. I showed pK₅₀ 6.5-10. In a paced isolated guinea pig myenteric plexus - elec.-field stimulation assay for antagonism activity, compds. I showed pA₂ values typically 26.5 for the histamine H₃ receptor.
 IT 911133-16-9P, 2-[4-[3-(2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]-1,3-oxazole 911133-75-0P, N-(Cyclopropylmethyl)-4-methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-N-propyl-1,3-oxazole-5-carboxamide
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (drug candidate; preparation of oxazole and thiazole derivs. as histamine H₃-receptor ligands with numerous therapeutic uses)
 RN 911133-16-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 911133-75-0 CAPLUS
 CN 5-Oxazolecarboxamide, N-(cyclopropylmethyl)-4-methyl-2-[4-[3-(2-methyl-1-pyrrolidinyl)propoxy]phenyl]-N-propyl- (9CI) (CA INDEX NAME)




IT 911133-56-7P, 1-[[2-[4-[3-(2-Methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]acetyl]piperidine 911133-57-8P, 1-[3-[4-[4-[2-Oxo-2-(piperidin-1-yl)ethyl]-1,3-oxazol-2-yl]phenoxy]propyl]piperidine 911133-68-1P, 4-[[2-[4-[3-(2-Methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]carbonyl]morpholine 911133-69-2P, 1-Cyclopentyl-4-[[2-[4-[3-(piperidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]carbonyl]piperazine 911133-70-5P, 1-[[2-[4-[3-(2-Methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]carbonyl]piperidine 911133-71-6P, 1-Cyclopentyl-4-[[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-

L5 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 oxazol-4-yl]carbonyl]piperazine 911133-74-9P,

1-[[4-Methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-5-yl]carbonyl]piperidine 911133-76-1P, N-Cyclopentyl-4-methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole-5-carboxamide 911133-77-2P, Methyl 4-[(benzylamino)methyl]-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole-5-carboxylate 911133-79-4P, 2-[4-[3-(2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(piperidin-1-ylmethyl)-1,3-oxazole-5-carboxylic acid 911133-80-7P
 N-(Cyclopropylmethyl)-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-N-propyl-1,3-oxazole-4-carboxamide 911133-81-8P,


N-Cyclopentyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole-4-carboxamide 911133-82-9P, N-(4-Fluorobenzyl)-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole-4-carboxamide 911133-83-0P, N-Benzyl-4-methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazole-5-carboxamide 911133-84-1P, 1-Cyclopentyl-4-[[4-methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-5-yl]carbonyl]piperazine 911133-85-2P, 2-[4-[3-(2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-(pyrrolidin-1-ylcarbonyl)-1,3-oxazole 911133-86-3P,

4-[[4-Methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-5-yl]carbonyl]morpholine 911133-87-4P, 4-[[4-Methyl-2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-5-yl]carbonyl]morpholine 911133-88-5P, 4-[[4-Methyl-2-[4-[3-(2S)-2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-5-yl]carbonyl]morpholine 911134-14-0P, N-(4-Fluorophenyl)-2-[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]acetamide 911134-18-4P, 2-[4-[3-(2-Methylpyrrolidin-1-yl)propoxy]phenyl]-4-[[2S)-2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl]carbonyl]-1,3-oxazole 911134-19-5P, 4-[[2-[4-[3-(2-Methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]acetyl]morpholine 911134-20-8P, N-Cyclopentyl-2-[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]acetamide 911134-21-9P, N-(Cyclopropylmethyl)-2-[2-[4-[3-(2-methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]-N-propylacetamide 911134-22-0P, 1-[[2-[4-[3-(2-Methylpyrrolidin-1-yl)propoxy]phenyl]-1,3-oxazol-4-yl]acetyl]azepane
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (drug candidate; prepn. of oxazole and thiazole derivs. as histamine H₃-receptor ligands with numerous therapeutic uses)
 RN 911133-56-7 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 911133-57-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


L5 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 911133-68-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 911133-69-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 911133-70-5 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 911133-71-6 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




L5 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 RN 911133-74-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 911133-76-1 CAPLUS
 CN 5-Oxazolecarboxylic acid, N-cyclopentyl-4-methyl-2-[4-[3-(2-methyl-1-pyrrolidinyl)propoxy]phenyl]- (9CI) (CA INDEX NAME)




RN 911133-77-2 CAPLUS
 CN 5-Oxazolecarboxylic acid, 2-[4-[3-(2-methyl-1-pyrrolidinyl)propoxy]phenyl]-4-[(phenylmethyl)amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 911133-79-4 CAPLUS
 CN 5-Oxazolecarboxylic acid, 2-[4-[3-(2-methyl-1-pyrrolidinyl)propoxy]phenyl]-4-(1-piperidinylmethyl)- (9CI) (CA INDEX NAME)




RN 911133-80-7 CAPLUS
CN 4-Oxazolecarboxamide, N-(cyclopropylmethyl)-2-[4-{3-(2-methyl-1-pyrrolidinyl)propoxy}phenyl]-N-propyl- (9CI) (CA INDEX NAME)



RN 911133-81-8 CAPLUS
CN 4-Oxazolecarboxamide, N-cyclopentyl-2-[4-{3-(2-methyl-1-pyrrolidinyl)propoxy}phenyl]- (9CI) (CA INDEX NAME)




RN 911133-82-9 CAPLUS
CN 4-Oxazolecarboxamide, N-(4-fluorophenyl)methyl-2-[4-{3-(2-methyl-1-pyrrolidinyl)propoxy}phenyl]- (9CI) (CA INDEX NAME)




RN 911133-83-0 CAPLUS
CN 5-Oxazolecarboxamide, 4-methyl-2-[4-{3-(2-methyl-1-pyrrolidinyl)propoxy}phenyl]-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 911133-88-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry. Rotation (+).





RN 911134-14-0 CAPLUS
CN 4-Oxazoleacetamide, N-(4-fluorophenyl)-2-[4-{3-(2-methyl-1-pyrrolidinyl)propoxy}phenyl]- (9CI) (CA INDEX NAME)




RN 911134-18-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


Absolute stereochemistry.




RN 911133-84-1 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 911133-85-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 911133-86-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 911133-87-4 CAPLUS


RN 911134-19-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 911134-20-8 CAPLUS
CN 4-Oxazoleacetamide, N-cyclopentyl-2-[4-{3-(2-methyl-1-pyrrolidinyl)propoxy}phenyl]- (9CI) (CA INDEX NAME)



RN 911134-21-9 CAPLUS
CN 4-Oxazoleacetamide, N-(cyclopropylmethyl)-2-[4-{3-(2-methyl-1-pyrrolidinyl)propoxy}phenyl]-N-propyl- (9CI) (CA INDEX NAME)




RN 911134-22-0 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




IT 911134-52-6P, Methyl 2-[4-{3-(chloropropoxy)phenyl]-4-methyl-1,3-oxazole-5-carboxylate 911134-53-7P, [2-[4-{3-(chloropropoxy)phenyl]-4-methyl-1,3-oxazol-5-yl]methanol 911134-54-8P, Methyl 2-[2-[4-{3-(chloropropoxy)phenyl]-1,3-oxazol-4-yl]acetate 911134-55-9P, [2-[4-{3-(chloropropoxy)phenyl]-1,3-oxazol-4-yl]acetic acid 911134-56-0P, 2-[4-{3-

L5 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 Chloropropoxy)phenyl]-4-[2-oxo-2-(pyrrolidin-1-yl)ethyl]-1,3-oxazole
 911134-57-1P; 1-[[2-[4-(3-chloropropoxy)phenyl]-1,3-oxazol-4-
 yl]acetyl]piperidine 911134-58-2P, 2-[2-[4-(3-
 Chloropropoxy)phenyl]-1,3-oxazol-4-yl]-N-(4-fluorophenyl)acetamide
 911134-59-3P, 4-[[2-[4-(3-chloropropoxy)phenyl]-1,3-oxazol-4-
 yl]acetyl]morpholine 911134-60-6P, 2-[2-[4-(3-
 Chloropropoxy)phenyl]-1,3-oxazol-4-yl]-N-cyclopentylacetamide
 911134-61-7P, 2-[2-[4-(3-chloropropoxy)phenyl]-1,3-oxazol-4-yl]-N-
 (cyclopropylmethyl)-N-propylacetamide 911134-62-8P,
 1-[[2-[4-(3-chloropropoxy)phenyl]-1,3-oxazol-4-yl]acetyl]azepane
 911134-72-0P, Ethyl 2-[4-(3-chloropropoxy)phenyl]-1,3-oxazole-4-
 carboxylate 911134-73-1P, 2-[4-(3-chloropropoxy)phenyl]-1,3-
 oxazole-4-carboxylic acid 911134-74-2P, 4-[[2-[4-(3-
 Chloropropoxy)phenyl]-1,3-oxazol-4-yl]carbonyl]morpholine
 911134-75-3P, 1-[[2-[4-(3-chloropropoxy)phenyl]-1,3-oxazol-4-
 yl]carbonyl]piperidine 911134-76-4P, 1-[[2-[4-(3-
 Chloropropoxy)phenyl]-1,3-oxazol-4-yl]carbonyl]-4-cyclopentylpiperazine
 911134-77-5P, 2-[4-(3-chloropropoxy)phenyl]-N-(cyclopropylmethyl)-
 N-propyl-1,3-oxazole-4-carboxamide 911134-79-7P,
 2-[4-(3-chloropropoxy)phenyl]-N-cyclopentyl-1,3-oxazole-4-carboxamide
 911134-81-1P, 2-[4-(3-chloropropoxy)phenyl]-N-(4-fluorobenzyl)-1,3-
 oxazole-4-carboxamide 911134-82-2P, 2-[4-(3-
 Chloropropoxy)phenyl]-4-(pyrrolidin-1-ylcarbonyl)-1,3-oxazole
 911134-83-3P, 2-[4-(3-chloropropoxy)phenyl]-4-[[2S]-2-(pyrrolidin-
 1-ylmethyl)pyrrolidin-1-yl]carbonyl]-1,3-oxazole 911134-84-4P,
 2-[4-(3-chloropropoxy)phenyl]-4-methyl-1,3-oxazole-5-carboxylic acid
 911134-85-5P, 2-[4-(3-chloropropoxy)phenyl]-N-(cyclopropylmethyl)-
 4-methyl-N-propyl-1,3-oxazole-5-carboxamide 911134-86-6P,
 1-[[2-[4-(3-chloropropoxy)phenyl]-4-methyl-1,3-oxazol-5-
 yl]carbonyl]piperidine 911134-87-7P, 1-[[2-[4-(3-
 Chloropropoxy)phenyl]-4-methyl-1,3-oxazol-5-yl]carbonyl]-4-
 cyclopentylpiperazine 911134-88-8P, N-Benzyl-2-[4-(3-
 chloropropoxy)phenyl]-4-methyl-1,3-oxazole-5-carboxamide
 911134-89-9P, 4-[[2-[4-(3-chloropropoxy)phenyl]-4-methyl-1,3-
 oxazol-5-yl]carbonyl]morpholine 911134-90-2P,
 2-[4-(3-chloropropoxy)phenyl]-N-cyclopentyl-4-methyl-1,3-oxazole-5-
 carboxamide 911134-91-3P, Methyl 2-[2-(4-hydroxyphenyl)-1,3-
 oxazol-4-yl]acetate 911134-92-4P, Methyl 2-[2-[4-(2-
 chloroethoxy)phenyl]-1,3-oxazol-4-yl]acetate 911134-93-5P,
 Methyl 2-[2-[4-[2-(2-methylpyrrolidin-1-yl)ethoxy]phenyl]-1,3-oxazol-4-
 yl]acetate 911134-94-6P, [2-[4-[2-(2-methylpyrrolidin-1-
 yl)ethoxy]phenyl]-1,3-oxazol-4-yl]acetic acid 911134-95-7P,
 1-[[2-[4-[2-(2-methylpyrrolidin-1-yl)ethoxy]phenyl]-1,3-oxazol-4-
 yl]acetyl]piperidine 911135-33-6P, Methyl 4-(bromomethyl)-2-[4-
 (3-chloropropoxy)phenyl]-1,3-oxazole-5-carboxylate 911135-34-7P,
 Ethyl 4-(bromomethyl)-2-[4-(3-chloropropoxy)phenyl]-1,3-oxazole-5-
 carboxylate 911135-35-8P, Methyl 4-(benzylamino)methyl-2-[4-(3-
 chloropropoxy)phenyl]-1,3-oxazole-5-carboxylate 911135-36-9P,
 Ethyl
 2-[4-(3-chloropropoxy)phenyl]-4-(piperidin-1-ylmethyl)-1,3-oxazole-5-
 carboxylate 911135-37-0P, Ethyl 2-[4-(3-(2-methylpyrrolidin-1-
 yl)propoxy)phenyl]-4-(piperidin-1-ylmethyl)-1,3-oxazole-5-carboxylate
 911135-41-6P, 2-[4-(3-chloropropoxy)phenyl]oxazole-4-
 carboxaldehyde
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (prepn. of oxazole and thiazole derivs. as histamine H3-receptor
 ligands with numerous therapeutic uses)
 RN 911134-52-6 CAPLUS
 CN 5-Oxazolecarboxylic acid, 2-[4-(3-chloropropoxy)phenyl]-4-methyl-, methyl


L5 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ester (9CI) (CA INDEX NAME)




RN 911134-53-7 CAPLUS
 CN 5-Oxazolemethanol, 2-[4-(3-chloropropoxy)phenyl]-4-methyl- (9CI) (CA INDEX NAME)




RN 911134-54-8 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 911134-55-9 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 911134-56-0 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




L5 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 911134-57-1 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 911134-58-2 CAPLUS
 CN 4-Oxazoleacetamide, 2-[4-(3-chloropropoxy)phenyl]-N-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 911134-59-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED



RN 911134-60-6 CAPLUS
 CN 4-Oxazoleacetamide, 2-[4-(3-chloropropoxy)phenyl]-N-cyclopentyl- (9CI) (CA INDEX NAME)




RN 911134-61-7 CAPLUS
 CN 4-Oxazoleacetamide, 2-[4-(3-chloropropoxy)phenyl]-N-(cyclopropylmethyl)-N-propyl- (9CI) (CA INDEX NAME)




RN 911134-62-8 CAPLUS


L5 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN INDEX NAME NOT YET ASSIGNED




RN 911134-72-0 CAPLUS
 CN 4-Oxazolecarboxylic acid, 2-[4-(3-chloropropoxy)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 911134-73-1 CAPLUS
 CN 4-Oxazolecarboxylic acid, 2-[4-(3-chloropropoxy)phenyl]- (9CI) (CA INDEX NAME)



RN 911134-74-2 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 911134-75-3 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED




RN 911134-76-4 CAPLUS
 CN INDEX NAME NOT YET ASSIGNED


L5 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 911134-77-5 CAPLUS
CN 4-Oxazolecarboxamide,
2-[4-(3-chloropropoxy)phenyl]-N-(cyclopropylmethyl)-
N-propyl- (9CI) (CA INDEX NAME)




RN 911134-79-7 CAPLUS
CN 4-Oxazolecarboxamide, 2-[4-(3-chloropropoxy)phenyl]-N-cyclopentyl- (9CI)
(CA INDEX NAME)



RN 911134-81-1 CAPLUS
CN 4-Oxazolecarboxamide, 2-[4-(3-chloropropoxy)phenyl]-N-[(4-fluorophenyl)methyl]- (9CI) (CA INDEX NAME)




RN 911134-82-2 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 911134-83-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.


L5 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 911134-87-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 911134-88-8 CAPLUS
CN 5-Oxazolecarboxamide, 2-[4-(3-chloropropoxy)phenyl]-4-methyl-N-(phenylmethyl)- (9CI) (CA INDEX NAME)




RN 911134-89-9 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


L5 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 911134-84-4 CAPLUS
CN 5-Oxazolecarboxylic acid, 2-[4-(3-chloropropoxy)phenyl]-4-methyl- (9CI)
(CA INDEX NAME)




RN 911134-85-5 CAPLUS
CN 5-Oxazolecarboxamide,
2-[4-(3-chloropropoxy)phenyl]-N-(cyclopropylmethyl)-
4-methyl-N-propyl- (9CI) (CA INDEX NAME)




RN 911134-86-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED


L5 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 911134-90-2 CAPLUS
CN 5-Oxazolecarboxamide,
2-[4-(3-chloropropoxy)phenyl]-N-cyclopentyl-4-methyl-
(9CI) (CA INDEX NAME)




RN 911134-91-3 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 911134-92-4 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 911134-93-5 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 911134-94-6 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 911134-95-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED




RN 911135-33-6 CAPLUS
CN 5-Oxazolecarboxylic acid, 4-(bromomethyl)-2-[4-(3-chloropropoxy)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 911135-34-7 CAPLUS
CN 5-Oxazolecarboxylic acid, 4-(bromomethyl)-2-[4-(3-chloropropoxy)phenyl]-, ethyl ester (9CI) (CA INDEX NAME)


L5 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
CN 4-Oxazolecarboxaldehyde, 2-[4-(3-chloropropoxy)phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT




RN 911135-35-8 CAPLUS
CN 5-Oxazolecarboxylic acid, 2-[4-(3-chloropropoxy)phenyl]-4-[[4-(phenylmethyl)amino]methyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 911135-36-9 CAPLUS
CN 5-Oxazolecarboxylic acid, 2-[4-(3-chloropropoxy)phenyl]-4-[[4-(piperidinylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 911135-37-0 CAPLUS
CN 5-Oxazolecarboxylic acid, 2-[4-(3-(2-methyl-1-pyrrolidinyl)propoxy)phenyl]-4-[[4-(1-piperidinylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 911135-41-6 CAPLUS

L5 ANSWER 3 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2006:1033643 CAPLUS
DOCUMENT NUMBER: 145:397502
TITLE: Preparation of oxazoline and thiazoline derivatives as histamine H3-receptor ligands with numerous therapeutic uses
INVENTOR(S): Celanire, Sylvain; Talaga, Patrice; Leurs, Regorius; Denonne, Frederic; Timmerman, Hendrik; Lebon, Florence
PATENT ASSIGNEE(S): Ucb S.A., Belg.
SOURCE: PCT Int. Appl., 106pp.
CODEN: PIXX02
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006103057	A1	20061005	WO 2006-EP2860	20060329

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DL, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPL. INFO.: EP 2005-6971 A 20050331

OTHER SOURCE(S): MARPAT 145:397502
GI



AB The present invention relates to compds. comprising an oxazoline or thiazoline moiety (shown as I; variables defined below; e.g. 1-[3-[4-(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)phenoxy]propyl]piperidine (I)), processes for preparing them (synthetic intermediates but no methods of preparation are claimed), pharmaceutical compns. comprising said compds. and their uses (no data) as H3-receptor ligands. For I: A1 is CH, CMe or N; R1 is H or halogen; R2 is II; A2 is O or S; R3 is H, halogen, C1-4 alkyl or C1-4 alkoxy; R4 is H, halogen, C1-4 alkyl, C1-4 alkoxy, trifluoromethyl or -O(CH2)nNR12aR12b each CH2 in -O(CH2)nNR12aR12b being (un)substituted by one or two C1-4 alkyl; R5 is H

L5 ANSWER 3 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 or -O(CH₂)_nNR13aR13b, each CH₂ in -O(CH₂)_nNR13aR13b being (un)substituted by one or two C1-4 alkyl, and at least one of R4 and R5 should be a -O(CH₂)_nNR12a/13aR12b/13b group; addnl. details including provisos are given in the claims. Although the methods of prepn. are not claimed, preps. and/or characterization data for >30 examples of I are included. For example, 1 was prepd. in 5 steps (80, 99, 95, 97 and 83 %) starting from 4-benzyloxybenzoic acid and 2-amino-2-methylpropan-1-ol to give 4-(benzyloxy)-N-(2-hydroxy-1,1-dimethylethyl)benzamide, with subsequent formation of the following intermediates: 2-[4-(benzyloxy)phenyl]-4,4-dimethyl-4,5-dihydro-1,3-oxazole, 4-(4,4-dimethyl-4,5-dihydro-1,3-oxazol-2-yl)phenol and 2-[4-(3-chloropropoxy)phenyl]-4,4-dimethyl-4,5-dihydro-1,3-oxazole. In an [35S]GTPγS-binding assay using human histamine H3-receptor, compds. I showed pIC₅₀ 6.5-10. In a paced isolated guinea pig myenteric plexus - elec.-field stimulation assay for antagonism activity, compds. I showed pA₂ values typically 26.5 for the histamine H3 receptor.


IT 911198-84-OP, Methyl 2-[4-(3-(piperidin-1-yl)propoxy)phenyl]-4,5-dihydro-1,3-oxazole-4-carboxylate 911198-85-1P, [2-[4-(3-(piperidin-1-yl)propoxy)phenyl]-4,5-dihydro-1,3-oxazol-4-yl]methanol

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

H3-receptor (preparation of oxazoline and thiazoline derivs. as histamine ligands with numerous therapeutic uses)


RN 911198-84-0 CAPLUS

CN 4-Oxazolecarboxylic acid, 4,5-dihydro-2-[4-(3-(1-piperidinyl)propoxy)phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 911198-85-1 CAPLUS

CN 4-Oxazolemethanol, 4,5-dihydro-2-[4-(3-(1-piperidinyl)propoxy)phenyl]- (9CI) (CA INDEX NAME)




REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

IT 21256-18-8, Oxaprosin .
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (comps. comprising β-blockers in combination with ACE inhibitor, angiotensin receptor blocker, anabolic steroid, anti-inflammatory agent, or glyceric acid or fatty acid for ameliorating inflammation and cachexia)

RN 21256-18-8 CAPLUS

CN 2-Oxazolepropanoic acid, 4,5-diphenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 4 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:1011167 CAPLUS

DOCUMENT NUMBER: 145:383494

TITLE: Compositions comprising β-blockers and methods for ameliorating cachexia

INVENTOR(S): Bascomb, Newell; Maki, John; Young, Fredric

PATENT ASSIGNEE(S): Vicus Therapeutics Spe 1, LLC, USA

SOURCE: PCT Int. Appl., 136pp.

CODEN: PIXKD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006102476	A2	20060928	WO 2006-US10510	20060321
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			US 2005-664225P	P 20050321
			US 2005-713526P	P 20050831
			US 2005-735432P	P 20051110
			US 2005-753436P	P 20051222

AB The invention provides preps., formulations, kits and other products of manufacture (e.g., blister pack) comprising combinations of beneficial ingredients that are serviceable as therapies for improving states and disease symptoms such as involving inflammation, excessive sympathoneural drive, cachexia, anorexia, and anorexia-cachexia, as well as stress or anxiety related thereto, and methods of making and using them. The invention provides compns. and therapies comprising use of a β-adrenergic antagonist (β-blockers, e.g., propranolol) in combination with an anti-inflammatory agent, e.g., a nonsteroidal anti-inflammatory drug (NSAID), an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), an anabolic steroid, a natural oil or fatty acid or any combination thereof. The therapeutic combination or pharmaceutical composition is formulated or manufactured as feed, a food, a liquid, an elixir, an aerosol, a spray, a powder, a tablet, a pill, a capsule, a gel, a gelat., a nanosuspension, a nanoparticle a microgel or a suppository. Thus, a treatment protocol for subjects with non-hematol. metastatic cancer was proposed comprising a combination of β-blocker atenolol (Tenormin) 12.5 to 100 mg per day and NSAID etodolac (Iodine). Since the effect of atenolol and etodolac are opposite on blood pressure, it is important that patient compliance be maintained for safety. Dose was increased to obtain a heart rate of approx. 60 bpm with blood pressure

L5 ANSWER 5 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2006:888121 CAPLUS

DOCUMENT NUMBER: 145:292724

TITLE: Aryl ketoamide derivatives as cytokine inhibitors and their preparation, pharmaceutical composition and use in therapy

INVENTOR(S): Bonnan, Erik; Ceide, Susanna Conde; Dahl, Russell; Ernst, Justin; Kahl, Jeffrey; Montalban, Antonio; Garrido; Wang, Zhinjun; Larson, Christopher; Salah, Eddine

PATENT ASSIGNEE(S): Kemia, Inc., USA

SOURCE: PCT Int. Appl., 315pp.

CODEN: PIXKD2

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006091862	A2	20060831	WO 2006-US6682	20060223
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			US 2005-656196P	P 20050224
			US 2005-679294P	P 20050509


OTHER SOURCE(S): MARPAT 145:292724

GI



AB The invention relates to low mol. weight compds. of formula I and compns.

L5 ANSWER 5 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 thereof, useful as cytokine inhibitors, and their prepn. Comps. of
 formula I wherein G is (un)substituted C3-10 carbocyclyl, (un)substituted
 5- to 8-membered heterocyclyl, and (un)substituted 8- to 11-membered
 bicyclic heterocyclyl; X is CO, CS and CH2; Ar is (un)substituted
 (mono/bi)cyclic (hetero)aryl, (un)substituted alkyl(hetero)aryl, etc.; L
 is covalent bond, (un)satd. (un)branched C1-10 (hetero)alkyl; Q is H, NH2
 and deriva., (un)substituted cycloalkyl, (un)substituted aryl,
 (un)substituted heterocyclyl, (un)substituted C1-6 alkoxy, etc.; and
 their
 stereoisomers, tautomers, solvates, prodrugs, and pharmaceutically
 acceptable salts thereof are claimed. The invention further relates to
 methods of prevention and treatment of cytokine-mediated disorders, in
 particular inflammatory disorders, pain and cancer. The invention also
 relates to pharmaceutical comps. and dosing regimens. In particular,
 the
 invention relates to the use of cytokine inhibitors, optionally in
 conjunction with other therapies, for cancer, more particularly glioma,
 glioblastoma, osteosarcoma and bone metastases. Addnl., the invention
 relates to methods of treating, modifying and managing pain, more
 particularly neuropathic pain, which comprise the administration of a
 cytokine inhibitor alone or in combination with known therapeutics.
 Example compd. II was prepd. by demethylation of [4-(2-
 dimethylaminopyridin-4-ylamino)naphthalen-1-yl]oxoacetic acid Me ester;
 the resulting [4-(2-dimethylaminopyridin-4-ylamino)naphthalen-1-
 yl]oxoacetic acid underwent coupling with N-(3-amino-5-tert-butyl-2-
 methoxyphenyl) propanesulfonamide to give compd. II. All the invention
 comps. were evaluated for their cytokine inhibitory activity. From the
 assay, it was detd. that compd. II and several other example comps.
 exhibited IC50 values below 10 µM.
 IT 21256-18-8, Oxaproxin
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (preparation of aryl ketoamide deriva. as cytokine inhibitors useful
 as
 therapeutics)
 RN 21256-18-8 CAPLUS
 CN 2-Oxazolepropanoic acid, 4,5-diphenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 6 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)

L5 ANSWER 6 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2006:273323 CAPLUS
 DOCUMENT NUMBER: 144:305169
 TITLE: Compositions for enhancing memory and methods
 therefor
 INVENTOR(S): Baudry, Michel; Bischoff, Serge
 PATENT ASSIGNEE(S): Lifelike Biomatic, Inc., USA
 SOURCE: U.S. Pat. Appl. Publ., 28 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 200603707	A1	20060323	US 2005-229423	20050916
WO 2006034196	A1	20060330	WO 2005-US3489	20050916

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2004-611207P P 20040917
 US 2005-647514P P 20050127

OTHER SOURCE(S): MARPAT 144:305169
 AB Comps. for enhancing memory of a subject comprising a combination of a pos. modulator of an AMPA receptor and a pos. modulator of an NMDA receptor are provided, wherein each modulator of the combination is present at a subtherapeutic dose for effecting memory enhancement. Methods for using such comps. in the treatment of cognitive impairment associated with aging, age-related diseases, and CNS disorders, for example, are provided. New fusion mols. are also provided that combine the pos. modulator functionalities into one mol.
 IT 709656-07-5
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (comps. for enhancing memory and methods therefor using combination of
 AMPA receptor and NMDA receptor agonist)
 RN 709656-07-5 CAPLUS
 CN 4-Oxazolecarboxylic acid, 4,5-dihydro-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 7 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2006:74852 CAPLUS
 DOCUMENT NUMBER: 144:164276
 TITLE: Treating neurodegenerative conditions
 INVENTOR(S): Mandelkow, Eckard; Mandelkow, Eva-Maria; Biernat, Jacek; Bergen, Martin V.; Fieckhardt, Markus
 PATENT ASSIGNEE(S): Max Planck Gesellschaft zur Foerderung der Wissenschaft, Germany
 SOURCE: PCT Int. Appl., 136 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006007864	A1	20060126	WO 2004-EP8031	20040717


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SJ, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 2006223812 A1 20061005 US 2006-351884 20060210
 PRIORITY APPLN. INFO.: WO 2004-EP8031 A2 20040717
 US 2005-652284P P 20050211

OTHER SOURCE(S): MARPAT 144:164276
 AB The present invention relates to the use of comps. capable of inhibiting protein aggregate formation and capable of depolyng. protein aggregates for the preparation of a pharmaceutical composition for treating neurodegenerative conditions such as Alzheimer disease.
 IT 874374-79-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (comps. to treat neurodegenerative conditions)
 RN 874374-79-5 CAPLUS
 CN L-Proline, 1-[[[4-((5-methyl-2-phenyl-4-oxazolyl)acetyl)amino]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

ACCESSION NUMBER: 2005:1292048 CAPLUS
DOCUMENT NUMBER: 144:36353
TITLE: Preparation of heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
INVENTOR(S): Edwards, Louise; Isaac, Methvin; Johansson, Martin; Kers, Annika; Malmberg, Johan; McLeod, Donald; Mindis, Alexander; Staaf, Karin; Slassi, Abdelmalik; Stefanac, Tomislav; Stormann, Thomas; Wensbo, David; Xin, Tao; Arora, Jalej
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.; Nps Pharmaceuticals Inc.
SOURCE: U.S. Pat. Appl. Publ., 175 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005272779	A1	20051208	US 2005-53752	20050209
AU 2005270208	A1	20060209	AU 2005-270208	20050215
CA 2555566	AA	20060209	CA 2005-2555566	20050215
WO 2006014185	A1	20060209	WO 2005-US4774	20050215

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW


RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

EP 1723144 A1 20061122 EP 2005-802855 20050215


R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU

PRIORITY APPLN. INFO.: US 2004-608960P P 20040218
WO 2005-US4774 W 20050215

OTHER SOURCE(S): MARPAT 144:36353
GI



AB The present invention presents the syntheses of heteropolycyclic compds., e.g. I and II, for use as metabotropic glutamate receptor antagonists. For example, adding BuLi to 4-(4-cyclopropyl-5-methyl-4H-(1,2,4)triazol-3-yl)pyridine in THF at -78°C for 15 mins and then adding 3-(1-bromoethyl)-5-(3-chlorophenyl)-[1,2,4]oxadiazole in THF gave I. The compds. are designed for the prevention and/or treatment of mGluR5 receptor-mediated disorders.
IT 154405-97-7P, 2-(3-Chlorophenyl)oxazole-4-carboxylic acid methyl ester
RL: SPN (Synthetic preparation); PREP (Preparation) (preparation of heteropolycyclic compds. for treating and/or preventing mGluR5 receptor-mediated disorders)
RN 154405-97-7 CAPLUS
CN 4-Oxazolecarboxylic acid, 2-(3-chlorophenyl)-, methyl ester (9CI) (CA INDEX NAME)



ACCESSION NUMBER: 2005:1288059 CAPLUS
DOCUMENT NUMBER: 144:36255
TITLE: Preparation of heteroaryl amides for therapeutic use as cannabinoid receptor modulators
INVENTOR(S): Amin, Kozrat; Broddsfalk, Johan; Desfosses, Helene; Evertsson, Emma; Liu, Ziping; Milburn, Claire; Nilsson, Karolina; Tremblay, Maxime; Walpole, Christopher; Wei, Zhong-Yong; Yang, Hua
PATENT ASSIGNEE(S): AstraZeneca AB, Swed.
SOURCE: PCT Int. Appl., 257 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115986	A1	20051208	WO 2005-SE753	20050520

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


PRIORITY APPLN. INFO.: SE 2004-1345 A 20040525

OTHER SOURCE(S): MARPAT 144:36255
GI




AB Heteroaryl amides, such as I [A1, A2, A3, A4 = N, CR1; R = (CH2)nR4; R1 = H, CN, NH2, NHC(=O), OH, halogen, alkylamino, alkoxy, etc.; R2 = aryl, heterocyclyl; R3 = H, alkyl; R4 = cycloalkyl, aryl, heterocyclyl, heterocyclylamino, etc.; m = 0-2; n = 0-5], were prepared for use in pharmaceutical compns. as cannabinoid types CB1 and CB2 receptor modulators which are useful in therapy, in particular in the management of pain. These amides are also claimed for use in the treatment of functional gastrointestinal disorders, irritable bowel syndrome, anxiety, cancer, multiple sclerosis, Parkinson's disease, Huntington's chorea, Alzheimer's disease, and cardiovascular disorders. Thus, N-(cyclobutylmethyl)-3-[(1-naphthalenyl)carbamoyl]amino-2-pyridinecarboxamide II (R2 = 1-naphthalenyl) was prepared starting from cyclobutylmethylamine, 1-naphthalenecarbonyl chloride, and 3-amino-2-pyridinecarboxylic acid. Some of the prepared amides were assayed

L5 ANSWER 9 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 for CB1 and CB2 receptor binding activity.
 IT 870970-56-2P 870970-58-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of heteroaryl amides for therapeutic use as cannabinoid receptor modulators)
 RN 870970-56-2 CAPLUS
 CN 2-Pyridinecarboxamide, N-[(5-phenyl-4-oxazolyl)carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 870970-58-4 CAPLUS
 CN 2-Pyridinecarboxamide, 3-[(5-phenyl-4-oxazolyl)carbonyl]amino]-N-[(tetrahydro-2H-pyran-4-yl)methyl]- (9CI) (CA INDEX NAME)



IT 337508-64-2, 5-Phenyl-1,3-oxazole-4-carbonyl chloride
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of heteroaryl amides for therapeutic use as cannabinoid receptor modulators)
 RN 337508-64-2 CAPLUS
 CN 4-Oxazolecarbonyl chloride, 5-phenyl- (9CI) (CA INDEX NAME)

L5 ANSWER 10 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2005:1200420 CAPLUS
 DOCUMENT NUMBER: 143:460176
 TITLE: Preparation of 5,6,7,8-tetrahydro-2-quinazolinamines and related compounds as norepinephrine reuptake inhibitors
 INVENTOR(S): Oberboersch, Stefan; Sundermann, Bernd; Sundermann, Corinna; Haurand, Michael; Hennies, Hagen-Heinrich; Bijsterveld, Edward
 PATENT ASSIGNEE(S): Gruenenthal G.m.b.H., Germany
 SOURCE: PCT Int. Appl., 193 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005105759	A1	20051110	WO 2005-EP4489	20050427
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 102004020908				
PRIORITY APPLN. INFO.: DE 2004-102004020908 20040428				
OTHER SOURCE(S): MARPAT 143:460176				
GI				

L5 ANSWER 9 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L5 ANSWER 10 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB Title compds. I (X = CH(NHR2), NR2a: R1 = COR3, COOR4; R2, R2a = COR5, SO2R6; R3 = alkyl with provisios; R4 = (un)substituted aryl, heteroaryl;
 R5 = alkyl with provisios; R6 = NR10R11; R10, R11 = alkyl] and their pharmaceutically acceptable salts were prepared. For example, sequential Boc-deprotection of amine II and N-acylation with 3-trifluorobenzoic acid afforded claimed quinazolinamine in 55% yield. In norepinephrine reuptake assays, 51-examples of compds. I at 10 µM exhibited 29-96% inhibition.
 IT 869197-09-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of tetrahydroquinazolinamines and related compds. as norepinephrine reuptake inhibitors)
 RN 869197-09-1 CAPLUS
 CN 4-Oxazolecarboxamide, 5-phenyl-N-[5,6,7,8-tetrahydro-2-[(2-thienyl)carbonyl]amino]-6-quinazolinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

ACCESSION NUMBER: 2005:115527 CAPLUS
 DOCUMENT NUMBER: 143:422366
 TITLE: Preparation of pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists
 INVENTOR(S): Neustadt, Bernard R.; Hao, Jinsong; Liu, Hong; Boyle, Craig D.; Chackalamannil, Samuel; Shah, Umesh G.; Stamford, Andrew; Harris, Joel M.
 PATENT ASSIGNEE(S): Schering Corporation, USA
 SOURCE: U.S. Pat. Appl. Publ., 81 pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005239795	A1	20051027	US 2005-108916	20050419
WO 2005103055	A1	20051103	WO 2005-US13454	20050419
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
PRIORITY APPLN. INFO.:			US 2004-563913P	P 20040421
			US 2004-609966P	P 20040915

OTHER SOURCE(S): MARPAT 143:422366
 GI


* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [R = (un)substituted Ph, furanyl, thienyl, pyridyl, pyridyl N-oxide, oxazolyl or pyrrolyl, or cycloalkenyl; R1, R2, R3, R4 and R5 = H, alkyl or alkoxyalkyl; Z = (un)substituted aryl or heteroaryl], and their pharmaceutically acceptable salt thereof, are prepared and disclosed as adenosine A2a receptor antagonists. Thus, e.g., II was prepared by reaction of III (preparation given) with the corresponding piperazine.
 In binding assays to adenosine A2a receptors, Ki values of 0.4 to 10 nM were observed. Also disclosed is the use I in the treatment of central nervous system diseases, in particular Parkinson's disease, alone or in combination with other agents for treating Parkinson's disease, and pharmaceutical compns. comprising them.
 IT 868244-18-2P 868244-19-3P 868244-20-6P


868244-21-7P 868244-22-8P 868244-23-9P
 868244-24-0P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine adenosine A2a receptor antagonists)
 RN 868244-18-2 CAPLUS
 CN 2-Oxazolemethanol, 4-[3-[4-[2-[5-amino-2-(2-pyridinyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-7-yl]ethyl]-1-piperazinyl]-4-fluorophenyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)




RN 868244-19-3 CAPLUS
 CN 2-Oxazolemethanol, 4-[3-[4-[2-[5-amino-2-(3-methyl-2-pyridinyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-7-yl]ethyl]-1-piperazinyl]-4-fluorophenyl]-α,α-dimethyl- (9CI) (CA INDEX NAME)




RN 868244-20-6 CAPLUS
 CN 2-Oxazolemethanol, 4-[3-[4-[2-[5-amino-2-(2-pyridinyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-7-yl]ethyl]-1-piperazinyl]-4-fluorophenyl]-α-methyl- (9CI) (CA INDEX NAME)



RN 868244-21-7 CAPLUS
 CN 2-Oxazolemethanol, 4-[3-[4-[2-[5-amino-2-(3-methyl-2-pyridinyl)-7H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-7-yl]ethyl]-1-piperazinyl]-4-fluorophenyl]-α-methyl- (9CI) (CA INDEX NAME)



RN 868244-22-8 CAPLUS
 CN 7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine, 7-[2-[4-[2-fluoro-5-(2-(methoxymethyl)-4-oxazolyl)phenyl]-1-piperazinyl]ethyl]-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)




PAGE 1-A

PAGE 1-B

L5 ANSWER 11 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 868244-23-9 CAPLUS
CN 7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine,
7-[2-[4-[2-fluoro-5-[(2-methoxymethyl)-4-oxazolyl]phenyl]-1-
piperazinyl]ethyl]-2-(3-methyl-2-pyridinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe

RN 868244-24-0 CAPLUS
CN 7H-Pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine,
7-[2-[4-[2-fluoro-5-[2-(methoxymethyl)-4-oxazolyl]phenyl]-1-
piperazinyl]ethyl]-2-(3-fluoro-2-pyridinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B

—OMe

IT 868245-85-6 868245-86-7 868245-87-8
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of pyrazolo-[4,3-e]-1,2,4-triazolo-[1,5-c]-pyrimidine
adenosine
A2a receptor antagonists)

L5 ANSWER 12 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1123812 CAPLUS
DOCUMENT NUMBER: 143:379815
TITLE: Method of reducing C-reactive protein using growth
hormone secretagogues
INVENTOR(S): Polvino, William J.; Carpi, David B.; Smith, Roy G.
PATENT ASSIGNEE(S): Rejuvenon Corporation, USA
SOURCE: PCT Int. Appl., 135 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097261	A1	20051020	WO 2005-US10927	20050330
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
ZW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005261201	A1	20051124	US 2005-94339	20050330
PRIORITY APPLN. INFO.:		US 2004-557466P	P	20040330

OTHER SOURCE(S): MARPAT 143:379815


AB The invention discloses a method for reducing C-reactive protein in a subject in need of treatment thereof, wherein the subject is at risk of having or the subject has already had a vascular event or suffering from an inflammatory disease or disorder. In one embodiment, the vascular event is a cardiovascular event (e.g., myocardial infarction). In another embodiment, the vascular event is a cerebrovascular event (e.g., stroke, transient ischemic attacks). In yet another embodiment the vascular event is a peripheral vascular event (e.g., intermittent claudication). The method comprises administering a therapeutically effective amount of at least one growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof. The growth hormone secretagogue can be coadministered with a second growth hormone secretagogue, HMG CoA reductase inhibitor, an ACAT inhibitor, a CETP inhibitor, an anti-inflammatory agent, an ACE inhibitor, a Beta blocker, a cholesterol absorption inhibitor, a nicotinic acid, a fibrin acid derivative, a bile acid sequestering agent or a combination thereof.

IT 21256-18-8, Oxaprozin
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(growth hormone secretagogues for reducing C-reactive protein, and use with other agents)


RN 21256-18-8 CAPLUS
CN 2-Oxazolepropanoic acid, 4,5-diphenyl- (9CI) (CA INDEX NAME)

L5 ANSWER 11 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 868245-85-6 CAPLUS
CN 2-Oxazolemethanol, 4-[4-fluoro-3-(1-piperazinyl)phenyl]- α,α -dimethyl- (9CI) (CA INDEX NAME)




RN 868245-86-7 CAPLUS
CN 2-Oxazolemethanol, 4-[4-fluoro-3-(1-piperazinyl)phenyl]- α -methyl- (9CI) (CA INDEX NAME)



RN 868245-87-8 CAPLUS
CN Piperazine, 1-[2-fluoro-5-[2-(methoxymethyl)-4-oxazolyl]phenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 12 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L5 ANSWER 13 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:1049851 CAPLUS
DOCUMENT NUMBER: 143:339666
TITLE: Methods using farnesyl transferase inhibitors for the treatment of synucleinopathies
INVENTOR(S): Lansbury, Peter T.; Liu, Zhihua
PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., USA
SOURCE: PCT Int. Appl., 205 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005089515	A2	20050929	WO 2005-US9396	20050318
WO 2005089515	C2	20060126		
WO 2005089515	A3	20060427		


W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2005272722 A1 20051208 US 2005-84739 20050318
PRIORITY APPLN. INFO.: US 2004-555071P P 20040318

OTHER SOURCE(S): MARPAT 143:339666
AB Methods are provided of treating synucleinopathies, such as Parkinson's disease, diffuse Lewy body disease and multiple system atrophy, comprising administering to a synucleinopathic subject a farnesyl transferase inhibitor compound
IT 195978-93-9
RL: PAC (Pharmacological activity): THU (Therapeutic use); BIOL (Biological study): USES (Uses)
(farnesyl transferase inhibitors for treatment of synucleinopathies)
RN 195978-93-9 CAPLUS
CN 1H-1,4-Benzodiazepine, 2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-7-phenyl-4-[(5-phenyl-4-oxazolyl)carbonyl]-, dihydrochloride (9CI) (CA INDEX NAME)

L5 ANSWER 13 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



● 2 HCl

L5 ANSWER 14 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:962041 CAPLUS
DOCUMENT NUMBER: 143:242034
TITLE: DPP-IV inhibitors for neurodegenerative and cognitive disorders
INVENTOR(S): Hughes, Thomas Edward
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005079795	A2	20050901	WO 2005-EP1729	20050218
WO 2005079795	A3	20051110		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2005215136 A1 20050901 AU 2005-215136 20050218
CA 2555399 AA 20050901 CA 2005-2555399 20050218
PRIORITY APPLN. INFO.: US 2004-546229P P 20040220
US 2004-607902P P 20040908
WO 2005-EP1729 W 20050218

AB The invention relates to the use of a dipeptidyl peptidase IV inhibitor (DPP-IV inhibitor) or a pharmaceutically acceptable salt thereof for the prevention, delay of progression or the treatment of neurodegenerative disorders, cognitive disorders and for improving memory (both short term and long term) and learning ability.
IT 21256-18-8, Oxaprozine
RL: THU (Therapeutic use); BIOL (Biological study): USES (Uses)
(DPP-IV inhibitors for neurodegenerative and cognitive disorders)
RN 21256-18-8 CAPLUS
CN 2-Oxazolepropanoic acid, 4,5-diphenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 15 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:612299 CAPLUS
DOCUMENT NUMBER: 143:133380
TITLE: Preparation of azabicyclic heterocycles as cannabinoid receptor modulators
INVENTOR(S): Gu, Guixue; Ewing, William R.; Mikkilineni, Amarendra S.; Pendri, Annapurna; Ellsworth, Bruce A.; Sher, Philip M.; Gerritz, Samuel; Sun, Chongqing;
Murugesan,
Natesan; Wu, Ximao
Bristol-Myers Squibb Company, USA
PATENT ASSIGNEE(S):
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005063762	A1	20050714	WO 2004-US42878	20041217

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG


AU 20040309368 A1 20050714 AU 2004-309368 20041217
CA 2550375 AA 20050714 CA 2004-2550375 20041217
US 2005171110 A1 20050804 US 2004-16198 20041217
EP 1697371 A1 20060906 EP 2004-815007 20041217

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU

EP 1699796 A1 20060913 EP 2004-814691 20041220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU

NO 2006002689 A 20060912 NO 2006-2689 20060612
NO 2006002691 A 20060914 NO 2006-2691 20060612
PRIORITY APPLN. INFO.: US 2003-531451P P 20031219
US 2004-16198 A 20041217
WO 2004-US42878 W 20041217
WO 2004-US42542 W 20041220

OTHER SOURCE(S): MARPAT 143:133380
GI



AB The present application describes compds. I [R1, R2 = halo, CN, alkyl, etc.; R3 = H alkyl, alkenyl, cycloalkyl, etc.; R4 is absent when n is a double bond; R4 = H, alkyl, cycloalkyl, etc.; R5 = halo, (un)substituted OH, NH2, etc. when m is a single bond; R5 = O when m = a double bond; m,

n = a single or double bond; when m is a single bond, n is a double bond; when m is a double bond, n is a single bond], pharmaceutical compns. comprising at least one compound I and optionally one or more addnl. therapeutic agents and methods of treatment using the compds. I both

alone and in combination with one or more addnl. therapeutic agents. Over 40 compds. I were prepared E.g., a multi-step synthesis of II, starting from


dichloromandelic anhydride, was given. The exemplified compds. I showed the CB-1 receptor binding Ki values in the range of 0.01 nM to 10000 nM.

IT 141200-24-0 170861-63-9 196808-45-4 331741-94-7

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (co-drug; preparation of azabicyclic heterocycles as cannabinoid receptor modulators)

RN 141200-24-0 CAPLUS

CN 2,4-Thiazolidinedione, 5-[[4-[[3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl]phenyl]methyl]- (9CI) (CA INDEX NAME)



RN 170861-63-9 CAPLUS

CN 3,5-Isloxazolidinedione, 4-[[4-[[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)

ACCESSION NUMBER: 2005:508983 CAPLUS

DOCUMENT NUMBER: 143:115571

TITLE: Preparation of 1,3-ethanopiperazines as nicotinic acetylcholine receptor ligands

INVENTOR(S): Ernst, Glen; Frette, William; Jacobs, Robert;

SOURCE: Phillips, Edion Astrazeneca AB, Swed. PCT Int. Appl., 40 pp.

DOCUMENT TYPE: Patent

LANGUAGE: English


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005061510	A1	20050707	WO 2004-SE1941	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, UA, UG, UZ, VC, VN, YU, ZA, ZH, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004303738	A1	20050707	AU 2004-303738	20041220
CA 2550655	AA	20050707	CA 2004-2550655	20041220
EP 1699801	A1	20060913	EP 2004-809114	20041220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
PRIORITY APPLN. INFO.:			US 2003-531710P	P 20031222
			WO 2004-SE1941	W 20041220

OTHER SOURCE(S): MARPAT 143:115571

GI



AB Title compds. I [D = O, S, N(R1)2; X = Ar1; Ar1 = 5- or 6-membered aromatic or heteroarom. ring with provisoes; E = single bond, O, S, etc.; G = H, alkoxy, 5- or 6-membered aromatic or heteroarom. ring, etc.;] and their pharmaceutically acceptable salts were prepared For example, coupling of




RN 196808-45-4 CAPLUS

CN L-Tyrosine,


N-(2-benzoylphenyl)-O-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethyl)-(9CI)] (CA INDEX NAME)

Absolute stereochemistry.



RN 331741-94-7 CAPLUS

CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[(4-[(2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl)methyl]- (9CI)] (CA INDEX NAME)



REFERENCE COUNT: 3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

1,4-diazabicyclo[3.2.1]octane dihydrochloride and

5-(2-pyridyl)thiophene-2-carboxylic acid afforded ethanopiperazine II in 60% yield. In nicotinic receptor $\alpha 7$ affinity binding assays, compds. I exhibited specific binding of 75% (sic).

IT 857334-74-8P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of ethanopiperazines as nicotinic acetylcholine receptor ligands)

RN 857334-74-8 CAPLUS

CN 1,4-Diazabicyclo[3.2.1]octane, 4-[(5-phenyl-2-oxazolyl)carbonyl]-, monohydrochloride, (1R,5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 13575-16-1P, 5-Phenyloxazole-2-carboxylic acid ethyl ester


857334-82-8P, Lithium 5-phenyloxazole-2-carboxylate

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of ethanopiperazines as nicotinic acetylcholine receptor ligands)


RN 13575-16-1 CAPLUS

CN 2-Oxazolecarboxylic acid, 5-phenyl-, ethyl ester (8CI, 9CI) (CA INDEX NAME)



RN 857334-82-8 CAPLUS

CN 2-Oxazolecarboxylic acid, 5-phenyl-, lithium salt (9CI) (CA INDEX NAME)



● L1



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

ACCESSION NUMBER: 2005:572592 CAPLUS
DOCUMENT NUMBER: 143:97378
TITLE: Preparation of azabicyclic heterocycles as
cannabinoid
receptor modulators
INVENTOR(S): Yu, Guixue; Ewing, William R.; Mikkilineni, Amarendra
B.; Pendri, Annapurna; Sher, Philip M.; Gerritz,
Samuel; Ellsworth, Bruce A.; Wu, Gang; Huang,
Yanting;
Sun, Chongqing; Murugesan, Natesan; Gu, Zhengxiang;
Wang, Ying; Sitkoff, Doree; Johnson, Stephen R.; Wu,
Ximao
Bristol-Myers Squibb Co, USA
U.S. Pat. Appl. Publ., 196 pp.
PATENT ASSIGNER(S):
SOURCE: CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005143381	A1	20050630	US 2004-16135	20041217
AU 2004309365	A1	20050714	AU 2004-309365	20041217
CA 2550435	AA	20050714	CA 2004-2550435	20041217
WO 2005063761	A1	20050714	WO 2004-US42820	20041217
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005192278	A1	20050901	US 2004-15876	20041217
US 7037910	B2	20060502		
EP 1697370	A1	20060906	EP 2004-814952	20041217
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
WO 2005061509	A1	20050707	WO 2004-US42542	20041220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1699796	A1	20060913	EP 2004-814691	20041220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR, IS, YU				
NO 2006002704	A	20060905	NO 2006-2704	20060612

L5 ANSWER 17 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
NO 2006002689 A 20060912 NO 2006-2689 20060612
PRIORITY APPLN. INFO.: US 2003-531451P P 20031219
US 2004-16135 A 20041217
WO 2004-US42820 W 20041217
WO 2004-US42542 W 20041220

OTHER SOURCE(S): MARPAT 143:97378
GI




AB The present application describes compds. I [R1, R2 = halo, CN, alkyl, etc.; R3 = alkyl, alkenyl, cycloalkyl, etc.; R6 = H, alkyl, cycloalkyl, etc.; R7 is absent when double bond; or R7 = H, alkyl, cycloalkyl, etc.], pharmaceutical compns. comprising at least one compound I and optionally


one or more addnl. therapeutic agents and methods of treatment using the compds. I both alone and in combination with one or more addnl. therapeutic agents. Over 400 compds. I were prepared E.g., a multi-step synthesis of II, starting from dibromopyridazinone, was given. Representative compds. I showed the CB-1 receptor binding Ki values in

the range of 0.01 nM to 10000 nM.
IT 141200-24-0, Darglitazone 170861-63-9, JTT-501
196808-45-4 331741-94-7, Muraglitazar
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-drug: preparation of azabicyclic heterocycles as cannabinoid
receptor
modulators)

RN 141200-24-0 CAPLUS
CN 2,4-Thiazolidinedione, 5-[[4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl]phenyl]methyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 17 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 170861-63-9 CAPLUS
CN 3,5-Isloxazolidinedione, 4-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 196808-45-4 CAPLUS
CN L-Tyrosine,
N-(2-benzoylphenyl)-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 331741-94-7 CAPLUS
CN Glycine, N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 18 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:471944 CAPLUS
DOCUMENT NUMBER: 143:26594
TITLE: Preparation of thiazoles and oxazoles useful as modulators of ATP-binding cassette (ABC) transporters
INVENTOR(S): Hadida Ruah, Sarah S.; Miller, Mark T.; Grootenhuys, Peter D. J.; Hamilton, Matthew
PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
SOURCE: PCT Int. Appl., 146 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005049018	A1	20050602	WO 2004-US38566	20041115
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004290581	A1	20050602	AU 2004-290581	20041115
CA 2545719	AA	20050602	CA 2004-2545719	20041115
US 2005130970	A1	20050616	US 2004-989218	20041115
EP 1682127	A1	20060726	EP 2004-811321	20041115
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
NO 200602773	A	20060808	NO 2006-2773	20060613
PRIORITY APPL. INFO.:			US 2003-520355P	P 20031114
			WO 2004-US38566	W 20041115

OTHER SOURCE(S): MARPAT 143:26594
GI



AB A method of modulating ABC transporter activity comprises administration of title compds. [I: X = O, S; R1 = H, 3-8 membered (substituted) (unsatd.) (heterocyclic) ring; Z = bond, (substituted) (heteroatom-interrupted) alkylidene; R2 = halo, CF3, cyano, NO2, TqR; R3 = UmR'; R4 = VpCyl; m, p, q = 0, 1; U, V, T = (substituted) (heteroatom-interrupted) alkylidene; Cyl = 3-8 membered (substituted)]

L5 ANSWER 19 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:238947 CAPLUS
DOCUMENT NUMBER: 142:316831
TITLE: Preparation of amides of pyrazolamines and anilines
as well as analogs as cytokine inhibitors for the treatment of inflammatory diseases
INVENTOR(S): Boman, Erik; Ceide, Susana C.; Dahl, Russell; Delaet, Nancy G. J.; Ernst, Justin; Montalban, Antonio G.; Kahl, Jeffrey D.; Larson, Christopher; Miller, Stephen; Nakanishi, Hiroshi; Roberts, Edward; Saiah, Eddine; Sullivan, Robert; Wang, Zhijun
PATENT ASSIGNEE(S): Kemia, Inc., USA
SOURCE: PCT Int. Appl., 316 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005023761	A2	20050317	WO 2004-US29372	20040910
WO 2005023761	A3	20050714		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004270733	A1	20050317	AU 2004-270733	20040910
CA 2538820	AA	20050317	CA 2004-2538820	20040910
US 2005107399	A1	20050519	US 2004-939324	20040910
EP 1670787	A2	20060621	EP 2004-809707	20040910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, SN, TD, TG				
BR 2004014313	A	20061107	BR 2004-14313	20040910
PRIORITY APPL. INFO.:			US 2003-502569P	P 20030911
			US 2003-531234P	P 20031218
			US 2004-575704P	P 20040528
			US 2004-585012P	P 20040702
			WO 2004-US29372	W 20040910

OTHER SOURCE(S): MARPAT 142:316831
GI

L5 ANSWER 18 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
(unsatd.) (heterocyclic) ring; R = H, (substituted) aliphatic; R' = R, (substituted) (unsatd.) (heterocyclic) ring]. Thus, 2-(4-methoxybenzyl)thiazole-4-carboxylic acid, C-[1-(3,4-dimethoxyphenyl)cyclopentyl]methanamine (prepn. given), Et3N, and O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate were stirred together for 16 h in MeCN to give 43.9% 2-(4-methoxybenzyl)thiazole-4-carboxylic acid [1-(3,4-dimethoxyphenyl)cyclopentyl]methanamide. Some I exhibit a relative modulating efficacy of >30%.



IT 852639-48-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Preparation of thiazoles and oxazoles useful as modulators of ATP-binding cassette transporters)
RN 852639-48-6 CAPLUS
CN 4-Oxazolecarboxamide, N-[[1-(3,4-dimethoxyphenyl)cyclopentyl]methyl]-2-phenyl-5-(trifluoromethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 19 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




III

AB Title compds., such as I and II (four Markush structures are claimed), wherein X = C(O), C(S) or CH2; G = (un)substituted carbocyclyl or heterocyclyl; Ar = indazolyl, indolyl, pyrazolyl, alkyl, etc.; L = covalent bond or (un)substituted carbon chain; Q = H, (un)substituted amino, cycloalkyl, heterocyclyl, alkoxy or sulfonyl; with some limitations and exclusions, and stereoisomers, tautomers, solvates, prodrugs and pharmaceutically acceptable salts thereof, were prepared as cytokine inhibitors. For instance, cyclization of p-tolylhydrazine hydrochloride with 4,4-dimethyl-3-oxopentenenitrile to the corresponding pyrazolamine (92% yield) followed by EDC-mediated coupling with indazole-3-carboxylic acid gave indazolepyrazole III (40% yield). I were found to have activity in the TNFα ELISA assay, with some compds. having IC50 < 10 μM. Therefore, I and their pharmaceutical compns. are useful in preventing or treating conditions mediated by cytokines, such as arthritis and inflammatory diseases.

IT 21256-18-8, Oxaprozin
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(compns. comprising of: preparation of amides of pyrazolamines and anilines as well as analogs as cytokine inhibitors)

RN 21256-18-8 CAPLUS
CN 2-Oxazolepropanoic acid, 4,5-diphenyl- (9CI) (CA INDEX NAME)




L5 ANSWER 20 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:158537 CAPLUS
DOCUMENT NUMBER: 142:233351
TITLE: Methods using PPARy agonists for the treatment of Parkinson's disease
INVENTOR(S): Landreth, Gary; Combs, Colin; Hirsch, Ettiene; Heneka,
Michael; Breidert, Tilo
PATENT ASSIGNEE(S): Case Western Reserve University, USA
SOURCE: PCT Int. Appl., 80 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016339	A1	20050224	WO 2003-US23082	20030724
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003254146	A1	20050307	AU 2003-254146	20030724
PRIORITY APPLN. INFO.:			WO 2003-US23082	A 20030724

AB The invention discloses methods and compns. for treating Parkinson's disease and for treating subjects susceptible to Parkinson's disease. In particular, the invention provides agents that slow the progression of dopaminergic neuron loss in the substantia nigra, and that reduce the inflammatory responses of microglial cells and astrocytes in the substantia nigra. Compds. of the invention include PPARy agonists. Preparation of e.g. an indole-5-acetic acid derivative is included.

IT 196808-45-4, Fargilitazar 196809-22-0, GW7845
RI: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(PPARy agonists for treatment of Parkinson's disease)
RN 196808-45-4 CAPLUS
CN L-Tyrosine,
N-(2-benzoylphenyl)-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 21 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2005:140811 CAPLUS
DOCUMENT NUMBER: 142:240429
TITLE: Five-membered heterocycle derivatives useful as monoamine oxidase inhibitors, lipid peroxidation inhibitors, and sodium channel modulators, and the production thereof, and use thereof as medicaments
INVENTOR(S): Chabrier De Laussaniers, Pierre-etienne; Hammett, Jeremiah; Bigg, Dennis; Liberatore, Ann-Marie;
Pommier,
Jacques; Lannoy, Jacques; Thuriereau, Christophe; Dong, Zheng Xin
PATENT ASSIGNEE(S): U.S. Pat. Appl. Publ., 154 pp., Cont.-in-part of U.S. Ser. 681,002.
SOURCE: CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005028087	A1	20050217	US 2004-915001	20040810
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		
FR 2812546	A1	20020208	FR 2000-10151	20000801
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
WO 2001026656	A3	20020418		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
EP 1228760	A2	20020807	EP 2002-76763	20001010
EP 1228760	A3	20040128		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
EP 1589007	A2	20051026	EP 2005-76749	20001010
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CY			
FR 2823208	A1	20021011	FR 2001-4943	20010410
FR 2823208	B1	20040319		
WO 2002083656	A2	20021024	WO 2002-FR1218	20020409
WO 2002083656	A3	20030103		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
ZA 2003007750	A	20040726	ZA 2003-7750	20031003
US 2004132789	A1	20040708	US 2003-681002	20031008
WO 2005035510	A1	20050421	WO 2004-FR2537	20041008

L5 ANSWER 20 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
RN 196809-22-0 CAPLUS
CN L-Tyrosine, N-[2-(methoxycarbonyl)phenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L5 ANSWER 21 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1675836 A1 20060705 EP 2004-791489 20041008
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
PRIORITY APPLN. INFO.:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 1999-12643	A	19991011		
FR 2000-10151	A	20000801		
FR 2000-11169	A	20000901		
WO 2000-FR2805	W	20001010		
FR 2001-4943	A	20010410		
FR 2002-1811	A	20020214		
US 2002-89993	A2	20020404		
WO 2002-FR1218	A1	20020409		
US 2003-681002	A2	20031008		
EP 2000-967988	A3	20001010		
US 2004-915001	A	20040810		
WO 2004-FR2537	W	20041008		

OTHER SOURCE(S): MARPAT 142:240429
GI



AB The invention relates to pharmaceutical use of heterocyclic compds. of general formula Het(A)(B)-(CH₂)_n-CR₁R₂-Q (I; wherein the substituted heterocyclic ring Het(A)(B) = Q1-Q4; A = various aryl or heteroaryl systems, especially a substituted Ph or biphenyl radical, or also alkyl, cycloalkyl, or cycloalkylalkyl; B = especially H or alkyl, or also aryl or substituted alkyl; X = especially NH or S, or also substituted NH; Y = O or S; n = 0-6; R₁, R₂ = especially H, alkyl, or cycloalkyl; Q = NR₃R₄ or OR₅; R₃ and R₄ = especially H, alkyl, cycloalkyl, alkynyl, cyanoalkyl, alkoxyalkyl, aralkoxyalkyl or (cycloalkyl)alkoxyalkyl; R₅ = H, alkyl, alkynyl, or cyanoalkyl]. I and their racemates, enantiomers, and/or salts can be used for producing medicaments for inhibiting monoamine oxidases (MAO), inhibiting lipid peroxidn., and/or for acting as modulators of sodium channels. The resulting medicaments are particularly for use in treating neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, or pain. Approx. 500 synthetic examples of I and their salts are given, and numerous free bases of I are claimed. For instance, protection of sarcosinamide-HCl with BOC anhydride gave 72% BOC-N(Me)CH₂CONH₂, which was converted to the thioamide with (P2S5)₂ in 65% yield. Cyclocondensation of the thioamide with 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (28%), followed by deprotection (73%) and salfication (92%), gave thiazole derivative II as the HCl salt. II inhibited binding of the MAO-B specific ligand [3H]-Ro-19-6327 to rat mitochondrial preps. with IC₅₀ < 10 μM. Selected I also inhibited formation of malondialdehyde by lipid peroxidn. in rat cerebral cortex preps., and inhibited specific binding of [3H]-batrachotoxin to voltage-dependent

ACCESSION NUMBER: 2004:1037064 CAPLUS
DOCUMENT NUMBER: 142:736
TITLE: Heterocyclic compounds and uses thereof
INVENTOR(S): Lockhart, David J.; Patel, Hitesh K.; Mehta, Shamal Anil; Milanov, Zdravko V.; Grotzfeld, Robert M.; Lai, Andilly G.
PATENT ASSIGNEE(S): Ambit Biosciences Corporation, USA
SOURCE: PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004103959	A2	20041202	WO 2004-US15542	20040517
WO 2004103959	A3	20050506		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004242673	A1	20041202	US 2004-847897	20040517
US 2004248972	A1	20041209	US 2004-848515	20040517
US 2004248957	A1	20041209	US 2004-848521	20040517
PRIORITY APPLN. INFO.:				
			US 2003-471425P	P 20030516
			US 2003-480289P	P 20030620
			US 2003-480475P	P 20030620
			US 2003-488172P	P 20030716
			US 2003-488178P	P 20030716
			US 2003-516610P	P 20031030
			US 2003-516616P	P 20031030
			US 2003-516651P	P 20031030

OTHER SOURCE(S): MARPAT 142:736


AB The invention provides compds. having the imidazole, oxazole, or thiazole skeleton and uses thereof. The compds. described herein bind to phosphodiesterase 6D. The compds. disclosed herein can be used to modulate the activity of phosphodiesterase 6. The invention provides methods of using the compds. and/or compns. in the treatment of a variety of diseases and unwanted conditions in subjects. Kits comprising the compds. of the invention are also provided.

IT 21256-18-8
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(heterocyclic PD6 inhibitors for cancer inflammation stroke therapy)


IT 206122-78-3, 2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4-oxazoleethanol
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use);
BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
RN 206122-78-3 CAPLUS
CN 4-Oxazoleethanol, 2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]- (9CI)
(CA INDEX NAME)



IT 206123-20-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxidn. inhibitors, and sodium channel modulators)
RN 206123-20-8 CAPLUS
CN 4-Oxazoleethanol, 2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]- (9CI)
(CA INDEX NAME)




RN 21256-18-8 CAPLUS
CN 2-Oxazolepropanoic acid, 4,5-diphenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 23 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2004:857547 CAPLUS
DOCUMENT NUMBER: 141:350174
TITLE: Preparation of benzaldehyde or heterocycle
carboxaldehyde hydrazone derivatives as inhibitors of
agglutination and/or deposition of an amyloid protein or
amyloid-like protein
INVENTOR(S): Kawagoe, Keiichi; Motoki, Kayoko; Odagiri, Takashi;
Suzuki, Nobuyuki; Chen, Chun-Jen; Mimura, Tetsuya
PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan
SOURCE: PCT Int. Appl., 236 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004087641	A1	20041014	WO 2004-JP4607	20040331
W: AL, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, AY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2521056	AA	20041014	CA 2004-2521056	20040331
EP 1612204	A1	20060104	EP 2004-724752	20040331
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
PRIORITY APPLN. INFO.: JP 2003-94257			A 20030331	
			WO 2004-JP4607	W 20040331

OTHER SOURCE(S): MARPAT 141:350174
GI




AB Comps. represented by the general formula (I), salts thereof, or solvates
of either[R1, R2 = H, alkyl, alkenyl, alkynyl, aralkyl, NH2, alkylamino, cyano, halo, haloalkyl, haloalkenyl, haloalkynyl, CO2H, alkoxycarbonyl, CONH2, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-hydroxyalkylcarbamoyl, each (un)saturated aryl, (un)saturated 5- to 7-membered heterocyclyl, (un)saturated bi- or tricyclic condensed heterocyclyl, arylalkenyl, (un)saturated heterocyclylalkenyl, or (un)saturated bi- or tricyclic condensed heterocyclylalkenyl; R3 = H, (un)saturated alkyl, acyl, alkoxycarbonyl; Ar = a divalent group derived from aromatic hydrocarbon, (un)saturated 5- to

L5 ANSWER 23 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 774236-71-4 CAPLUS
CN 4-Pyridinecarboxaldehyde, [4-[(4-hydroxymethyl)-5-oxazolyl]phenyl]hydrazone (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT


L5 ANSWER 23 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
7-membered heterocyclic group, or (un)satd. bi- or tricyclic condensed heterocyclic group; X = a single bond, a single bond, each
(un)satd. bi- or tricyclic condensed heterocyclic group; X = a single bond, a single bond, each
CO: linear or branched C1-3 alkylene, C1-3 alkenylene, or C1-3 alkynylene,
G = halo, haloalkyl, haloalkenyl, haloalkynyl, alkoxy, alkoxycarbonyl, N-alkylamino, N,N-dialkylamino, each (un)satd. bi- or tricyclic condensed heterocyclic group, (un)satd. 5- to 7-membered heterocyclyl, or (un)satd. bi- or tricyclic heterocyclyl are prepd. Also disclosed is (1) an agent for inhibiting the agglutination and/or deposition of an amyloid protein or amyloid-like protein or (2) a preventive and/or remedy for conformational diseases or diseases caused by amyloid accumulation, which contains the compd. I, its salt, or solvate thereof. In particular, disclosed is a preventive and/or remedy for Alzheimer's disease, Down's syndrome, Creutzfeldt-Jakob disease, type II diabetes, dialysis amyloidosis, AA amyloidosis, Gerstmann-Strausler-Scheinker (GSS) syndrome, Muckle-Wells syndrome, localized atrial amyloidosis, thyroid medullary carcinoma, skin amyloidosis, localized tuberous amyloidosis, AL amyloidosis, AM amyloidosis, familial Mediterranean fever, Parkinson's disease, tauopathy, ALS, or CAG repeat disease. A radiocontrast agent contg. radionuclide-labeled, in particular radioactive iodine-labeled compd. I is also disclosed. Thus, 1.0 g 4-(oxazol-5-yl)phenylhydrazine and 0.61 g 4-pyridinecarboxaldehyde were heated in ethanol at reflux overnight to give, after recrystn. from ethanol, 1.03 g 4-pyridinecarboxaldehyde N-[4-(oxazol-5-yl)phenyl]hydrazone (II). II inhibited the formation of amyloid from amyloid β protein with IC50 of 2.94 μ M vs. 0.87 and 3.23 μ M for Congo Red and 2-(1,1-dicyanopropen-2-yl)-6-dimethylaminonaphthalene (DDNP), resp.
IT 774236-70-3P 774236-71-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of benzaldehyde or heterocycle carboxaldehyde hydrazone derivs. as inhibitors of agglutination and/or deposition of amyloid protein or amyloid-like protein)
RN 774236-70-3 CAPLUS
CN Hydrazinecarboxylic acid, [4-[(4-(hydroxymethyl)-5-oxazolyl]phenyl]-(4-pyridinyl)methylene-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

L5 ANSWER 24 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2004:550745 CAPLUS
DOCUMENT NUMBER: 141:106475
TITLE: Preparation of 5-membered heterocycle derivatives for treating neurodegenerative disorders or pain
INVENTOR(S): Chabrier De Lassunier, Pierre-Etienne; Harnett, Jeremiah; Bagg, Dennis; Liberatore, Anne-Marie; Pommier, Jacques; Lannoy, Jacques; Thureau, Christophe
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 150 pp., Cont.-in-part of U.S. Ser. No. 89,993.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004132788	A1	20040708	US 2003-681002	20031008
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		
FR 2812546	A1	20020208	FR 2000-10151	20000801
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
WO 2001026656	A3	20020418		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1228760	A2	20020807	EP 2002-76763	20001010
EP 1228760	A3	20040128		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
EP 1589007	A2	20051026	EP 2005-76749	20001010
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CY				
FR 2823208	A1	20021011	FR 2001-4943	20010410
FR 2823208	B1	20040319		
ZA 2003007750	A	20040726	ZA 2003-7750	20031003
US 2005038087	A1	20050217	US 2004-915001	20040810
WO 2005035510	A1	20050421	WO 2004-FR2537	20041008
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, AY, BG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1675836	A1	20060705	EP 2004-791489	20041008
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				

L5 ANSWER 24 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 PRIORITY APPLN. INFO.: FR 1999-12643 A 19991011
 FR 2000-10151 A 20000801
 FR 2000-11169 A 20000901
 WO 2000-FR2805 W 20001010
 FR 2001-4943 A 20010410
 FR 2002-1811 A 20020214
 US 2002-89993 A2 20020404
 EP 2000-967988 A3 20001010
 WO 2002-FR1218 A1 20020409
 US 2003-681002 A2 20031008
 US 2004-915001 A 20040810
 WO 2004-FR2537 W 20041008

OTHER SOURCE(S): MARPAT 141:106475
 GI




AB The invention relates to thiazole, oxazole, imidazole, isoxazole and isoxazoline derivs. of general formula (I) [wherein Het = thiazole, oxazole, imidazole, isoxazole or isoxazoline; n = an integer from 0 to 6; A = optionally substituted aromatic radical; B = H, alkyl, Ph; R1, R2 = alkyl, cycloalkyl; Ω = NR46R47 or OR48; R46, R47 = H, alkyl, cycloalkyl, (CH2)k-CO2R51; R51 = alkyl, haloalkyl; R48 = H, alkyl].

These compds. have advantageous pharmacol. properties which allow their use in a medicament intended to inhibit monoamine oxidases (MAO) and/or lipidic peroxidn. and/or to act as modulators of the sodium channels and notably their use in therapeutics for treating (1) central or peripheral nervous system, (2) neurodegenerative disorders selected from Parkinson's disease, Alzheimer's disease, Huntington's chorea and amyotrophic lateral sclerosis or (3) pain selected from the group consisting of postoperative pain, migraine, neuropathic pain, central pain, chronic inflammatory pain and pain linked to a cancer. Thus, 2-[[[(1,1-dimethylethoxy)carbonyl]methyl]amino]ethanethioamide (4.5 g, 2.11 mmol) and 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (6.9 g, 2.11 mmol) were dissolved in 75 mL benzene under argon atmospheric and stirred at


L5 ANSWER 25 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:452952 CAPLUS
 DOCUMENT NUMBER: 141:1296
 TITLE: Method of using a cyclooxygenase 2 (COX-2) inhibitor and a 5-HT1A receptor modulator as a combination therapy for pain, inflammation, and other conditions
 INVENTOR(S): Stephenson, Diane T.; Taylor, Duncan P.
 PATENT ASSIGNEE(S): Pharmacia Corporation, USA
 SOURCE: PCT Int. Appl., 195 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004045509	A2	20040603	WO 2003-US35739	20031111
WO 2004045509	A3	20040826		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RU, SC, SE, SG, SK, SL, SJ, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,				
TG				
US 2004147581	A1	20040729	US 2003-702403	20031105
AU 2003295431	A1	20040615	AU 2003-295431	20031111
PRIORITY APPLN. INFO.: US 2002-427198P P 20021118				
WO 2003-US35739 W 20031111				


AB Compns. and methods to treat or prevent pain, inflammation, or inflammation-related disorder, as well as a neuropathic disorder involving neurodegeneration involve a combination of a COX-2 inhibitor and a 5-HT1A receptor modulator.
 IT 21256-18-8, Oxaprozin
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (COX2 inhibitor-5-HT1A modulator combination for treatment of pain, inflammation, and other conditions)
 RN 21256-18-8 CAPLUS
 CN 2-Oxazolepropanoic acid, 4,5-diphenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 24 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 ambient temp. for 12 h to give, after workup and silica gel chromatog., 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-[(1,1-dimethylethoxy)carbonyl]-N-methyl-2-thiazolemethanamine which was treated with CF3COOH and triethylsilane in 50 mL CH2Cl2 to give, after workup, 4-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-N-methyl-2-thiazolemethanamine (II). II showed IC50 of lower than 10 μ M for inhibiting lipid peroxidn. of the cerebral cortex of rats.
 IT 206122-78-3P, 2-[3,5-Bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4-oxazoleethanol 206123-20-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of 5-membered heterocycle derivs. for treating diseases of central or peripheral nervous system, neurodegenerative disorders, or pain)
 RN 206122-78-3 CAPLUS
 CN 4-Oxazoleethanol, 2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




RN 206123-20-8 CAPLUS
 CN 4-Oxazoleethanol, 2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 26 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:119765 CAPLUS
 DOCUMENT NUMBER: 140:169654
 TITLE: Oral pharmaceutical formulations containing alkaline agents and binders
 INVENTOR(S): Kositprapa, Unchalee
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 9 pp., Cont.-in-part of U.S. Ser. No. 597,206.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004028735	A1	20040212	US 2003-634321	20030804
US 6096340	A	20000801	US 1997-970489	19971114
US 6174548	B1	20010116	US 1998-143167	19980828
US 6077541	A	20000620	US 1999-335575	19990618
US 6602522	B1	20030805	US 2000-597206	20000620
US 2003113376	A1	20030619	US 2002-279622	20021023
US 6780435	B2	20040824		
PRIORITY APPLN. INFO.: US 1997-970489 A3 19971114				
US 1998-143167 A2 19980828				
US 1999-335575 A2 19990618				
US 2000-597206 A2 20000620				
US 2000-607293 B1 20000630				


AB An oral pharmaceutical formulation, e.g., a tablet core, contains an uncoated granule of a drug, an optional surfactant, an alkaline agent and a combination of a water-soluble binder and a water-insol. binder. The controlled release of drugs is achieved by way of the water soluble and water insol. binders. The formulation for making granules contained: Rudragit NE30D 33.0, Plasdone K30 98.0, sodium lauryl sulfate 6.0, Avicel PH102 1439.0, felodipine 244.0, and water 1600.0 g. The granules were formed into tablets by compressing felodipine granules 160.7, glyceryl monostearate 13.5, Crospovidone 79.6, and Avicel PH101 16.2 g.
 IT 21256-18-8, Oxaprozin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (oral pharmaceutical formulations containing alkaline agents and binders)
 RN 21256-18-8 CAPLUS
 CN 2-Oxazolepropanoic acid, 4,5-diphenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 27 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2004:41465 CAPLUS
 DOCUMENT NUMBER: 140:111414
 TITLE: Preparation of imidazolpyrimidines and related compounds as JNK protein kinase inhibitors
 INVENTOR(S): Ledebner, Mark; Wang, Jian; Moon, Young Choom
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 129 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004005283	A1	20040115	WO 2003-US21524	20030709
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SI, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2491895	AA	20040115	CA 2003-2491895	20030709
AU 2003247959	A1	20040123	AU 2003-247959	20030709
US 2004097531	A1	20040520	US 2003-616560	20030709
EP 1554269	A1	20050720	EP 2003-763424	20030709
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006506330	T2	20060223	JP 2004-520090	20030709
PRIORITY APPLN. INFO.:			US 2002-395202P	F 20020709
			WO 2003-US21524	W 20030709

OTHER SOURCE(S): MARPAT 140:111414
 GI




AB Title compds. I [W = N, CH; G = H, alkyl with provisos; A = O, S, N-Tn-R; R = H, (un)substituted aliphatic; T = alkylidene chain wherein one methylene unit is optionally replaced by CO, CO₂, CONH, etc.; n = 0, 1; R₁ = Tn-R, Tn-Ar₁; Ar₁ = 3-7 membered monocyclic saturated, partially saturated or aromatic ring; R₂ = Qn-Ar₂; Q = alkylidene chain with provisos; Ar₂ = 3-7 membered monocyclic saturated, partially saturated or aromatic ring] and their pharmaceutically acceptable salts and formulations were prepared For example, condensation of enone II, e.g., prepared from 4-methoxybut-3-en-2-one in 3-steps, and N-(4-fluorophenyl)guanidine afforded imidazolpyrimidine III in 56% yield. In human JNK3 protein kinase inhibition assays, 36-examples of compds. I exhibited K_i values ranging from 0.1->1.0 μM. Compds. I are claimed useful as inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli.

IT 191925-66-3P, 1-(2-Phenyl-5-oxazol-5-yl)ethanone 647031-08-1P, 3-Dimethylamino-1-(2-phenyl-5-oxazol-5-yl)propanone
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of imidazolpyrimidines and related compds. as JNK protein kinase inhibitors)
 RN 191925-66-3 CAPLUS
 CN Ethanone, 1-(2-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)



RN 647031-08-1 CAPLUS
 CN 2-Propen-1-one, 3-(dimethylamino)-1-(2-phenyl-5-oxazolyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L5 ANSWER 28 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:855795 CAPLUS
DOCUMENT NUMBER: 139:345939
TITLE: Monotherapy for the treatment of Parkinson's
disease with cyclooxygenase 2 (COX2) inhibitor(s)
INVENTOR(S): Stephenson, Diane T.; Isakson, Peter C.; Maziasz,
Timothy J.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 186 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003088959	A2	20031030	WO 2003-US11517	20030414
WO 2003088959	A3	20031231		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2482510	AA	20031030	CA 2003-2482510	20030414
AU 2003226379	A1	20031103	AU 2003-226379	20030414
US 2004006100	A1	20040108	US 2003-412970	20030414
BR 200309337	A	20050215	BR 2003-9337	20030414
EP 1505962	A2	20050216	EP 2003-746984	20030414
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005532293	T2	20051027	JP 2003-585711	20030414
PRIORITY APPLN. INFO.:			US 2002-373317P	P 20020418
			WO 2003-US11517	W 20030414


OTHER SOURCE(S): MARPAT 139:345939
AB The invention provides a method for treating, preventing, or inhibiting Parkinson's disease (PD), in a subject in need of such treatment, inhibition or prevention. The method comprises treating the subject with one or more COX2 selective inhibitor(s), ester(s), salt(s) or prodrug(s) thereof, wherein the amount of the cyclooxygenase-2 selective inhibitor(s), ester(s), salt(s) or prodrug(s) thereof constitutes a PD treatment-, inhibition- or prevention-effective amount of the COX2 inhibitor(s).
IT 163303-38-6 163303-55-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cyclooxygenase 2 (COX2) inhibitor for treatment of Parkinson's disease)
RN 163303-38-6 CAPLUS
CN 2-Oxazoleacetic acid, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 29 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2003:855794 CAPLUS
DOCUMENT NUMBER: 139:345938
TITLE: Combination therapy including cyclooxygenase 2 (COX2) inhibitor(s) for the treatment of Parkinson's disease
INVENTOR(S): Stephenson, Diane T.; Isakson, Peter C.; Maziasz, Timothy J.
PATENT ASSIGNEE(S): Pharmacia Corporation, USA.
SOURCE: PCT Int. Appl., 266 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003088958	A2	20031030	WO 2003-US11269	20030414
WO 2003088958	A3	20040819		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2481934	AA	20031030	CA 2003-2481934	20030414
AU 2003223579	A1	20031103	AU 2003-223579	20030414
US 2004034083	A1	20040219	US 2003-413348	20030414
EP 1494664	A2	20050112	EP 2003-719717	20030414
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 200309259	A	20050209	BR 2003-9259	20030414
JP 2005528403	T2	20050922	JP 2003-585710	20030414
PRIORITY APPLN. INFO.:			US 2002-373311P	P 20020418
			WO 2003-US11269	W 20030414

OTHER SOURCE(S): MARPAT 139:345938
AB The invention discloses a method for treating, preventing, or inhibiting Parkinson's disease (PD) in a subject in need of such treatment, inhibition, or prevention. The method comprises treating the subject with one or more COX2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof, in combination with one or more second drugs, wherein the amount of the COX2 selective inhibitor(s) or isomer(s) or pharmaceutically acceptable salt(s), ester(s), or prodrug(s) thereof in combination with the amount of second drug(s) constitutes a PD treatment-, inhibition- or prevention-effective amount.
IT 163303-38-6 163303-55-7
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination therapy including cyclooxygenase 2 inhibitor for treatment of Parkinson's disease)
RN 163303-38-6 CAPLUS


L5 ANSWER 28 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)




RN 163303-55-7 CAPLUS
CN 2-Oxazoleacetic acid, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-α-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 29 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
CN 2-Oxazoleacetic acid, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-α-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)





RN 163303-55-7 CAPLUS
CN 2-Oxazoleacetic acid, 4-(4-fluorophenyl)-5-[4-(methylsulfonyl)phenyl]-α-(phenylmethyl)-, ethyl ester (9CI) (CA INDEX NAME)



L5 ANSWER 30 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2003:610420 CAPLUS
 DOCUMENT NUMBER: 139:164713
 TITLE: Preparation of isoquinoline derivatives as phosphodiesterase (PDE) 7 inhibitors
 INVENTOR(S): Ohhata, Akira; Takaka, Yoshikazu; Ogawa, Mikio;
 NAKAI, Hisao; Yamamoto, Susumu; Ochiai, Hiroshi
 PATENT ASSIGNEE(S): Ono Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 665 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003064389	A1	20030807	WO 2003-JP877	20030130
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, ME, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005222138	A1	20051006	US 2004-502884	20040730
PRIORITY APPLN. INFO.:			JP 2002-23845	A 20020131
			JP 2002-23846	A 20020131
			WO 2003-JP877	W 20030130

OTHER SOURCE(S): MARPAT 139:164713
 GI



AB The title compds. with general formula of I (wherein R1 and R2 = independently H or alkyl; or R1 and R2 together form a ring with the

L5 ANSWER 30 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 carbon atom attached; Z = O, S, a single bond, or (un)substituted CH2; R5 and R6 = independently H or alkyl; or R5 and R6 together form a ring with the carbon atom attached; R7 and R8 = independently H, OH, CN, halo, cyclyl, alkynyl, NO2, CHO, acyl, alkylthio, O-cyclyl, (un)substituted CO2H, CONH2, NH2, alkyl, NHCOR, NHCOR2, SO2NH2, alkenyl, CH=NOH, alkylene-NH-alkylene-H, alkoxy, or OSO2H; R9 = none or H; with provisos] and pharmaceutically acceptable salts thereof are prepd. For example,

the compd. II was prepd. in a multi-step synthesis. II showed IC50 of 0.023 µM against human phosphodiesterase 7. I are useful in preventing and/or treating various diseases, namely, autoimmune diseases, inflammatory diseases, allergic diseases, rejection in organ transplantation, severe graft vs. host disease (GVHD), diabetic diseases, osteoporosis, bone fracture, restenosis, atheroma arteriosclerosis, obesity, ischemic reperfusion injury, depression, Parkinson's disease, dementia, leukemia, etc. (no data). Formulations contg. I as an active ingredient were also described.


IT 575434-85-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of isoquinoline derivs. as phosphodiesterase (PDE) 7 inhibitors)

RN 575434-85-4 CAPLUS

CN Ethanone, 2-(3,4-dihydro-3,3-dimethyl-1(2H)-isoquinolinylidene)-1-(5-methyl-2-phenyl-4-oxazolyl)-, (2Z)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L5 ANSWER 31 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2003:376867 CAPLUS
 DOCUMENT NUMBER: 138:368782
 TITLE: Preparation of N-(azabicycyl)arylamides for therapeutic use as nicotinic acetylcholine receptor agonists
 INVENTOR(S): Piotrowski, David W.; Myers, Jason K.; Rogers, Bruce N.; Jacobsen, E. Jon; Bodnar, Alice L.; Groppi, Vincent E., Jr.; Walker, Daniel P.; Acker, Brad A.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 166 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040147	A1	20030515	WO 2002-US33618	20021106
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SC, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2466375	AA	20030515	CA 2002-2466375	20021106
US 2003207913	A1	20031106	US 2002-288863	20021106
US 6919359	B2	20050719		
EP 1442041	A2	20040804	EP 2002-793805	20021106
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002014031	A	20041019	BR 2002-14031	20021106
JP 2005511613	T2	20050428	JP 2003-542193	20021106
PRIORITY APPLN. INFO.:			US 2001-336977P	P 20011108
			US 2001-350108P	P 20011113
			US 2002-357906P	P 20020219
			US 2002-358142P	P 20020219
			US 2002-358159P	P 20020219
			WO 2002-US33618	W 20021106

OTHER SOURCE(S): MARPAT 138:368782
 GI

L5 ANSWER 31 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB N-(azabicycyl)arylamides, such as RNRIC(X)W [R = azabicycyl; R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; W = heteroaryl; X = O, S], were prepared

for therapeutic use as nicotinic acetylcholine receptor agonists. These amides are useful for the treatment of central nervous system disorders, such as cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy

Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la

Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Thus, the fumarate salt of amide I was prepared via a multistep synthetic sequence which included intramol. cyclization of trans-3-(tert-butoxycarbonylamino)-4-(2-hydroxyethyl)-1-(phenylmethyl)pyrrolidine to form exo-3-(tert-butoxycarbonylamino)-1-azabicyclo[2.2.1]heptane, which contains the target azabicyclic ring, and subsequent amidation of the corresponding azabicyclic amine with 5-bromothiophene-2-carboxylic acid. The prepared amides were assayed for human α7-5HT3 receptor binding activity.

IT 524013-17-0P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)


(preparation of N-(azabicycyl)arylamides for therapeutic use as nicotinic

acetylcholine receptor agonists)


RN 524013-17-0 CAPLUS

CN 2-Oxazolecarboxamide, 5-(4-aminophenyl)-N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 524012-60-0P 524012-90-6P 524012-91-7P
 524012-96-2P 524012-98-4P 524013-07-8P
 524013-09-0P 524013-10-3P 524013-32-9P
 524014-17-3P 524014-18-4P 524014-19-5P
 524014-20-8P 524014-21-9P 524014-22-0P
 524014-23-1P 524014-24-2P 524014-25-3P
 524014-26-4P 524014-27-5P 524014-28-6P
 524014-29-7P 524014-30-0P 524014-31-1P
 524014-32-2P 524014-33-3P 524014-34-4P
 524014-35-5P 524014-36-6P 524014-37-7P
 524014-38-8P 524015-17-6P 524015-18-7P
 524015-19-8P 524015-20-1P 524015-21-2P
 524015-22-3P 524015-23-4P 524015-25-6P
 524015-26-7P 524015-28-9P 524015-29-0P
 524015-30-3P 524015-32-5P 524015-34-7P
 524015-36-9P 524015-38-1P 524015-40-5P
 524015-42-7P 524015-44-9P 524015-46-1P
 524015-48-3P 524015-50-7P 524015-51-8P
 524015-53-0P 524016-41-9P 524016-42-0P
 524016-43-1P 524016-44-2P 524016-46-4P
 524016-47-5P 524016-48-6P 524016-50-0P
 524016-51-1P 524016-53-3P 524016-55-5P
 524016-57-7P 524016-59-9P 524016-61-3P
 524016-63-5P 524016-65-7P 524016-67-9P
 524016-69-1P 524016-71-5P 524016-73-7P
 524016-75-9P 524016-77-1P 524016-79-3P
 524016-80-6P 524016-81-7P 524017-71-8P
 524017-72-9P 524017-73-0P 524017-74-1P
 524017-75-2P 524017-76-3P 524017-77-4P
 524017-78-5P 524017-79-6P 524017-80-9P
 524017-81-0P 524017-82-1P 524017-83-2P
 524017-84-3P 524017-85-4P 524017-86-5P
 524017-87-6P 524017-88-7P 524017-89-8P
 524017-90-1P 524017-91-2P 524017-92-3P
 524017-93-4P 524017-94-5P 524017-95-6P
 524697-93-6P 524697-94-7P 524697-95-8P
 524697-96-9P 524697-97-0P 524697-98-1P
 524697-99-2P 524698-00-8P 524698-01-9P
 524698-02-0P 524698-03-1P 524698-04-2P
 524698-05-3P 524698-06-4P 524698-07-5P
 524698-08-6P 524698-09-7P 524698-10-0P
 524698-11-1P 524698-12-2P 524698-14-4P
 524698-16-6P 524698-18-8P 524698-19-9P
 524698-20-2P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU




CH 2
 CRN 110-17-8
 CMF C4 H4 O4

Double bond geometry as shown.



RN 524012-96-2 CAPLUS
 CN 2-Oxazolocarbonyl, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-phenyl-,
 rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 524012-98-4 CAPLUS
 CN 2-Oxazolocarbonyl, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-phenyl-,
 monohydrochloride, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.


L5 ANSWER 31 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (prep. of N-(azabicyclo[2.2.1]hept-3-yl-5-phenyl-3-aminocarbonyl)
 acetylcholine receptor agonists)
 RN 524012-60-0 CAPLUS
 CN 2-Oxazolocarbonyl, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-phenyl-,
 chlorophenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 524012-90-6 CAPLUS
 CN 2-Oxazolocarbonyl, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-phenyl-,
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524012-91-7 CAPLUS
 CN 2-Oxazolocarbonyl, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-phenyl-,
 (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CH 1

CRN 524012-90-6
 CMF C16 H17 N3 O2


Absolute stereochemistry.



● HCl

RN 524013-07-8 CAPLUS
 CN 2-Oxazolocarbonyl, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-phenyl-,
 monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 524013-09-0 CAPLUS
 CN 2-Oxazolocarbonyl, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-phenyl-,
 (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524013-10-3 CAPLUS
 CN 2-Oxazolocarbonyl, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-,
 (2E)-2-butenedioate (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 524013-09-0
CMF C19 H22 N4 O3


Absolute stereochemistry.



CM 2


CRN 110-17-8
CMF C4 H4 O4

Double bond geometry as shown.




RN 524013-32-9 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-phenyl-2-oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-phenyl-2-oxazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-17-3 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(2-fluorophenyl)-2-oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(2-fluorophenyl)-2-oxazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-21-9 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(3-chlorophenyl)-2-oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(3-chlorophenyl)-2-oxazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-22-0 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(4-chlorophenyl)-2-oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(4-chlorophenyl)-2-oxazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-23-1 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(2-methoxyphenyl)-2-oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(2-methoxyphenyl)-2-oxazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-18-4 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(3-fluorophenyl)-2-oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(3-fluorophenyl)-2-oxazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-19-5 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(4-fluorophenyl)-2-oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(4-fluorophenyl)-2-oxazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-20-8 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(2-chlorophenyl)-2-oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(2-chlorophenyl)-2-oxazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-24-2 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(3-methoxyphenyl)-2-oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(3-methoxyphenyl)-2-oxazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-25-3 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(4-methoxyphenyl)-2-oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(4-methoxyphenyl)-2-oxazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-26-4 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(2-methylphenyl)-2-oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(2-methylphenyl)-2-oxazolecarboxamide (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-27-5 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(3-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-28-6 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-29-7 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-33-3 CAPLUS
CN 2-Oxazolecarboxamide, 5-(3-aminophenyl)-N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-34-4 CAPLUS
CN 2-Oxazolecarboxamide, 5-[2-(acetylamino)phenyl]-N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-35-5 CAPLUS
CN 2-Oxazolecarboxamide, 5-[2-(acetylamino)phenyl]-N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-30-0 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-31-1 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-32-2 CAPLUS
CN 2-Oxazolecarboxamide, 5-(2-aminophenyl)-N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-36-6 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-[2-((trifluoroacetyl)amino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-37-7 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-[3-((trifluoroacetyl)amino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524014-38-8 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-5-[4-((trifluoroacetyl)amino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-17-6 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-18-7 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-19-8 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-23-4 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-25-6 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-26-7 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-20-1 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-(2-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-21-2 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-(4-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-22-3 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-28-9 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-(3-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-29-0 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-30-3 CAPLUS
CN 2-Oxazolecarboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-32-5 CAPLUS
CN 2-Oxazolecaboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-34-7 CAPLUS
CN 2-Oxazolecaboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-36-9 CAPLUS
CN 2-Oxazolecaboxamide, 5-[2-(4-aminophenyl)]-N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-44-9 CAPLUS
CN 2-Oxazolecaboxamide, 5-[3-(acetylamino)phenyl]-N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-46-1 CAPLUS
CN 2-Oxazolecaboxamide, 5-[4-(acetylamino)phenyl]-N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-48-3 CAPLUS
CN 2-Oxazolecaboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-[2-((trifluoroacetyl)amino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-38-1 CAPLUS
CN 2-Oxazolecaboxamide, 5-(3-aminophenyl)-N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-40-5 CAPLUS
CN 2-Oxazolecaboxamide, 5-(4-aminophenyl)-N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-42-7 CAPLUS
CN 2-Oxazolecaboxamide, 5-[2-(acetylamino)phenyl]-N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-50-7 CAPLUS
CN 2-Oxazolecaboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-[3-((trifluoroacetyl)amino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-51-8 CAPLUS
CN 2-Oxazolecaboxamide, N-(1R,3R,4S)-1-azabicyclo[2.2.1]hept-3-yl-5-[4-((trifluoroacetyl)amino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524015-53-0 CAPLUS
CN 2-Oxazolecaboxamide, N-(3R)-1-azabicyclo[3.2.2]non-3-yl-5-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 524016-41-9 CAPLUS
CN 2-Oxazolecaboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-phenyl- (9CI) (CA INDEX NAME)




RN 524016-42-0 CAPLUS
CN 2-Oxazolecaboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 524016-43-1 CAPLUS
CN 2-Oxazolecaboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 524016-44-2 CAPLUS
CN 2-Oxazolecaboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 524016-50-0 CAPLUS
CN 2-Oxazolecaboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 524016-51-1 CAPLUS
CN 2-Oxazolecaboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 524016-53-3 CAPLUS
CN 2-Oxazolecaboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 524016-46-4 CAPLUS
CN 2-Oxazolecaboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(2-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 524016-47-5 CAPLUS
CN 2-Oxazolecaboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 524016-48-6 CAPLUS
CN 2-Oxazolecaboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 524016-55-5 CAPLUS
CN 2-Oxazolecaboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 524016-57-7 CAPLUS
CN 2-Oxazolecaboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 524016-59-9 CAPLUS
CN 2-Oxazolecaboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 524016-61-3 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 524016-63-5 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 524016-65-5 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 524016-73-7 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-[2-(aminophenyl)]- (9CI) (CA INDEX NAME)




RN 524016-75-9 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-[3-(acetaminophenyl)]- (9CI) (CA INDEX NAME)




RN 524016-77-1 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-[4-(acetaminophenyl)]- (9CI) (CA INDEX NAME)




RN 524016-67-9 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(2-aminophenyl)- (9CI) (CA INDEX NAME)




RN 524016-69-1 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(3-aminophenyl)- (9CI) (CA INDEX NAME)




RN 524016-71-5 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-(4-aminophenyl)- (9CI) (CA INDEX NAME)




RN 524016-79-3 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-[2-(trifluoroacetyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 524016-80-6 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-[3-(trifluoroacetyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 524016-81-7 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-5-yl-5-[4-(trifluoroacetyl)amino]phenyl]- (9CI) (CA INDEX NAME)





RN 524017-71-8 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-phenyl- (9CI) (CA INDEX NAME)




RN 524017-72-9 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-(2-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 524017-73-0 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)



RN 524017-78-5 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 524017-79-6 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-(3-methoxyphenyl)- (9CI) (CA INDEX NAME)




RN 524017-80-9 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)


RN 524017-74-1 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)




RN 524017-75-2 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-(2-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 524017-76-3 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-(3-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 524017-77-4 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 524017-81-0 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-(2-methylphenyl)- (9CI) (CA INDEX NAME)




RN 524017-82-1 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-(3-methylphenyl)- (9CI) (CA INDEX NAME)




RN 524017-83-2 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)




RN 524017-84-3 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 524017-85-4 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 524017-86-5 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)




RN 524017-87-6 CAPLUS
CN 2-Oxazolecarboxamide, 5-(2-aminophenyl)-N-2-azabicyclo[2.2.1]hept-6-yl- (9CI) (CA INDEX NAME)




RN 524017-88-7 CAPLUS
CN 2-Oxazolecarboxamide, 5-(3-aminophenyl)-N-2-azabicyclo[2.2.1]hept-6-yl- (9CI) (CA INDEX NAME)




RN 524017-89-8 CAPLUS
CN 2-Oxazolecarboxamide, 5-(4-aminophenyl)-N-2-azabicyclo[2.2.1]hept-6-yl- (9CI) (CA INDEX NAME)




RN 524017-90-1 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-[2-(aminophenyl)]- (9CI) (CA INDEX NAME)




RN 524017-91-2 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-[3-(acetaminophenyl)]- (9CI) (CA INDEX NAME)




RN 524017-92-3 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-[4-(acetaminophenyl)]- (9CI) (CA INDEX NAME)




RN 524017-93-4 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-[2-[(trifluoroacetyl)amino]phenyl]- (9CI) (CA INDEX NAME)



RN 524017-94-5 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-[3-[(trifluoroacetyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 524017-95-6 CAPLUS
CN 2-Oxazolecarboxamide, N-2-azabicyclo[2.2.1]hept-6-yl-5-[4-[(trifluoroacetyl)amino]phenyl]- (9CI) (CA INDEX NAME)




RN 524697-93-6 CAPLUS
CN 2-Oxazolecarboxamide, N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524697-94-7 CAPLUS
CN 2-Oxazolecarboxamide, 5-(2-fluorophenyl)-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524697-95-8 CAPLUS
CN 2-Oxazolecarboxamide, 5-(3-fluorophenyl)-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524697-99-2 CAPLUS
CN 2-Oxazolecarboxamide, 5-(4-chlorophenyl)-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-00-8 CAPLUS
CN 2-Oxazolecarboxamide, 5-(2-methoxyphenyl)-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-01-9 CAPLUS
CN 2-Oxazolecarboxamide, 5-(3-methoxyphenyl)-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524697-96-9 CAPLUS
CN 2-Oxazolecarboxamide, 5-(4-fluorophenyl)-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524697-97-0 CAPLUS
CN 2-Oxazolecarboxamide, 5-(2-chlorophenyl)-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524697-98-1 CAPLUS
CN 2-Oxazolecarboxamide, 5-(3-chlorophenyl)-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-02-0 CAPLUS
CN 2-Oxazolecarboxamide, 5-(4-methoxyphenyl)-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-03-1 CAPLUS
CN 2-Oxazolecarboxamide, N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-04-2 CAPLUS
CN 2-Oxazolecarboxamide, N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-05-3 CAPLUS
CN 2-Oxazolecaboxamide, N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-06-4 CAPLUS
CN 2-Oxazolecaboxamide, 5-(2-hydroxyphenyl)-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-07-5 CAPLUS
CN 2-Oxazolecaboxamide, 5-(3-hydroxyphenyl)-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-11-1 CAPLUS
CN 2-Oxazolecaboxamide, 5-(4-aminophenyl)-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-12-2 CAPLUS
CN 2-Oxazolecaboxamide, 5-[2-(acetamino)phenyl]-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-14-4 CAPLUS
CN 2-Oxazolecaboxamide, N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-[3-(acetamino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-08-6 CAPLUS
CN 2-Oxazolecaboxamide, 5-(4-hydroxyphenyl)-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-09-7 CAPLUS
CN 2-Oxazolecaboxamide, 5-(2-aminophenyl)-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-10-0 CAPLUS
CN 2-Oxazolecaboxamide, 5-(3-aminophenyl)-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-16-6 CAPLUS
CN 2-Oxazolecaboxamide, 5-[4-(acetamino)phenyl]-N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-18-8 CAPLUS
CN 2-Oxazolecaboxamide, N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-[2-(trifluoroacetyl)amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-19-9 CAPLUS
CN 2-Oxazolecaboxamide, N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-[3-(trifluoroacetyl)amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 524698-20-2 CAPLUS
CN 2-Oxazolecarboxamide, N-((1R,3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl)-5-(4-((trifluoroacetyl)amino)phenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 1014-14-8, 5-Phenyl-1,3-oxazole-2-carboxylic acid
1441-38-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-(azabicycyl)arylamides for therapeutic use as
nicotinic acetylcholine receptor agonists)
RN 1014-14-8 CAPLUS
CN 2-Oxazolecarboxylic acid, 5-phenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 1441-38-9 CAPLUS
CN 2-Oxazolecarboxylic acid, 5-(4-nitrophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




IT 400715-69-7P, Ethyl 5-(3-chlorophenyl)-1,3-oxazole-2-carboxylate
524013-15-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of N-(azabicycyl)arylamides for therapeutic use as
nicotinic acetylcholine receptor agonists)
RN 400715-69-7 CAPLUS
CN 2-Oxazolecarboxylic acid, 5-(3-chlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 524013-15-8 CAPLUS
CN 2-Oxazolecarboxamide, N-((1R,3R,5R)-1-azabicyclo[3.2.1]oct-3-yl)-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2003:242322 CAPLUS
DOCUMENT NUMBER: 138:271968
TITLE: Preparation of (heterocyclylcarbonyl)aspartic acid derivatives as caspase inhibitors
INVENTOR(S): Choong, Ingrid; Burdett, Matthew; Delano, Warren; Erlanson, Daniel A.; Lee, Dennis; Lew, Willard
PATENT ASSIGNEE(S): Sunesis Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 179 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003024955	A2	20030327	WO 2002-US29536	20020917
WO 2003024955	A3	20030814		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003114447	A1	20030619	US 2002-245912	20020917
US 6878743	B2	20050412		
PRIORITY APPLN. INFO.:			US 2001-323270P	P 20010918
			US 2002-371762P	P 20020411


OTHER SOURCE(S): MARPAT 138:271968

GI



L5 ANSWER 32 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 AB The present invention provides aspartic acid derivs. I (R1 = H, aliphatic, heteroaliph., aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl, heteroalkylheteroaryl; n = 0, 1; A, B, D, E, G, = independently CR, CR2, CO, S, NR, NR2, O; J = CR; each R = independently H, halo, OR2, NR22, SR2, CM, CO2R2, COR2, CONR22, SOR2, SO2R2, SO2NR22, NR2SO2R2, O2CNR22, NR2CONR22, NR2CSNR22, NR2SO2NR22, (un)substituted aliphatic, heteroaliph., aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl, heteroalkylheteroaryl; R2 = independently H, halo, OR3, NR32, SR3, CN, CO2R3, COR3, CONR32, SOR3, SO2R3, SO2NR32, NR3SO2R3, O2CNR32, NR3CONR32, NR3CSNR32, NR3SO2NR32, (un)substituted aliphatic, heteroaliph., aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl, heteroalkylheteroaryl; R3 = H, aliphatic, heteroaliph., aryl, heteroaryl, alkylaryl, alkylheteroaryl, heteroalkylaryl, heteroalkylheteroaryl; with provisos] and pharmaceutically acceptable derivs., and pharmaceutical compns. thereof, and methods for the use thereof as caspase inhibitors and for the treatment of disorders caused by excessive apoptotic activity (no data). Thus, Fmoc-Asp(OtBu)-CH2Br (Fmoc = 9-fluorenylmethoxycarbonyl) was coupled with 2-ClC6H4CH2SH to give sulfide Fmoc-Asp(OtBu)CH2SCH2C6H4Cl-2 (II). II was attached to a semicarbazide-derivatized Wang resin, deprotected with piperidine in DMF, coupled with Fmoc-protected aminomethylthiophenecarboxylic acid III, deprotected, and coupled with 5-chlorosulfonyl-2-hydroxybenzoic acid, and cleaved from the resin with CF3CO2H to give inhibitor IV.
 IT 476363-04-9P 476363-31-2P 503470-00-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of (heterocyclylcarbonyl)aspartic acid derivs. as caspase inhibitors)
 RN 476363-04-9 CAPLUS
 CN 2-Oxazolebutanoic acid, β -[[(5-[[[(3-carboxy-4-hydroxyphenyl)sulfonyl]amino]methyl]-3-pyridinyl]carbonyl]amino]-5-(2,6-dichlorophenyl)- γ -oxo-, (BS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 476363-31-2 CAPLUS
 CN 2-Oxazolebutanoic acid, β -[[(5-[[[(3-carboxy-4-hydroxyphenyl)sulfonyl]amino]methyl]-2-thienyl]carbonyl]amino]-5-(2,6-dichlorophenyl)- γ -oxo-, (BS)-(9CI) (CA INDEX NAME)

L5 ANSWER 32 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 503470-02-8 CAPLUS
 CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)- β -[[(5-[[[(1,1-dimethylethoxy)carbonyl]-4-hydroxyphenyl]sulfonyl]amino]methyl]-2-thienyl]carbonyl]amino]- γ -hydroxy-, 1,1-dimethylethyl ester, (BS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 503470-03-9 CAPLUS
 CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)- β -[[(5-[[[(1,1-dimethylethoxy)carbonyl]-4-hydroxyphenyl]sulfonyl]amino]methyl]-2-thienyl]carbonyl]amino]- γ -oxo-, 1,1-dimethylethyl ester, (BS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 32 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

Absolute stereochemistry.




RN 503470-00-6 CAPLUS
 CN 2-Oxazolebutanoic acid, β -amino-5-(2,6-dichlorophenyl)- γ -hydroxy-, 1,1-dimethylethyl ester, (BS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 192582-93-7P 503470-02-8P 503470-03-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of (heterocyclylcarbonyl)aspartic acid derivs. as caspase inhibitors)
 RN 192582-93-7 CAPLUS
 CN 2-Oxazolebutanoic acid, 5-(2,6-dichlorophenyl)- γ -hydroxy- β -[[(2-propenyloxy)carbonyl]amino]-, 1,1-dimethylethyl ester, (BS)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 33 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 2003:173607 CAPLUS
 DOCUMENT NUMBER: 138:204939
 TITLE: Preparation of N-[7-aza[2.2.1]bicycloheptanyl]arylamid es for therapeutic use as nicotinic acetylcholine receptor agonists
 INVENTOR(S): Wislaka, Donn G.; Myers, Jason K.; Rogers, Bruce N.; Jacobsen, Eric Jon; Piotrowski, David W.; Corbett, Jeffrey W.; Bodnar, Alice L.; Groppi, Vincent E., Jr.
 PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
 SOURCE: PCT Int. Appl., 195 pp.
 DOCUMENT TYPE: CODEN: PIXXD2
 LANGUAGE: Patent
 FAMILY ACC. NUM. COUNT: English
 PATENT INFORMATION: 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003018585	A1	20030306	WO 2002-US21326	20020814
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, BT, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003069290	A1	20030410	US 2002-218772	20020814
US 6562816	B2	20030513		
EP 1419161	A1	20040519	EP 2002-759115	20020814
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
BR 2002012101	A	20040824	BR 2002-12101	20020814
JP 2005504058	T2	20050210	JP 2003-523245	20020814
PRIORITY APPLN. INFO.:			US 2001-314768P	P 20010824
			US 2001-314772P	P 20010824
			US 2001-314773P	P 20010824
			US 2001-314851P	P 20010824
			US 2002-388712P	P 20020614
			WO 2002-US21326	W 20020814

OTHER SOURCE(S): MARPAT 138:204939
 GI




AB 7-Aza[2.2.1]bicycloheptane derivs., such as amides I [R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; R2 = H, benzyl, alkyl, haloalkyl, cycloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use as nicotinic acetylcholine receptor agonists. These amides are useful for the treatment of central nervous system disorders, such as cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.

Thus, amide hydrochloride II was prepared via a multistep synthetic sequence which included cycloaddn. of N-tert-butoxycarbonylpyrrole with B.C.tplbond.CO2Me to form the azabicyclic ring, and subsequent amidation reaction of tert-Bu (1S,2R,4R)-(+)-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate with 5-bromothiophene-2-carboxylic acid followed by an aromatic coupling reaction with phenylboronic acid. The prepared amides were assayed for human $\alpha 7$ -5HT3 receptor binding activity.

IT 500605-11-8P, N-[(1S,2R,4R)-7-Azabicyclo[2.2.1]hept-2-yl]-5-phenyl-1,3-oxazole-2-carboxamide hydrochloride 500605-34-5P
 500612-26-0P 500612-27-1P 500612-28-2P
 500612-29-3P 500612-30-6P 500612-31-7P
 500612-32-8P 500612-33-9P 500612-34-0P
 500612-35-1P 500612-49-7P 500612-50-0P
 500612-51-1P 500612-52-2P 500612-53-3P
 500612-54-4P 500612-55-5P 500612-56-6P
 500612-57-7P 500612-58-8P 500612-59-9P
 500612-60-2P 500612-61-3P 500612-62-4P
 500612-63-5P 500612-64-6P 500612-65-7P
 500612-66-8P 500612-67-9P 500612-68-0P
 500612-69-1P 500612-70-4P 500612-71-5P
 500612-72-6P 500612-73-7P 500612-74-8P
 500612-75-9P 500612-76-0P 500612-77-1P
 500613-12-7P 500614-27-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (Prepn. of N-[7-aza[2.2.1]bicycloheptanyl]arylamides for therapeutic use as nicotinic acetylcholine receptor agonists)
 RN 500605-11-8 CAPLUS
 CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-phenyl-, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 500605-34-5 CAPLUS
 CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-phenyl-, (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-26-0 CAPLUS
 CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(3-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-27-1 CAPLUS
 CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-28-2 CAPLUS
 CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-29-3 CAPLUS
 CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(4-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-30-6 CAPLUS
 CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(2-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-31-7 CAPLUS
 CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(2-methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-32-8 CAPLUS
 CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(4-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-33-9 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(2-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-34-0 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(3-cyanophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-35-1 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(4-bromophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-52-2 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-53-3 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-54-4 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 500612-49-7 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 500612-50-0 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 500612-51-1 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 500612-55-5 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-56-6 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-57-7 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(3,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-58-8 CAPLUS
CN 2-Oxazolocarbonyl-N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(2-bromophenyl)-9CI (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-59-9 CAPLUS
CN 2-Oxazolocarbonyl-N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(3-bromophenyl)-9CI (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-60-2 CAPLUS
CN 2-Oxazolocarbonyl-N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(2-cyanophenyl)-9CI (CA INDEX NAME)




RN 500612-64-6 CAPLUS
CN 2-Oxazolocarbonyl-N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(4-hydroxyphenyl)-9CI (CA INDEX NAME)

Absolute stereochemistry.



RN 500612-65-7 CAPLUS
CN 2-Oxazolocarbonyl-N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(4-nitrophenyl)-9CI (CA INDEX NAME)


Absolute stereochemistry.



RN 500612-66-8 CAPLUS
CN 2-Oxazolocarbonyl-N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(2-methylphenyl)-9CI (CA INDEX NAME)


Absolute stereochemistry.

Absolute stereochemistry.




RN 500612-61-3 CAPLUS
CN 2-Oxazolocarbonyl-N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(4-cyanophenyl)-9CI (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-62-4 CAPLUS
CN 2-Oxazolocarbonyl-N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(2-hydroxyphenyl)-9CI (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-63-5 CAPLUS
CN 2-Oxazolocarbonyl-N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(3-hydroxyphenyl)-9CI (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-67-9 CAPLUS
CN 2-Oxazolocarbonyl-N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(3-methylphenyl)-9CI (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-68-0 CAPLUS
CN 2-Oxazolocarbonyl-N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-(4-methylphenyl)-9CI (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-69-1 CAPLUS
CN 2-Oxazolocarbonyl-N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-[2-(methylamino)phenyl]-9CI (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-70-4 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-[3-(methylamino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-71-5 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-[4-(methylamino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-72-6 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-[2-(methylamino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-76-0 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-[3-(acetamido)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-77-1 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-[4-(acetamido)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500613-12-7 CAPLUS
CN 5-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-73-7 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-[3-aminophenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-74-8 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-[4-aminophenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500612-75-9 CAPLUS
CN 2-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-5-[2-aminophenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 500614-27-7 CAPLUS
CN 4-Oxazolecarboxamide, N-(1S,2R,4R)-7-azabicyclo[2.2.1]hept-2-yl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 13575-16-1
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of N-[7-aza[2.2.1]bicycloheptanyl]arylamides for
therapeutic use as nicotinic acetylcholine receptor agonists)
RN 13575-16-1 CAPLUS
CN 2-Oxazolecarboxylic acid, 5-phenyl-, ethyl ester (8CI, 9CI) (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 34 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2003:5963 CAPLUS
 DOCUMENT NUMBER: 138:73267
 TITLE: Preparation of 6-phenylpyrrolopyrimidinediones as A2 adenosine receptor inhibitors
 INVENTOR(S): Vidal Juan, Bernat; Esteve Trias, Cristina; Segarra Matamoros, Victor; Ravina Rubira, Enrique; Fernandez Gonzalez, Franco; Loza Garcia, Maria Isabel; Sanz Carreras, Ferran
 PATENT ASSIGNEE(S): Almirall Prodesfarma S.A., Spain
 SOURCE: PCT Int. Appl., 168 pp.
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003000694	A1	20030103	WO 2002-EP6727	20020618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
ES 2193839	A1	20031101	ES 2001-1452	20010622
ES 2193839	B1	20050216		
EP 1409489	A1	20040421	EP 2002-780834	20020618
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004534828	T2	20041118	JP 2003-507097	20020618
US 2005070558	A1	20050331	US 2004-481728	20041019
PRIORITY APPLN. INFO.:			ES 2001-1452	A 20010622
			WO 2002-EP6727	W 20020618

OTHER SOURCE(S): MARPAT 138:73267
 GI




AB The title compds. [I: R1, R2 = H, (CH2)nR7, (un)substituted alkyl (wherein n = 0-4; R7 = cycloalkyl, (un)substituted Ph, 3-7 membered (non)aromatic ring

L5 ANSWER 34 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE
 FORMAT

L5 ANSWER 34 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 contg. 1-4 heteroatoms and which is optionally fused to (hetero)arom. ring; R3 = H, halo, NO2, etc.; R4, R5 = H, halo, alkyl, etc.; L1 = a direct bond, O, S, etc.; R6 = CONR10R11, SO2NR10R11, ON:CR12R13, aryl, etc.; R10, R11 = H, alkyl, cycloalkyl, etc.; R12, R13 = defined as R10 and R11, except that either or both of R12 and R13 can be an amino, alkylamino or dialkylamino which have therapeutic potential as A2 adenosine receptor inhibitors (biol. data given), were prepd. and formulated. Thus, coupling [4-(2-(5-nitro-2,6-dioxo-1,3-dipropyl-1,2,3,6-tetrahydropyrimidin-4-yl)vinyl)phenoxy]acetic acid (prepn. given) with aniline (yield 42%) followed by reductive cyclization of the resulting intermediate mediated by triethylphosphite (46%) afforded I (R1, R2 = Pr; R3-R5 = H; L1 = OCH2; R6 = CONHPh).
 IT 480993-32-6P 480993-33-7P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 receptor (preparation of 6-phenylpyrrolopyrimidinediones as A2 adenosine inhibitors)
 RN 480993-32-6 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-[(4,5-dihydro-5-phenyl-2-oxazolyl)methoxy]phenyl]-1,3-dipropyl- (9CI) (CA INDEX NAME)



RN 480993-33-7 CAPLUS
 CN 1H-Pyrrolo[3,2-d]pyrimidine-2,4(3H,5H)-dione, 6-[4-[[[(4R,5S)-4,5-dihydro-4-methyl-5-phenyl-2-oxazolyl)methoxy]phenyl]-1,3-dipropyl-, rel- (9CI) (CA INDEX NAME)


Relative stereochemistry.

L5 ANSWER 35 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN
 ACCESSION NUMBER: 2002:814116 CAPLUS
 DOCUMENT NUMBER: 137:325417
 TITLE: Preparation and application of 5-membered heterocycles
 as medicaments
 INVENTOR(S): Harnett, Jeremiah; Bigg, Dennis; Liberatore, Anne-Marie; Rolland, Alain
 PATENT ASSIGNEE(S): Societe De Conseils De Recherches Et D'applications Scientifiques (SCRAS), Fr.
 SOURCE: PCT Int. Appl., 132 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002083656	A2	20021024	WO 2002-FR1218	20020409
WO 2002083656	A3	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CH, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
FR 2823208	A1	20021011	FR 2001-4943	20010410
FR 2823208	B1	20040319		
CA 2443403	AA	20021024	CA 2002-2443403	20020409
EP 1379514	A2	20040114	EP 2002-761921	20020409
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 200303799	A2	20040301	HU 2003-3799	20020409
CN 1535267	A	20041006	CN 2002-807937	20020409
JP 2004531526	T2	20041014	JP 2002-581412	20020409
NZ 528645	A	20041126	NZ 2002-528645	20020409
BR 2002008703	A	20060221	BR 2002-8703	20020409
RU 2288224	C2	20061127	RU 2003-132471	20020409
ZA 2003007750	A	20040726	ZA 2003-7750	20031003
NO 2003004524	A	20031029	NO 2003-4524	20031009
US 2005038087	A1	20050217	US 2004-915001	20040810
PRIORITY APPLN. INFO.:			FR 2001-4943	A 20010410
			FR 2002-1811	A 20020214
			FR 1999-12643	A 19991011
			FR 2000-10151	A 20000801
			FR 2000-11169	A 20000901
			WO 2000-FR2805	W 20001010
			US 2002-89993	A2 20020404
			FR 2002-1218	A 20020409

L5 ANSWER 35 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
WO 2002-FR1218 W 20020409
US 2003-681002 A2 20031008

GI




II

AB The invention relates to thiazole, oxazole or imidazole derivs. having at least one of the following pharmacol. activities: inhibition of monoamine oxidases (MAO); inhibition of lipid peroxidn.; modulation of sodium channels. The inventive compds. comprise, for example, 2,6-di(tert-butyl)-4-(2-(2-(methylamino)ethyl)-1,3-thiazol-4-yl)phenol (I); and 4-methylpentyl 2-[4-(1,1'-biphenyl-4-yl)-1H-imidazol-2-yl]ethyl carbamate (II). Thus, I-HCl was prepared from N-methyl-B-alanine derivative via N-protection with (Boc)2O in CH2Cl2 containing EtN(CHMe2)2, sulfuration with H2S in EtOH containing Et3N, cyclocondensation with α -bromo-1-[3,5-di(tert-butyl)-4-hydroxyphenyl]ethanone and acid-catalyzed deprotection with HCl in EtOAc. By virtue of their pharmacol. properties, said compds. can be used to treat one of the following disorders or diseases: Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, schizophrenia, depression, psychoses, migraine or pain, especially neuropathic pain. The pharmacol. activity of I was determined [CI50 \leq 10 μ M vs. monoamine oxidase B; CI50 \leq 10 μ M vs. lipid peroxidn.; CI50 \leq 1.0 μ M on sodium channels from the cerebral cortex of rats].

L5 ANSWER 36 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2002:754196 CAPLUS
DOCUMENT NUMBER: 137:257677
TITLE: Methods of treating or preventing Alzheimer's disease using 4-aryl-3-alkoxypiperidines and -azabicyclooctanes
INVENTOR(S): Nieman, James A.; Fang, Lawrence; Jagodzinska, Barbara
PATENT ASSIGNEE(S): Elan Pharmaceuticals, Inc., USA; Pharmacia & Upjohn Company
SOURCE: PCT Int. Appl., 449 pp.
CODEN: PIKXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002076440	A2	20021003	WO 2002-US9100	20020321
WO 2002076440	A3	20021128		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002306848	A1	20021008	AU 2002-306848	20020321
US 2006079533	A1	20060413	US 2004-472868	20040202
PRIORITY APPL. INFO.: US 2001-278371P P 20010323				
US 2001-308729P P 20010730				
WO 2002-US9100 W 20020321				

OTHER SOURCE(S): MARPAT 137:257677
GI



AB Disclosed are methods for treating or preventing Alzheimer's disease, and other diseases, and/or inhibiting β -secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, using 3,4-disubstituted piperidyl compds. (I) wherein the variables R1, R2, R3, R4, Q, W, X, Z, m, and n are defined below. Although neither the compds. nor the methods of preparation are claimed, approx. 150 example preps. translations from the German examples of patent WO 9709311, are included. I inhibit β -secretase with IC50 < 50 μ M; compds. that are

L5 ANSWER 35 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
IT 206123-20-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(Preparation of 5-membered heterocycles with one of the following pharmacol. activities: monoamine oxidase inhibition, lipid peroxidation or sodium channel modulation)
RN 206123-20-8 CAPLUS
CN 4-oxazolemethanol, 2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 36 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
effective inhibitors of β -secretase activity demonstrate reduced cleavage of the substrate as compared to a control. In I, R1 is aryl, heterocycle; R2 is Ph, naphthyl, acenaphthyl, cyclohexyl, pyridyl, pyrimidinyl, pyrazinyl, oxopyridinyl, diaziny, triazoly, thienyl, oxazolyl, oxadiazolyl, thiazolyl, pyrrolyl, or furyl, optionally substituted. R3 is: H, hydroxy, lower-alkoxy, or lower-alkenyl; R4 is: H, lower-alkyl, lower-alkenyl, lower-alkoxy, hydroxy-lower-alkyl, lower-alkoxy-lower-alkyl, benzyl, oxo, or where R3 and R4 together are a bond, or as specified in the claims. Q is: ethylene, or is absent; X is: a bond, -O-, -S-, -CH-R11- (R11 defined in claims), -CHOR9- (R9 defined in claims), -OCO-, -CO-, or C:ROR10- (R10 is carboxyalkyl, alkoxy, carbonylalkyl, alkyl or H), with the bond emanating from an O or S atom joining to a satd. C atom of group Z or to R1; W is: -O-, or -S-; Z is: lower-alkylene, lower-alkenylene, hydroxy-lower-alkylidene, -O-, -S-, -O-Alk- (Alk is a lower alkylene), -S-Alk-, -Alk-O-, or -Alk-S. N is: 1, or 0 or 1 when X is -O-CO-; and where m is 0 or 1; with provisos.
IT 188877-54-5P, Piperidine, 3-[(1,4-dimethoxy-2-naphthalenyl)methoxy]-4-[4-[(2-phenyl-5-oxazolyl)methoxy]phenyl]-, trans-188878-84-4P, Pyrimidine, 2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-5-[3-(2-naphthalenyl)methoxy]-4-piperidinyl-, trans-RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(Methods of treating or preventing Alzheimer's and other diseases using 4-aryl-3-alkoxypiperidines and -azabicyclooctanes)


RN 188877-54-5 CAPLUS
CN Piperidine, 3-[(1,4-dimethoxy-2-naphthalenyl)methoxy]-4-[4-[(2-phenyl-5-oxazolyl)methoxy]phenyl]-, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 188878-84-4 CAPLUS
CN Pyrimidine, 2-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]-5-[3-(2-naphthalenyl)methoxy]-4-piperidinyl-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 103788-65-4, 4-Oxazoleethanol, 5-methyl-2-phenyl-
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (methods of treating or preventing Alzheimer's and other diseases
 using 4-aryl-3-alkoxy-piperidines and -azabicyclooctanes)
 RN 103788-65-4 CAPLUS
 CN 4-Oxazoleethanol, 5-methyl-2-phenyl- (9CI) (CA INDEX NAME)






IT 188877-87-4P, 1-Piperidinecarboxylic acid, 3-[(1,4-dimethoxy-2-naphthalenyl)methoxy]-4-[4-[(2-phenyl-5-oxazolyl)methoxy]phenyl]-, 1,1-dimethylethyl ester, trans-
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (methods of treating or preventing Alzheimer's and other diseases
 using 4-aryl-3-alkoxy-piperidines and -azabicyclooctanes)
 RN 188877-87-4 CAPLUS
 CN 1-Piperidinecarboxylic acid, 3-[(1,4-dimethoxy-2-naphthalenyl)methoxy]-4-[4-[(2-phenyl-5-oxazolyl)methoxy]phenyl]-, 1,1-dimethylethyl ester, (3R,4R)-rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.

ACCESSION NUMBER: 2002:716244 CAPLUS
 DOCUMENT NUMBER: 137:232438
 TITLE: Preparation of aminoalkoxybenzenesulfonamides as pH-dependent NMDA receptor antagonists
 INVENTOR(S): Dingledine, Raymond J.; Liotta, Dennis C.; Traynelis, Stephen P.; Snyder, James P.
 PATENT ASSIGNEE(S): Emory University, USA
 SOURCE: PCT Int. Appl., 100 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002072542	A2	20020919	WO 2002-US7033	20020308
WO 2002072542	A3	20030227		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2440284	AA	20020919	CA 2002-2440284	20020308
EP 1436258	A2	20040714	EP 2002-719157	20020308
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO, CY, TR			
JP 200506292	T2	20050303	JP 2002-571458	20020308
US 2004138502	A1	20040715	US 2004-469824	20040225
PRIORITY APPLN. INFO.:			US 2001-274205P	P 20010308
			WO 2002-US7033	W 20020308

OTHER SOURCE(S): CASREACT 137:232438; MARPAT 137:232438
 GI




AB Title compds. I (R1, R5 = H, F, etc.; R2-4 = H, F, Cl, Br, I, alkoxy, etc.; R6-6' = H, F; R7 = alkyl, CH2Ac, CH2CH2Ac, CH2CH2FAC, CH2CF2Ac; Ar = aryl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,6-difluorophenyl, 2,3,4-trifluorophenyl, 2,3,4,5,6-pentafluorophenyl; R8 = OH, alkoxy, F; R9-R12 = H, F, Cl, Br, I, alkyl; R13 = alkyl, aralkyl, aryl and derivs. thereof) were prepared. For instance, (S)-glycidyl p-aminophenyl ether (preparation given) was treated with MeCl (CH2Cl2, DIEA) and the resulting product reacted with 3,4-dichlorophenethylamine to afford (S)-1-[(4-methanesulfonamidophenoxy)-3-(3,4-dichlorophenethylamino)-2-propanol. Reductive alkylation of this intermediate with the corresponding aldehyde produced II. At pH 6.9, II had IC50 = 0.058 µM for the NR1-1a/NR2B NMDA receptor and exhibited >50 fold increase in potency between pH 7.6 and pH 6.9. Selected example compds. also showed anticonvulsant activity (rats). I are neuroprotective drugs that are useful in stroke, traumatic brain injury, epilepsy, and other neuropath events that involve acidification of brain or spinal cord tissue.

Compds. and methods of this invention are used for treating neurodegeneration resulting from NMDA receptor activation. The compds. described herein have enhanced activity in brain tissue having lower-than normal pH due to pathol. conditions such as hypoxia resulting from stroke, traumatic brain injury, global ischemia that may occur during cardiac surgery, hypoxia that may occur following cessation of breathing, pre-eclampsia, spinal cord trauma, epilepsy, chronic pain, vascular dementia and glioma tumors. Compds. described herein are also useful in preventing neurodegeneration in patients with Parkinson's Alzheimer's, Huntington's chorea, ALS, and other neurodegenerative conditions known to the art to be responsive to treatment using NMDA receptor blockers. Preferably the compds. provided herein are allosteric NMDA inhibitors.

IT 457898-13-4P 457898-14-5P 457898-44-1P
 457898-45-2P


L5 ANSWER 37 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (intermediate; prepn. of aminoalkoxybenzenesulfonamides as
 pH-dependent NMDA receptor antagonists)
 RN: 457898-13-4 CAPLUS
 CN: Oxazolidine,
 3-[2-(3,4-dichlorophenyl)ethyl]-5-[(4-nitrophenoxy)methyl]-2-
 phenyl-, (5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN: 457898-14-5 CAPLUS
 CN: Benzenamine, 4-[[[(5S)-3-[2-(3,4-dichlorophenyl)ethyl]-2-phenyl-5-oxazolidinyl)methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L5 ANSWER 38 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:588980 CAPLUS
 DOCUMENT NUMBER: 137:135080
 TITLE: Modification of NSAIDs by sulfur-containing functional groups
 INVENTOR(S): Lai, Ching-San; Wang, Tingmin
 PATENT ASSIGNEE(S): Medinor, Inc., USA
 SOURCE: U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 602,688.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6429223	B1	20020806	US 2000-715767	20001117
US 6355666	B1	20020312	US 2000-602688	20000623
CA 2414150	AA	20020103	CA 2001-2414150	20010619
WO 2002000167	A2	20020103	WO 2001-US19750	20010619
WO 2002000167	A3	20020404		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OL, OM, OS, PA, PE, PG, PH, PI, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001070010	A5	20020108	AU 2001-70010	20010619
EP 1296929	A2	20030402	EP 2001-948537	20010619
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004517037	T2	20040610	JP 2002-504950	20010619
US 2003220468	A1	20031127	US 2003-434371	20030507
PRIORITY APPLN. INFO.:				US 2000-602688 A2 20000623
				US 2000-715767 A 20001117
				WO 2001-US19750 W 20010619
				US 2002-97197 A2 20020312

AB A method for the alleviation of side effects induced by the administration of a nonsteroidal anti-inflammatory drug (NSAID) to a subject comprises chemical modifying the NSAID by covalent attachment of a sulfur-containing functional group, such as sulfoxide, sulfonate, reverse sulfonate, sulfonamide, reverse sulfonamide, sulfone, sulfinate, or reverse sulfinate to provide prodrugs. The maximum blood concentration (C_{max}) of the prodrug is reduced relative to the unmodified NSAID by about 10-90%. For example, oral administration of a naproxen prodrug, i.e., a conjugate of naproxen and tosylate (preparation given), resulted in the release of free naproxen. In rats, the prodrug had equivalent pharmacol. efficacy and greatly improved gastrointestinal safety profile compared to naproxen.


L5 ANSWER 37 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN: 457898-44-1 CAPLUS
 CN: Oxazolidine,
 3-[2-(3,4-dichlorophenyl)ethyl]-5-[(4-nitrophenoxy)methyl]-2-phenyl-, (5R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN: 457898-45-2 CAPLUS
 CN: Benzenamine, 4-[[[(5R)-3-[2-(3,4-dichlorophenyl)ethyl]-2-phenyl-5-oxazolidinyl)methoxy]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 38 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 IT: 21256-18-8, Oxaprozin
 RL: ADV (Adverse effect, including toxicity); RCT (Reactant); BIOL (Biological study); RACT (Reactant or reagent)
 (prodrugs of NSAIDs containing sulfur-containing functional groups for alleviation of side effects during therapy)
 RN: 21256-18-8 CAPLUS
 CN: 2-Oxazolepropanoic acid, 4,5-diphenyl- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 39 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:487382 CAPLUS
 DOCUMENT NUMBER: 137:41765
 TITLE: PPAR γ agonists in treatment of neuronal degeneration
 INVENTOR(S): Chapman, Gayle; Vinson, Mary
 PATENT ASSIGNEE(S): Smithkline Beecham P.L.C., UK
 SOURCE: PCT Int. Appl., 17 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002049626	A2	20020627	WO 2001-GB5488	20011212
WO 2002049626	A3	20021017		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002022180	A5	20020701	AU 2002-22180	20011212
EP 1345598	A2	20030924	EP 2001-271216	20011212
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004518652	T2	20040624	JP 2002-550968	20011212
US 2004077525	A1	20040422	US 2003-450885	20031028
			GB 2000-30845	A 20001218
PRIORITY APPLN. INFO.:			WO 2001-GB5488	W 20011212

AB A method for the promotion of growth and/or repair of neurons in diseases or conditions characterized by neuron degeneration, injury or impaired plasticity which method comprises the administration of an effective, non-toxic and pharmaceutically acceptable amount of a peroxisome proliferator activated receptor- γ (PPAR γ) agonist or a pharmaceutically acceptable derivative thereof.


IT 196808-45-4
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (PPAR γ agonists in treatment of neuronal degeneration)
 RN 196808-45-4 CAPLUS
 CN L-Tyrosine,
 N-(2-benzoylphenyl)-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 40 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2002:449662 CAPLUS
 DOCUMENT NUMBER: 137:33310
 TITLE: Preparation of anilinopyrimidines as IKK inhibitors
 INVENTOR(S): Kois, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
 PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 194 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046171	A2	20020613	WO 2001-US46403	20011205
WO 2002046171	A3	20030123		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 200303926	A1	20031030	US 2001-4642	20011204
US 7122544	B2	20061017		
CA 2431160	AA	20020613	CA 2001-2431160	20011205
AU 2002020195	A5	20020618	AU 2002-20195	20011205
EP 1349841	A2	20031008	EP 2001-999564	20011205
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004523497	T2	20040805	JP 2002-547910	20011205
US 2006030576	A1	20060209	US 2005-211383	20050824
PRIORITY APPLN. INFO.:			US 2000-251816P	P 20001206
			US 2001-4642	A1 20011204
			WO 2001-US46403	W 20011205

OTHER SOURCE(S): MARPAT 137:33310
 GI




AB The title compds. [I: R¹ = (un)substituted (hetero)aryl; R² = H; R³ = H, alkyl; R⁴ = halo, OH, alkyl, alkoxy; R⁵, R⁶ = R⁸, (CH₂)₂acOR⁹, (CH₂)₂acOR⁹,

L5 ANSWER 39 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L5 ANSWER 40 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 etc.; or NR5R6 = (un)substituted heterocycle; R⁸, R⁹ = H, alkyl, aryl, etc.; a = 0-4) having activity as inhibitors of IKK, particularly IKK-2, were prepd. E.g., a multi-step synthesis of I [R¹ = 4-ClC₆H₄; R²-R⁶ = H] having an IC₅₀ of $\leq 1 \mu\text{M}$ in the IKK-2 enzyme assay, was given.
 Such compds. I have utility in the treatment of a wide range of conditions that are responsive to IKK inhibition. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compns. contg. one or more compds. of the above compds.
 IT 21256-18-8, Oxaprozol
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (antiinflammatory agent; preparation of anilinopyrimidines as IKK inhibitors)
 RN 21256-18-8 CAPLUS
 CN 2-Oxazolepropanoic acid, 4,5-diphenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 41 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2002:449661 CAPLUS
DOCUMENT NUMBER: 137:33309
TITLE: Preparation of anilinopyrimidines as JNK pathway inhibitors
INVENTOR(S): Koia, Adam; MacFarlane, Karen J.; Satoh, Yoshitaka; Bhagwat, Shripad S.; Parnes, Jason S.; Palanki, Moorthy S. S.; Erdman, Paul E.
PATENT ASSIGNEE(S): Signal Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 199 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002046170	A2	20020613	WO 2001-US46402	20011205
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2430966	AA	20020613	CA 2001-2430966	20011205
AU 2002027214	A5	20020618	AU 2002-27214	20011205
EP 1349840	A2	20031008	EP 2001-996103	20011205
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004534728	T2	20041118	JP 2002-547909	20011205
PRIORITY APPL. INFO.:			US 2000-251904P	P 20001206
			WO 2001-US46402	W 20011205

OTHER SOURCE(S): MARPAT 137:33309
GI




AB The title compds. [I: R1 = (un)substituted (hetero)aryl; R2 = H; R3 = H, alkyl; R4 = halo, OH, alkyl, alkoxy; R5, R6 = R8, (CH2)2COR9, (CH2)2CO2R9, etc.; or NR5R6 = (un)substituted heterocycle; R8, R9 = H, alkyl, aryl, etc.; s = 0-4] having activity as inhibitors of the JNK pathway, were prepared. E.g., a multi-step synthesis of I [R1 = 4-ClC6H4; R2-R6 = H] having an IC50 of $\leq 10 \mu\text{M}$ in the JNK2 assay, was given. Such compds. I have utility in the treatment of a wide range of conditions that

L5 ANSWER 42 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN
ACCESSION NUMBER: 2002:158129 CAPLUS
DOCUMENT NUMBER: 136:200338
TITLE: Preparation of N-quinuclidinyl-heteroaryl amides for pharmaceutical use in the treatment of neurological disorders
INVENTOR(S): Myers, Jason K.; Rogers, Bruce N.; Groppi, Vincent E., Jr.; Piotrowski, David W.; Bodnar, Alice L.; Jacobsen, Eric Jon; Corbett, Jeffrey W.
PATENT ASSIGNEE(S): Pharmacia & Upjohn Company, USA
SOURCE: PCT Int. Appl., 247 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 6
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002017358	A2	20020228	WO 2001-US21139	20010817
WO 2002017358	A3	20020530		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001082875	A5	20020304	AU 2001-82875	20010817
US 2002042428	A1	20020411	US 2001-932309	20010817
US 6492385	B2	20021210		
US 2002042429	A1	20020411	US 2001-932612	20010817
US 6500840	B2	20021231		
PRIORITY APPL. INFO.:			US 2000-226652P	P 20000821
			US 2001-284849P	P 20010419
			US 2001-284850P	P 20010419
			US 2001-284967P	P 20010419
			US 2000-226164P	P 20000818
			US 2001-284832P	P 20010419
			WO 2001-US21139	W 20010817

OTHER SOURCE(S): MARPAT 136:200338
GI

L5 ANSWER 41 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
are responsive to inhibition of the JNK pathway. Thus, methods of treating such conditions are also disclosed, as are pharmaceutical compds.
contg. one or more compds. of the above compds.
IT 21256-18-8, Oxaprozol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antiinflammatory agent; preparation of anilinopyrimidines as JNK pathway inhibitors)
RN 21256-18-8 CAPLUS
CN 2-Oxazolepropanoic acid, 4,5-diphenyl- (9CI) (CA INDEX NAME)



L5 ANSWER 42 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



AB N-quinuclidinyl-heteroaryl amides, such as I [R1 = H, alkyl, cycloalkyl, haloalkyl, aryl; R2 = H, benzyl, alkyl, haloalkyl, cycloalkyl, aryl; W = heteroaryl; X = O, S], were prepared for therapeutic use in the treatment of neurol. disorders, such as attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulimia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependent drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain. Thus, the hydrochloride salt of quinuclidine carboxamide II was prepared in 57% yield by an amidation reaction of (3R)-3-aminoquinuclidine hydrochloride and 5-phenylthiophene-2-carboxylic acid using di-Ph chlorophosphate and Et3N in CH2Cl2 and DMF/H2O (5:1). The prepared quinuclidinyl amides were tested for nicotinic acetylcholine receptor binding activities.
IT 400714-28-5P 400714-29-6P 400714-30-9P 400714-31-0P 400714-32-1P 400714-33-2P 400714-34-3P 400714-35-4P 400714-36-5P 400714-37-6P 400715-30-2P 400715-31-3P 400715-34-6P 400715-35-7P 400715-36-8P 400715-37-9P 400717-13-7P 400717-37-5P 400718-97-0P 400719-45-1P 400728-10-1P 400779-54-6P 400779-55-7P 400779-56-8P 400779-58-0P 400779-59-1P 400779-60-4P 400779-61-5P 400779-62-6P 400779-63-7P 400779-64-8P 400831-58-3P 400832-52-2P 400833-20-7P 401459-76-5P 401459-77-6P 401459-78-7P 401459-79-8P 401459-80-1P 401459-81-2P 401459-82-3P 401459-83-4P 401459-84-5P 401459-85-6P 401459-86-7P 401459-87-8P 401459-88-9P 401459-89-0P 401459-90-3P 401459-91-4P 401459-92-3P 401459-93-6P 401459-94-7P 401459-95-8P 401459-96-9P 401459-97-0P 401459-98-1P 401459-99-2P 401460-00-2P 401460-01-3P 401460-02-4P 401460-03-5P 401460-04-6P 401484-38-6P 401484-42-2P 401484-45-5P 401484-48-8P 401484-51-3P 401491-97-2P

L5 ANSWER 42 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

401491-98-3P 401491-99-4P 401492-00-0P
401492-01-1P 401492-02-2P 401492-03-3P
401492-04-4P 401492-05-5P 401492-06-6P
401492-07-7P 401492-08-8P 401492-09-9P
401492-10-2P 401492-11-3P 401492-12-4P
401492-13-5P 401492-14-6P 401492-15-7P
401492-16-8P 401492-17-9P 401492-18-0P
401492-19-1P 401492-20-4P 401492-21-5P
401492-22-6P 401492-23-7P 401492-24-8P
401492-25-9P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(prepn. of N-quinuclidinyl-heteroaryl amides for pharmaceutical use in
the treatment of neurol. disorders)

RN 400714-28-5 CAPLUS

CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3-
methoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 400714-29-6 CAPLUS


CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3-
methoxyphenyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 400714-28-5

CMF C18 H21 N3 O3


Absolute stereochemistry.



CM 2

L5 ANSWER 42 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CRN 104-15-4
CMF C7 H8 O3 S



RN 400714-32-1 CAPLUS

CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(2-
chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 400714-33-2 CAPLUS


CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(2-
chlorophenyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 400714-32-1

CMF C17 H18 Cl N3 O2

Absolute stereochemistry.




CM 2

CRN 104-15-4

CMF C7 H8 O3 S

L5 ANSWER 42 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


CRN 104-15-4
CMF C7 H8 O3 S



RN 400714-30-9 CAPLUS

CN 2-Oxazolecarboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3-nitrophenyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 400714-31-0 CAPLUS


CN 2-Oxazolecarboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3-nitrophenyl)-,
mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 400714-30-9


CMF C17 H18 N4 O4

Absolute stereochemistry.



CM 2


L5 ANSWER 42 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 400714-34-3 CAPLUS

CN 2-Oxazolecarboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3-cyanophenyl)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 400714-35-4 CAPLUS


CN 2-Oxazolecarboxamide,
N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3-cyanophenyl)-,
mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 400714-34-3

CMF C18 H18 N4 O2


Absolute stereochemistry.



CM 2


CRN 104-15-4

CMF C7 H8 O3 S



RN 400714-36-5 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(4-bromophenyl)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400714-37-6 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(4-bromophenyl)-
 , mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 400714-36-5
 CMF C17 H18 Br N3 O2

Absolute stereochemistry.




CM 2

CRN 104-15-4
 CMF C7 H8 O3 S

RN 400715-34-6 CAPLUS
 CN 5-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-phenyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry..




RN 400715-35-7 CAPLUS
 CN 5-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-phenyl-,
 mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1


CRN 400715-34-6
 CMF C17 H19 N3 O2

Absolute stereochemistry.




CM 2

CRN 104-15-4
 CMF C7 H8 O3 S




RN 400715-36-8 CAPLUS
 CN 4-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-phenyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 400715-30-2 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-phenyl- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 400715-31-3 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-phenyl-,
 mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1



CRN 400715-30-2
 CMF C17 H19 N3 O2

Absolute stereochemistry.



CM 2

CRN 104-15-4
 CMF C7 H8 O3 S




RN 400715-37-9 CAPLUS
 CN 4-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-2-phenyl-,
 mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1


CRN 400715-36-8
 CMF C17 H19 N3 O2

Absolute stereochemistry.




CM 2

CRN 104-15-4
 CMF C7 H8 O3 S




RN 400717-13-7 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(4-methoxyphenyl)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 400717-37-5 CAPLUS
CN 2-Oxazolecarboxamide, N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(2-nitrophenyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400718-97-0 CAPLUS
CN 2-Oxazolecarboxamide, N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(2-methoxyphenyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400719-45-1 CAPLUS
CN 2-Oxazolecarboxamide, N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(4-fluorophenyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400728-10-1 CAPLUS
CN 2-Oxazolecarboxamide, N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3-chlorophenyl)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400779-54-6 CAPLUS
CN 2-Oxazolecarboxamide, 5-(3-chlorophenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400779-55-7 CAPLUS
CN 2-Oxazolecarboxamide, 5-(3-methoxyphenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400779-56-8 CAPLUS
CN 2-Oxazolecarboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-(3-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400779-58-0 CAPLUS
CN 2-Oxazolecarboxamide, 5-(4-methoxyphenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400779-59-1 CAPLUS
CN 2-Oxazolecarboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-(2-nitrophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400779-60-4 CAPLUS
CN 2-Oxazolecarboxamide, 5-(2-methoxyphenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400779-61-5 CAPLUS
CN 2-Oxazolecarboxamide, 5-(4-fluorophenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400779-62-6 CAPLUS
CN 2-Oxazolecarboxamide, 5-(2-chlorophenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400779-63-7 CAPLUS
CN 2-Oxazolecarboxamide, 5-(3-cyanophenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 400779-64-8 CAPLUS
CN 2-Oxazolecarboxamide, 5-(4-bromophenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400831-58-5 CAPLUS
CN 2-Oxazolecarboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


RN 401459-77-6 CAPLUS
CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.





RN 401459-78-7 CAPLUS
CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3,4-difluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-79-8 CAPLUS
CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(2,4-difluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400832-52-2 CAPLUS
CN 5-Oxazolecarboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 400833-20-7 CAPLUS
CN 4-Oxazolecarboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-76-5 CAPLUS
CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(2-fluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-80-1 CAPLUS
CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3,5-difluorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-81-2 CAPLUS
CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(4-chlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-82-3 CAPLUS
CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3,4-dichlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-83-4 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(2,4-dichlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-84-5 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3,5-dichlorophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-85-6 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(2-bromophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-89-0 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(2-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-90-3 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3-hydroxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 401459-91-4 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(4-hydroxyphenyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 401459-92-5 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(4-nitrophenyl)- (9CI) (CA INDEX NAME)


RN 401459-86-7 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3-bromophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-87-8 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(2-cyanophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-88-9 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(4-cyanophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Absolute stereochemistry.




RN 401459-93-6 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-94-7 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-95-8 CAPLUS
 CN 2-Oxazolecarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-96-9 CAPLUS
CN 2-Oxazolocarbonyl-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[2-(methylamino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-97-0 CAPLUS
CN 2-Oxazolocarbonyl-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[3-(methylamino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-98-1 CAPLUS
CN 2-Oxazolocarbonyl-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[4-(methylamino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401460-02-4 CAPLUS
CN 2-Oxazolocarbonyl-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[2-(acetamido)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401460-03-5 CAPLUS
CN 2-Oxazolocarbonyl-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[3-(acetamido)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401460-04-6 CAPLUS
CN 2-Oxazolocarbonyl-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[4-(acetamido)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401459-99-2 CAPLUS
CN 2-Oxazolocarbonyl-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[2-(aminophenyl)-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401460-00-2 CAPLUS
CN 2-Oxazolocarbonyl-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[3-(aminophenyl)-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 401460-01-3 CAPLUS
CN 2-Oxazolocarbonyl-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[4-(aminophenyl)-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401484-38-6 CAPLUS
CN 2-Oxazolocarbonyl-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[3-chlorophenyl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CH 1


CRN 400728-10-1
CMF C17 H18 Cl N3 O2

Absolute stereochemistry.



CH 2

CRN 104-15-4
CMF C7 H8 O3 S




RN 401484-42-2 CAPLUS
CN 2-Oxazolocarbonyl-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[4-methoxyphenyl]-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)


CH 1

CRN 400717-13-7
CMF C18 H21 N3 O3

Absolute stereochemistry.




CM 2
CRN 104-15-4
CMF C7 H8 O3 S




RN 401484-45-5 CAPLUS
CN 2-Oxazolecarboxamide, N-((3R)-1-azabicyclo[2.2.2]oct-3-yl)-5-(2-nitrophenyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1
CRN 400717-37-5
CMF C17 H18 N4 O4


Absolute stereochemistry.



CM 2
CRN 104-15-4
CMF C7 H8 O3 S




CM 2
CRN 104-15-4
CMF C7 H8 O3 S




RN 401491-97-2 CAPLUS
CN 2-Oxazolecarboxamide, 5-(2-fluorophenyl)-N-((2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 401491-98-3 CAPLUS
CN 2-Oxazolecarboxamide, 5-(3-fluorophenyl)-N-((2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 401484-48-8 CAPLUS
CN 2-Oxazolecarboxamide, N-((3R)-1-azabicyclo[2.2.2]oct-3-yl)-5-(2-methoxyphenyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1
CRN 400718-97-0
CMF C18 H21 N3 O3

Absolute stereochemistry.




CM 2
CRN 104-15-4
CMF C7 H8 O3 S



RN 401484-51-3 CAPLUS
CN 2-Oxazolecarboxamide, N-((3R)-1-azabicyclo[2.2.2]oct-3-yl)-5-(4-fluorophenyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)


CM 1
CRN 400719-45-1
CMF C17 H18 F N3 O2

Absolute stereochemistry.




RN 401491-99-4 CAPLUS
CN 2-Oxazolecarboxamide, 5-(3,4-difluorophenyl)-N-((2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-00-0 CAPLUS
CN 2-Oxazolecarboxamide, 5-(2,4-difluorophenyl)-N-((2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-01-1 CAPLUS
CN 2-Oxazolecarboxamide, 5-(3,5-difluorophenyl)-N-((2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-02-2 CAPLUS
CN 2-Oxazolecaboxamide, 5-(4-chlorophenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-03-3 CAPLUS
CN 2-Oxazolecaboxamide, 5-(3,4-dichlorophenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-04-4 CAPLUS
CN 2-Oxazolecaboxamide, 5-(2,4-dichlorophenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-08-8 CAPLUS
CN 2-Oxazolecaboxamide, 5-(2-cyanophenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-09-9 CAPLUS
CN 2-Oxazolecaboxamide, 5-(4-cyanophenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-10-2 CAPLUS
CN 2-Oxazolecaboxamide, 5-(2-hydroxyphenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-05-5 CAPLUS
CN 2-Oxazolecaboxamide, 5-(3,5-dichlorophenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-06-6 CAPLUS
CN 2-Oxazolecaboxamide, 5-(2-bromophenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-07-7 CAPLUS
CN 2-Oxazolecaboxamide, 5-(3-bromophenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-11-3 CAPLUS
CN 2-Oxazolecaboxamide, 5-(3-hydroxyphenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-12-4 CAPLUS
CN 2-Oxazolecaboxamide, 5-(4-hydroxyphenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-13-5 CAPLUS
CN 2-Oxazolecaboxamide, 5-(4-nitrophenyl)-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-14-6 CAPLUS
CN 2-Oxazolecaboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-(2-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-15-7 CAPLUS
CN 2-Oxazolecaboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-(3-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-16-8 CAPLUS
CN 2-Oxazolecaboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-(4-methylphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-20-4 CAPLUS
CN 2-Oxazolecaboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-(2-aminophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-21-5 CAPLUS
CN 2-Oxazolecaboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-(3-aminophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-22-6 CAPLUS
CN 2-Oxazolecaboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-(4-aminophenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-17-9 CAPLUS
CN 2-Oxazolecaboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-[2-(methylamino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-18-0 CAPLUS
CN 2-Oxazolecaboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-[3-(methylamino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-19-1 CAPLUS
CN 2-Oxazolecaboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-[4-(methylamino)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-23-7 CAPLUS
CN 2-Oxazolecaboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-[2-(acetamido)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-24-8 CAPLUS
CN 2-Oxazolecaboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-[3-(acetamido)phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 401492-25-9 CAPLUS
CN 2-Oxazolecaboxamide, N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-5-[4-(acetamido)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




IT 1014-14-8 23012-16-0 106833-79-8
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (preparation of N-quinuclidinyl-heteroaryl amides for pharmaceutical
 use in the treatment of neurol. disorders)
 RN 1014-14-8 CAPLUS
 CN 2-Oxazolecarboxylic acid, 5-phenyl- (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 23012-16-0 CAPLUS
 CN 4-Oxazolecarboxylic acid, 2-phenyl- (6CI, 8CI, 9CI) (CA INDEX NAME)



RN 106833-79-8 CAPLUS
 CN 5-Oxazolecarboxylic acid, 2-phenyl- (9CI) (CA INDEX NAME)



IT 400715-69-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation of N-quinuclidinyl-heteroaryl amides for pharmaceutical
 use in the treatment of neurol. disorders)
 RN 400715-69-7 CAPLUS
 CN 2-Oxazolecarboxylic acid, 5-(3-chlorophenyl)-, ethyl ester (9CI) (CA
 INDEX NAME)

ACCESSION NUMBER: 2002:142506 CAPLUS
 DOCUMENT NUMBER: 136:177977
 TITLE: Methods for treating inflammatory diseases using PPAR
 agonists
 INVENTOR(S): Pershadsingh, Harrihar A.
 PATENT ASSIGNEE(S): USA
 SOURCE: PCT Int. Appl., 42 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002013812	A1	20020221	WO 2001-US25668	20010816
W: AU, CA, MX, NZ, US				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
AU 2001088271	A5	20020225	AU 2001-88271	20010816
PRIORITY APPLN. INFO.:			US 2000-225907P	P 20000817
			US 2000-230509P	P 20000906
			WO 2001-US25668	W 20010816

AB The present invention describes methods for the use of PPAR ligands in the treatment inflammatory endocrine, dermatol., cardiovascular immunol., neurol., ophthalmic, neoplastic, pulmonary diseases, and age-related dysregulations. In addition, methods are provided for treating said conditions and diseases comprising the step of administering to a human


or an animal in need thereof a therapeutic amount of pharmacol. compns. comprising a pharmaceutically acceptable carrier, and a PPARy agonist which cross-activates PPARalpha or PPARdelta or both, or a PPARy partial agonist, or a PPARy/RXR agonist, effective to reverse, slow, stop, or prevent the pathol. inflammatory or degenerative process.

IT 196809-22-0, GW 7845
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (GW 7845; methods for treating inflammatory diseases using PPAR agonists)
 RN 196809-22-0 CAPLUS
 CN L-Tyrosine, N-[2-(methoxycarbonyl)phenyl]-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 141200-24-0, Darglitazone 170861-63-9, JTT-501
 196808-45-4, GI262570 199794-30-4, JTT 601
 213411-83-7, BM 131258 258345-41-4, GW409544
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (methods for treating inflammatory diseases using PPAR agonists)
 RN 141200-24-0 CAPLUS
 CN 2,4-Thiazolidinedione, 5-[(4-[3-(5-methyl-2-phenyl-4-oxazolyl)-1-oxopropyl]phenyl)methyl]- (9CI) (CA INDEX NAME)




RN 170861-63-9 CAPLUS
 CN 3,5-isoxazolidinedione, 4-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]- (9CI) (CA INDEX NAME)




RN 196808-45-4 CAPLUS
 CN L-Tyrosine, N-(2-benzoylphenyl)-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 199794-30-4 CAPLUS
 CN Benzenepropanoic acid, alpha-(aminocarbonyl)-4-[2-(5-methyl-2-phenyl-4-oxazolyl)ethoxy]- (9CI) (CA INDEX NAME)



RN 213411-83-7 CAPLUS
CN 2,4-Thiazolidinedione, 5-[(4-{12-(5-methyl-2-phenyl-4-oxazolyl)ethoxy}benzo[b]thien-7-yl)methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A


RN 258345-41-4 CAPLUS
CN L-Tyrosine, N-[(12)-(1-methyl-3-oxo-3-phenyl-1-propenyl)-O-[2-(5-methyl-2-phenyl-4-oxazolyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.


ACCESSION NUMBER: 2001:545660 CAPLUS
DOCUMENT NUMBER: 135:137528
TITLE: Preparation of nitrogenous cyclic compounds and pharmaceutical compositions containing the same as calcium antagonists
INVENTOR(S): Yamamoto, Noboru; Suzuki, Yuichi; Kimura, Manami; Niidom, Tetsuhiro; Iimura, Yoichi; Teramoto, Tetsuyuki; Kaneda, Yoshihisa; Kaneko, Toshihiko; Kurusu, Nobuyuki; Shimmyo, Daisuke; Youskawa, Yukie; Hatakeyama, Shinji
PATENT ASSIGNEE(S): Eisai Co., Ltd., Japan
SOURCE: PCT Int. Appl., 289 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001053258	A1	20010726	WO 2001-JP288	20010118
W: AU, BR, CA, CN, HU, IL, KR, MX, NO, NZ, RU, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR				
CA 2398409	AA	20010726	CA 2001-2398409	20010118
AU 2001027059	A5	20010731	AU 2001-27059	20010118
AU 779870	B2	20050217		
JP 2001270861	A2	20011002	JP 2001-9591	20010118
EP 1254895	A1	20021106	EP 2001-901413	20010118
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY, TR				
BR 2001007733	A	20030311	BR 2001-7733	20010118
HU 200204071	A2	20030328	HU 2002-4071	20010118
RU 2230060	C2	20040610	RU 2002-122335	20010118
NZ 519981	A	20050225	NZ 2001-519981	20010118
ZA 2002005322	A	20030818	ZA 2002-5322	20020703
US 6906072	B1	20050614	US 2002-169837	20020710
NO 2002003456	A	20020920	NO 2002-3456	20020718
US 2004220193	A1	20041104	US 2004-855357	20040528
AU 2005201992	A1	20050602	AU 2005-201992	20050510
US 2006084658	A1	20060420	US 2005-229768	20050920
PRIORITY APPL. INFO.:			JP 2000-12176	A 20000120
			AU 2001-27059	A3 20010118
			WO 2001-JP288	W 20010118
			US 2002-169837	A3 20020710
			US 2004-855357	A3 20040528


OTHER SOURCE(S): MARPAT 135:137528
GI



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT



AB Title compds. [ArC1(CN)D1ED2AW1XW2B; Ar is a group derived from an optionally substituted 5- to 14-membered aromatic ring; ring A is one member selected from among piperazine, homopiperazine, and piperidine; ring B is an optionally substituted C3-14 hydrocarbon ring; E is a single bond, CO; R1 is hydrogen, halogeno, or hydroxyl; D1, D2, W1, W2 are each independently a single bond or optionally substituted C1-6 alkylene; X is a single bond, oxygen], salts, and hydrates are prepared as calcium antagonists, particularly neuroselective calcium antagonists, and are used in pharmaceutical compns. Thus, title compound I was prepared and biol. tested for calcium antagonism.
IT 59398-98-0
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of nitrogenous cyclic compound as calcium antagonists)
RN 59398-98-0 CAPLUS
CN 4-Oxazolemethanol, 2-phenyl- (6CI, 9CI) (CA INDEX NAME)




REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 45 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:283789 CAPLUS
 DOCUMENT NUMBER: 134:311210
 TITLE: 5-Membered heterocycle derivatives useful as
 monoamine
 and
 oxidase inhibitors, lipid peroxidation inhibitors,
 and
 sodium channel modulators, and the production
 thereof,
 and use thereof as medicaments
 INVENTOR(S): Chabrier de Lassaulniere, Pierre-Etienne; Harnett,
 Jeremiah; Blyg, Dennis; Pommier, Jacques; Lannoy,
 Jacques; Liberatore, Anne-Marie; Thureau, Christophe
 PATENT ASSIGNEE(S): Societe de Conseils de Recherches et d'Applications
 Scientifiques (S.C.R.A.S., Fr.
 SOURCE: PCT Int. Appl., 261 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: French
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001026656	A2	20010419	WO 2000-FR2805	20001010
WO 2001026656	A3	20020418		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LV, LU, MA, MD, MG, MK, MN, MW, MX, MY, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
FR 2799461	A1	20010413	FR 1999-12643	19991011
FR 2799461	B1	20020104		
FR 2812546	A1	20020208	FR 2000-10151	20000801
CA 2388505	AA	20010419	CA 2000-2388505	20001010
BR 2000014649	A	20020618	BR 2000-14649	20001010
EP 1223933	A2	20020724	EP 2000-967988	20001010
EP 1223933	B1	20060906		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
EP 1228760	A2	20020807	EP 2002-76763	20001010
EP 1228760	A3	20040128		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003511416	T2	20030325	JP 2001-529718	20001010
HU 200203841	A2	20030528	HU 2002-3841	20001010
NZ 518304	A	20040730	NZ 2000-518304	20001010
NZ 533429	A	20040924	NZ 2000-533429	20001010
AU 783129	B2	20050929	AU 2000-77965	20001010
EP 1589007	A2	20051026	EP 2005-76749	20001010
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, CY			
RU 2271355	C2	20060310	RU 2002-112227	20001010
AT 338547	E	20060915	AT 2000-967988	20001010
NO 2002001689	A	20020530	NO 2002-1689	20020410
US 2004132788	A1	20040708	US 2003-681002	20031008
US 2005038087	A1	20050217	US 2004-915001	20040810


L5 ANSWER 45 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 PRIORITY APPL. INFO.: FR 1999-12643 A 19991011
 FR 2000-10151 A 20000801
 FR 2000-11169 A 20000901
 EP 2000-967988 A3 20001010
 EP 2002-76763 A3 20001010
 WO 2000-FR2805 W 20001010
 FR 2001-4943 A 20010410
 FR 2002-1811 A 20020214
 US 2002-89993 A2 20020404
 WO 2002-FR1218 A1 20020409
 US 2003-681002 A2 20031008

OTHER SOURCE(S): MARPAT 134:311210
 GI



AB The invention relates to pharmaceutical use of heterocyclic compds. of general formula Het(A)(B)-(CH₂)_n-CR₁R₂-O [I; wherein the substituted heterocyclic ring Het(A)(B) = Q1-Q4; A = various aryl or heteroaryl systems, especially a substituted Ph or biphenyl radical, or also alkyl, cycloalkyl, or cycloalkylalkyl; B = especially H or alkyl, or also aryl or


L5 ANSWER 45 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 substituted alkyl; X = esp. NH or S, or also substituted NH; Y = O or S;
 n = 0-6; R1, R2 = esp. H, alkyl, or cycloalkyl; Q = NR3R4 or OR5; R3 and R4 = esp. H, alkyl, cycloalkyl, alkynyl, cyanoalkyl alkoxycarbonyl, azalkoxycarbonyl or (cycloalkyl)oxycarbonyl; R5 = H, alkyl, alkynyl, or cyanoalkyl. I and their racemates, enantiomers, and/or salts can be used for producing medicaments for inhibiting monoamine oxidases (MAO), inhibiting lipid peroxid., and/or for acting as modulators of sodium channels. The resulting medicaments are particularly for use in treating Parkinson's disease, senile dementia, Alzheimer's disease, Huntington's chorea, amyotrophic lateral sclerosis, schizophrenia, depression, psychosis, pain and epilepsy. Approx. 350 synthetic examples of I and their salts are given, and numerous free bases of I are claimed. For instance, protection of sarcosinamide-HCl with BOC anhydride gave 72% BOC-N(Me)CH₂CONH₂, which was converted to the thioamide with (P2S₅)₂ in 65% yield. Cyclocondensation of the thioamide with 2-bromo-1-(3,5-di-tert-butyl-4-hydroxyphenyl)ethanone (28), followed by deprotection (73%) and salification (92%), gave thiazole deriv. II as the HCl salt. II inhibited binding of the MAO-B specific ligand [3H]-Ro-19-6327 to rat mitochondrial preps. with IC₅₀ < 10 μM. Selected I also inhibited formation of malondialdehyde by lipid peroxid. in rat cerebral cortex preps., and inhibited specific binding of [3H]-batrachotoxin to voltage-dependent sodium channels in rat cerebral cortex homogenates.
 IT 206122-78-3, 2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]-4-oxazoleethanol
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses) (drug candidate); preparation of five-membered heterocycle derivs. as MAO inhibitors, lipid peroxid. inhibitors, and sodium channel modulators)
 RN 206122-78-3 CAPLUS
 CN 4-Oxazoleethanol, 2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 2001:152678 CAPLUS
 DOCUMENT NUMBER: 134:193433
 TITLE: Preparation of oxazoles and thiazoles useful as neurotrophin production/secretion promoting agents
 INVENTOR(S): Momose, Yu; Murase, Katsuhito
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 143 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001014372	A2	20010301	WO 2000-JP5681	20000824
WO 2001014372	A3	20020321		
W:	AE, AG, AL, AM, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CN, CR, CU, CZ, DM, DZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MA, MD, MG, MK, MN, MX, MY, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZA			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2382355	AA	20010301	CA 2000-2382355	20000824
JP 2001131161	A2	20010515	JP 2000-259390	20000824
JP 3558588	B2	20040825		
JP 2002080467	A2	20020319	JP 2001-205451	20000824
BR 2000013493	A	20020514	BR 2000-13493	20000824
EP 1206472	A1	20020522	EP 2000-954966	20000824
EP 1206472	B1	20031001		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
AT 251156	E	20031015	AT 2000-954966	20000824
HU 200302046	A2	20031028	HU 2003-2046	20000824
ES 2206292	T3	20040516	ES 2000-954966	20000824
PT 1206472	T	20040630	PT 2000-954966	20000824
AU 780307	B2	20050317	AU 2000-67276	20000824
RU 2260003	C2	20050910	RU 2002-107321	20000824
US 6605629	B1	20030812	US 2001-868304	20010629
ZA 200201044	A	20020206	ZA 2002-1044	20020206
NO 200200831	A	20020420	NO 2002-831	20020220
HK 1044762	A1	20040121	HK 2002-105926	20020813
PRIORITY APPL. INFO.:			JP 1999-238917	A 19990825
			JP 2000-259390	A3 20000824
			WO 2000-JP5681	W 20000824

OTHER SOURCE(S): MARPAT 134:193433
 GI




AB Neurotrophin production/secretion promoting agents which comprise an azole derivative I (e.g. 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-(3-(2-methylphenoxy)propyl)oxazole), wherein R1 = halogen, heterocyclic group, OH which may optionally be substituted, SH which may optionally be substituted, or an amino group which may optionally be substituted; A = acyl group, heterocyclic group, OH which may optionally be substituted, or carboxyl group which may optionally be esterified or amidated; B = aromatic group; X = O, S, N which may optionally be substituted; and Y = divalent hydrocarbon group or heterocyclic group, or a salt thereof, pharmaceutical compns. containing I, and their uses as agents for preventing or treating neuropathy are claimed. I scarcely produce side effects and can be used as prophylactic/therapeutic agents for peripheral neuropathies (e.g. diabetic neuropathy, cancer therapy-induced neuropathy), diabetic cardiomyopathy, peripheral nerve injury, spinal injury, amyotrophic lateral sclerosis, multiple sclerosis, Cerebral ischemic diseases, senile dementia of Alzheimer's type, Parkinson's disease or Huntington's chorea, depression, inflammatory bowel disease, chronic pain, behavioral abnormalities accompanied by dementia, anxiety, paresthesia or pain caused by a wound, diabetes, impaired glucose tolerance, hyperlipidemia, hyperinsulinemia, obesity, hyperphagia, hypertension, and cardiovascular diseases. I can also be used as ameliorating agents for peripheral neuropathies or cerebral metabolic disorders. The neurotrophin production/secretion promoting activity of 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-(3-(2-methylphenoxy)propyl)oxazole is presented. Although the methods of preparation are not claimed, >120 example preps. are included.


IT 198064-22-1P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolepropanol 198064-51-6P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolebutanol 198064-69-6P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolepentanol 327188-13-6P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-(3-(2-methylphenoxy)propyl)oxazole 327188-45-4P, Methyl 4-(4-chlorophenyl)-2-(2-pyrimidinylthio)-5-oxazolepropionate 327188-46-5P, 4-(4-Chlorophenyl)-2-(2-pyrimidinylthio)-5-oxazolepropanol 327188-51-2P, 2-Chloro-4-(4-chlorophenyl)-5-oxazolepropanol 327188-52-3P, 2-Chloro-4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl)oxazole 327188-72-7P, 4-(4-Fluorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolebutanol 327188-76-1P, 2-Chloro-4-(4-chlorophenyl)-5-(3-(2-methylphenoxy)propyl)oxazole 327189-04-8P, 4-(4-Methoxyphenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolebutanol 327189-24-2P, Ethyl 4-(4-(4-fluorophenyl)-2-oxo-4-oxazolin-5-yl)butanoate 327189-25-3P, Ethyl 2-chloro-4-(4-fluorophenyl)-5-oxazolebutanoate 327189-26-4P, Ethyl 4-(4-fluorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolebutanoate 327189-28-6P, 2-(2-Methyl-1-imidazolyl)-4-(4-(4-trifluoromethylphenyl)-5-oxazolepropanol 327189-30-0P, 4-(3,4-Dichlorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolepropanol 327189-39-9P, 4-(3-(4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolyloxy)propyl)-3-methylphenyl acetate 327189-41-3P, Methyl 3-(2-oxo-4-(4-trifluoromethylphenyl)-4-oxazolin-5-yl)propionate 327189-43-5P, Methyl 3-(4-(3,4-dichlorophenyl)-2-oxo-4-oxazolin-5-yl)propionate




RN 327188-45-4 CAPLUS
CN 5-Oxazolepropanoic acid, 4-(4-chlorophenyl)-2-(2-pyrimidinylthio)-, methyl ester (9CI) (CA INDEX NAME)



RN 327188-46-5 CAPLUS
CN 5-Oxazolepropanol, 4-(4-chlorophenyl)-2-(2-pyrimidinylthio)- (9CI) (CA INDEX NAME)




RN 327188-51-2 CAPLUS
CN 5-Oxazolepropanol, 2-chloro-4-(4-chlorophenyl)- (9CI) (CA INDEX NAME)




RN 327188-52-3 CAPLUS

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of oxazoles and thiazoles useful as neurotrophin prodn./secretion promoting agents)


RN 198064-22-1 CAPLUS
CN 5-Oxazolepropanol, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 198064-51-6 CAPLUS
CN 5-Oxazolebutanol, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 198064-69-6 CAPLUS
CN 5-Oxazolepentanol, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327188-13-6 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-(3-(2-methylphenoxy)propyl)- (9CI) (CA INDEX NAME)


CN Oxazole, 2-chloro-4-(4-chlorophenyl)-5-(3-(2-methoxyphenoxy)propyl)- (9CI) (CA INDEX NAME)




RN 327188-72-7 CAPLUS
CN 5-Oxazolebutanol, 4-(4-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327188-76-1 CAPLUS
CN Oxazole, 2-chloro-4-(4-chlorophenyl)-5-(3-(2-methylphenoxy)propyl)- (9CI) (CA INDEX NAME)




RN 327189-04-8 CAPLUS
CN 5-Oxazolebutanol, 4-(4-methoxyphenyl)-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327189-24-2 CAPLUS
CN 5-Oxazolebutanoic acid, 4-(4-fluorophenyl)-2,3-dihydro-2-oxo-, ethyl ester (9CI) (CA INDEX NAME)




RN 327189-25-3 CAPLUS
CN 5-Oxazolebutanoic acid, 2-chloro-4-(4-fluorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 327189-26-4 CAPLUS
CN 5-Oxazolebutanoic acid, 4-(4-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-, ethyl ester (9CI) (CA INDEX NAME)



RN 327189-28-6 CAPLUS
CN 5-Oxazolepropanoic acid, 2-(2-methyl-1H-imidazol-1-yl)-4-(4-(trifluoromethyl)phenyl)- (9CI) (CA INDEX NAME)




RN 327189-43-5 CAPLUS
CN 5-Oxazolepropanoic acid, 4-(3,4-dichlorophenyl)-2,3-dihydro-2-oxo-, methyl ester (9CI) (CA INDEX NAME)




IT 198064-25-4P, 4-(4-Chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327188-14-7P, 4-(4-Chlorophenyl)-5-[3-(4-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327188-15-8P, 4-(4-Chlorophenyl)-5-[3-(3-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327188-16-9P, 4-(4-Chlorophenyl)-5-[3-(2-ethoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327188-17-0P, 4-(4-Chlorophenyl)-5-[4-(2-methoxyphenoxy)butyl]-2-(2-methyl-1-imidazolyl)oxazole 327188-23-8P, Methyl 4-[4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolyl]butyrate 327188-24-9P, 4-(4-Chlorophenyl)-5-[4-(4-hydroxymethylphenoxy)butyl]-2-(2-methyl-1-imidazolyl)oxazole 327188-25-0P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-54-5P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-55-6P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-56-7P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-57-8P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-58-9P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-59-0P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-60-1P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-61-2P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-62-3P, 2-(1-Benzimidazolyl)-4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-64-7P, 4-(4-Chlorophenyl)-2-(3-hydroxymethyl-1-piperidinyl)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-65-8P, 4-(4-Chlorophenyl)-2-[N-(2-hydroxyethyl)-N-methylamino]-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-66-9P, 2-(1-Benzotriazolyl)-4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-67-0P, 4-(4-Chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-68-1P, 4-(4-Chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-69-2P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-70-5P, 5-[3-(4-Chloro-3-fluorophenoxy)propyl]-4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-71-6P, 4-(4-Chlorophenyl)-2-dimethylamino-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-73-8P, 4-(4-Fluorophenyl)-2-(2-methyl-1-imidazolyl)-5-[4-(2-methylphenoxy)butyl]oxazole 327188-77-2P, 4-(4-Chlorophenyl)-2-(1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole 327188-78-3P, 4-(4-Chlorophenyl)-2-(2-ethyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole 327188-79-4P, 4-(4-Chlorophenyl)-2-(2-ethyl-1-imidazolyl)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-80-7P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(3-methylphenoxy)propyl]oxazole 327188-81-8P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(4-methylphenoxy)propyl]oxazole 327188-82-9P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-83-0P, 4-(4-Chlorophenyl)-5-[3-(2-hydroxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327188-84-1P, 5-[3-(4-Chloro-2-methylphenoxy)propyl]-4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-85-2P, 5-[3-(4-Chloro-2-methoxyphenoxy)propyl]-4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-86-3P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[4-(2-methylphenoxy)butyl]oxazole 327188-87-4P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[5-(2-methylphenoxy)pentyl]oxazole 327188-89-6P, 4-(4-Chlorophenyl)-5-[3-(4-tert-butylphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327188-90-9P, 4-(4-Chlorophenyl)-5-[3-(2,4-dimethylphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327188-91-0P, Ethyl 1-[4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl]imidazole-2-carboxylate 327188-92-1P, 4-(4-Chlorophenyl)-2-(2-isopropyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole 327188-93-2P, 4-(4-Chlorophenyl)-5-[3-(2-methylphenoxy)propyl]-2-(2-phenyl-1-imidazolyl)oxazole 327188-94-3P, 4-(4-Chlorophenyl)-2-(3,5-dimethyl-1-pyrazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole 327188-95-4P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-phenoxypropyl]oxazole 327188-96-5P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2,3-dimethylphenoxy)propyl]oxazole 327188-97-6P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(3,3-dimethylphenoxy)propyl]oxazole 327188-98-7P, 4-(4-Chlorophenyl)-5-[3-(2,6-dimethylphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327188-99-8P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methyl-5-isopropylphenoxy)propyl]oxazole 327189-00-4P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-isopropylphenoxy)propyl]oxazole 327189-01-5P,


4-(4-Chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(1H-1,2,4-triazol-1-yl)oxazole 327188-43-2P, 4-(4-Chlorophenyl)-5-[3-(2-cyanophenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327188-44-3P, 4-(4-Chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-pyridylthio)oxazole 327188-47-6P, 4-(4-Chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-pyrimidinylthio)oxazole 327188-53-4P, 4-(4-Chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(1-methyl-2-imidazolylthio)oxazole 327188-54-5P, 4-(4-Chlorophenyl)-2-(3-hydroxy-1-propylthio)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-55-6P, N-[2-(4-(4-Chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl)-1-methylethyl]trifluoroacetamide 327188-56-7P, 4-(4-Chlorophenyl)-2-(4-morpholinyl)-5-[3-(2-



RN 327189-30-0 CAPLUS
CN 5-Oxazolepropanoic acid, 4-(3,4-dichlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 327189-39-9 CAPLUS
CN Phenol, 4-[3-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-oxazolyl]propoxy]-3-methyl-, acetate (ester) (9CI) (CA INDEX NAME)



RN 327189-41-3 CAPLUS
CN 5-Oxazolepropanoic acid, 2,3-dihydro-2-oxo-4-[4-(trifluoromethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)



methoxyphenoxy)propyl]oxazole 327188-57-8P, Ethyl N-[4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl]isonicotinate 327188-58-9P, 4-(4-Chlorophenyl)-2-(N-methyl-N-benzylamino)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-61-4P, 4-(4-Chlorophenyl)-2-(4,5-diphenyl-1-imidazolyl)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-62-5P, 2-(1-Benzimidazolyl)-4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-64-7P, 4-(4-Chlorophenyl)-2-(3-hydroxymethyl-1-piperidinyl)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-65-8P, 4-(4-Chlorophenyl)-2-[N-(2-hydroxyethyl)-N-methylamino]-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-66-9P, 2-(1-Benzotriazolyl)-4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-67-0P, 4-(4-Chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-68-1P, 4-(4-Chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-69-2P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-70-5P, 5-[3-(4-Chloro-3-fluorophenoxy)propyl]-4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-71-6P, 4-(4-Chlorophenyl)-2-dimethylamino-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-73-8P, 4-(4-Fluorophenyl)-2-(2-methyl-1-imidazolyl)-5-[4-(2-methylphenoxy)butyl]oxazole 327188-77-2P, 4-(4-Chlorophenyl)-2-(1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole 327188-78-3P, 4-(4-Chlorophenyl)-2-(2-ethyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole 327188-79-4P, 4-(4-Chlorophenyl)-2-(2-ethyl-1-imidazolyl)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-80-7P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(3-methylphenoxy)propyl]oxazole 327188-81-8P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(4-methylphenoxy)propyl]oxazole 327188-82-9P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methoxyphenoxy)propyl]oxazole 327188-83-0P, 4-(4-Chlorophenyl)-5-[3-(2-hydroxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327188-84-1P, 5-[3-(4-Chloro-2-methylphenoxy)propyl]-4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-85-2P, 5-[3-(4-Chloro-2-methoxyphenoxy)propyl]-4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)oxazole 327188-86-3P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[4-(2-methylphenoxy)butyl]oxazole 327188-87-4P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[5-(2-methylphenoxy)pentyl]oxazole 327188-89-6P, 4-(4-Chlorophenyl)-5-[3-(4-tert-butylphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327188-90-9P, 4-(4-Chlorophenyl)-5-[3-(2,4-dimethylphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327188-91-0P, Ethyl 1-[4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl]imidazole-2-carboxylate 327188-92-1P, 4-(4-Chlorophenyl)-2-(2-isopropyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole 327188-93-2P, 4-(4-Chlorophenyl)-5-[3-(2-methylphenoxy)propyl]-2-(2-phenyl-1-imidazolyl)oxazole 327188-94-3P, 4-(4-Chlorophenyl)-2-(3,5-dimethyl-1-pyrazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole 327188-95-4P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-phenoxypropyl]oxazole 327188-96-5P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2,3-dimethylphenoxy)propyl]oxazole 327188-97-6P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(3,3-dimethylphenoxy)propyl]oxazole 327188-98-7P, 4-(4-Chlorophenyl)-5-[3-(2,6-dimethylphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327188-99-8P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methyl-5-isopropylphenoxy)propyl]oxazole 327189-00-4P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-isopropylphenoxy)propyl]oxazole 327189-01-5P,

L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

4-(4-Chlorophenyl)-5-[3-(5-indanyloxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327189-02-6P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(5,6,7,8-tetrahydro-1-naphthoxy)propyl]oxazole 327189-03-7P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(5,6,7,8-tetrahydro-2-naphthoxy)propyl]oxazole 327189-05-9P, 4-(4-Methoxyphenyl)-2-(2-methyl-1-imidazolyl)-5-[4-(2-methylphenoxy)butyl]oxazole 327189-06-0P, 4-(4-Chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-propyl-1-imidazolyl)oxazole 327189-07-1P, 4-(4-Chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-undecyl-1-imidazolyl)oxazole 327189-09-3P, Methyl 1-[4-(4-chlorophenyl)-5-[3-(2-methylphenoxy)propyl]-2-oxazolyl]-2-imidazolepropionate 327189-10-6P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(3,4,5-trimethylphenoxy)propyl]oxazole 327189-11-7P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2,4,6-trimethylphenoxy)propyl]oxazole 327189-12-8P, 4-(4-Chlorophenyl)-5-[3-(2,3-dimethoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327189-13-9P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(3,4,5-trimethoxyphenoxy)propyl]oxazole 327189-14-0P, 4-(4-Chlorophenyl)-5-[3-(2,6-dimethoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327189-15-1P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylthiophenoxy)propyl]oxazole 327189-16-2P, Methyl 3-[2-(3-[4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolyl]propoxy]phenyl]propionate 327189-17-3P, 4-(4-Chlorophenyl)-5-[3-[2-(3-hydroxypropyl)phenoxy]propyl]-2-(2-methyl-1-imidazolyl)oxazole 327189-18-4P, 3-[2-[3-[4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolyl]propoxy]phenyl]propionic acid 327189-27-5P, Ethyl 4-[4-(fluorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolebutanoate hydrochloride 327189-29-7P, 2-(2-Methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]-4-(4-trifluoromethylphenyl)oxazole 327189-31-1P, 4-(3,4-Dichlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole 327189-32-2P, 4-(4-Chlorophenyl)-5-[3-(3-cyanophenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327189-33-3P, 4-(4-Chlorophenyl)-5-[3-(4-cyano-2-methoxyphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327189-34-4P, 4-(4-Chlorophenyl)-5-[3-(4-fluoro-2-methylphenoxy)propyl]-2-(2-methyl-1-imidazolyl)oxazole 327189-35-5P, Diethyl 4-[3-[4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolyl]propoxy]benzylphosphonate 327189-37-7P, 2-[4-[3-[4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolyl]propoxy]phenyl]acetonitrile 327189-38-8P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydro-2-naphthalenyl)oxy]propyl]oxazole 327189-40-2P, 4-[3-[4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolyl]propoxy]-3-methylphenol 327189-42-4P, Methyl 2-chloro-4-[4-(trifluoromethylphenyl)-5-oxazolepropionate 327189-44-6P, Methyl 2-chloro-4-[3,4-dichlorophenyl)-5-oxazolepropionate 327189-45-7P, Methyl 2-(2-methyl-1-imidazolyl)-4-(4-trifluoromethylphenyl)-5-oxazolepropionate 327189-46-8P, Methyl 4-[3,4-dichlorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolepropionate 327189-47-9P, 4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxy)propyl]oxazole hydrochloride



RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of oxazoles and thiazoles useful as neurotrophin

L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


prodn./secretion promoting agents)
RN 198064-25-4 CAPLUS
CN Oxazole,
4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327188-15-8 CAPLUS
CN Oxazole,
4-(4-chlorophenyl)-5-[3-(3-methoxyphenoxy)propyl]-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)


L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

CN Benzoic acid, 4-[4-[4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-oxazolyl]butoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 327188-24-9 CAPLUS
CN Benzenemethanol,
4-[4-[4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-oxazolyl]butoxy]- (9CI) (CA INDEX NAME)







RN 327188-26-1 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-[4-(trifluoromethoxy)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 327188-27-2 CAPLUS
CN Benzonitrile, 4-[3-[4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-oxazolyl]propoxy]- (9CI) (CA INDEX NAME)




RN 327188-28-3 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-[4-(trifluoromethyl)phenoxy]propyl]- (9CI) (CA INDEX NAME)




RN 327188-35-2 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(1H-imidazol-1-yl)-5-[3-(2-methoxyphenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 327188-36-3 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327188-37-4 CAPLUS
CN 1H-1,2,4-Triazole, 1-[4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl]- (9CI) (CA INDEX NAME)




RN 327188-43-2 CAPLUS
CN Benzonitrile, 2-[3-[4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-



RN 327188-44-3 CAPLUS
CN Pyridine, 2-[[4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)




RN 327188-47-6 CAPLUS
CN Pyrimidine, 2-[[4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)




RN 327188-53-4 CAPLUS

L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN Oxazole,
 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-[(1-methyl-1H-imidazol-2-yl)thio]- (9CI) (CA INDEX NAME)




RN 327188-54-5 CAPLUS
 CN 1-Propanol, 3-[[4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl]thio]- (9CI) (CA INDEX NAME)




RN 327188-55-6 CAPLUS
 CN Acetamide, N-[2-[[4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl]oxy]-1-methylethyl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)


L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 327188-56-7 CAPLUS
 CN Morpholine, 4-[4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl]- (9CI) (CA INDEX NAME)




RN 327188-57-8 CAPLUS
 CN 4-Piperidinecarboxylic acid, 1-[4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 327188-58-9 CAPLUS
 CN 2-Oxazoline,
 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-N-methyl-


L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 N-(phenylmethyl)- (9CI) (CA INDEX NAME)



RN 327188-61-4 CAPLUS
 CN Oxazole, 4-(4-chlorophenyl)-2-(4,5-diphenyl-1H-imidazol-1-yl)-5-[3-(2-methoxyphenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 327188-62-5 CAPLUS
 CN 1H-Benzimidazole, 1-[4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl]- (9CI) (CA INDEX NAME)




RN 327188-64-7 CAPLUS


L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 CN 3-Piperidinemethanol,
 1-[4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl]- (9CI) (CA INDEX NAME)



RN 327188-65-8 CAPLUS
 CN Ethanol, 2-[[4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl]methylamino]- (9CI) (CA INDEX NAME)




RN 327188-66-9 CAPLUS
 CN 1H-Benzotriazole, 1-[4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl]- (9CI) (CA INDEX NAME)




L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)

RN 327188-67-0 CAPLUS
CN Piperazine, 1-[4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl]-4-phenyl- (9CI) (CA INDEX NAME)




RN 327188-68-1 CAPLUS
CN Benzenesacetic acid, 4-[3-[4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-oxazolyl]propoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 327188-69-2 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-(4-phenoxyphenoxy)propyl]- (9CI) (CA INDEX NAME)


L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 327188-73-8 CAPLUS
CN Oxazole, 4-(4-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[4-(2-methylphenoxy)butyl]- (9CI) (CA INDEX NAME)




RN 327188-77-2 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(1H-imidazol-1-yl)-5-[3-(2-methylphenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 327188-78-3 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(2-ethyl-1H-imidazol-1-yl)-5-[3-(2-methylphenoxy)propyl]- (9CI) (CA INDEX NAME)

L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 327188-70-5 CAPLUS
CN Oxazole, 5-[3-(4-chloro-3-fluorophenoxy)propyl]-4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327188-71-6 CAPLUS
CN 2-Oxazoline, 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)


L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 327188-79-4 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(2-ethyl-1H-imidazol-1-yl)-5-[3-(2-methoxyphenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 327188-80-7 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-(3-methylphenoxy)propyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 327188-81-8 CAPLUS
 CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-(4-methylphenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 327188-82-9 CAPLUS
 CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-(2-propoxyphenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 327188-83-0 CAPLUS
 CN Phenol, 2-[3-[(4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-oxazolyl)propoxy]- (9CI) (CA INDEX NAME)


L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 327188-86-3 CAPLUS
 CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[4-(2-methylphenoxy)butyl]- (9CI) (CA INDEX NAME)




RN 327188-87-4 CAPLUS
 CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[5-(2-methylphenoxy)pentyl]- (9CI) (CA INDEX NAME)



L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 327188-84-1 CAPLUS
 CN Oxazole, 5-[3-(4-chloro-2-methylphenoxy)propyl]-4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327188-85-2 CAPLUS
 CN Oxazole, 5-[3-(4-chloro-2-methoxyphenoxy)propyl]-4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)

L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)


RN 327188-89-6 CAPLUS
 CN Oxazole, 4-(4-chlorophenyl)-5-[3-(4-(1,1-dimethylethyl)phenoxy)propyl]-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327188-90-9 CAPLUS
 CN Oxazole, 4-(4-chlorophenyl)-5-[3-(2,4-dimethylphenoxy)propyl]-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327188-91-0 CAPLUS
 CN 1H-Imidazole-2-carboxylic acid, 1-[4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-oxazolyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 327188-92-1 CAPLUS
CN Oxazole,
4-(4-chlorophenyl)-2-[2-(1-methylethyl)-1H-imidazol-1-yl]-5-[3-(2-methylphenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 327188-93-2 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-5-[3-(2-methylphenoxy)propyl]-2-(2-phenyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327188-94-3 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(3,5-dimethyl-1H-pyrazol-1-yl)-5-[3-(2-methylphenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 327188-95-4 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-(2-methylphenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 327188-96-5 CAPLUS
CN Oxazole,
4-(4-chlorophenyl)-5-[3-(2,3-dimethylphenoxy)propyl]-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327188-97-6 CAPLUS
CN Oxazole,
4-(4-chlorophenyl)-5-[3-(3,5-dimethylphenoxy)propyl]-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327188-98-7 CAPLUS
CN Oxazole,
4-(4-chlorophenyl)-5-[3-(2,6-dimethylphenoxy)propyl]-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327188-99-8 CAPLUS
CN Oxazole,
4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-(2-methyl-5-(1-methylethyl)phenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 327189-00-4 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-5-[3-[2-(1-methylethyl)phenoxy]propyl]-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327189-01-5 CAPLUS
CN Oxazole,
4-(4-chlorophenyl)-5-[3-[(2,3-dihydro-1H-inden-5-yl)oxy]propyl]-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 327189-02-6 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-[(5,6,7,8-tetrahydro-1-naphthalenyl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 327189-03-7 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-[(5,6,7,8-tetrahydro-2-naphthalenyl)oxy]propyl]- (9CI) (CA INDEX NAME)




RN 327189-05-9 CAPLUS
CN Oxazole, 4-(4-methoxyphenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[4-(2-methylphenoxy)butyl]- (9CI) (CA INDEX NAME)


RN 327189-09-3 CAPLUS
CN 1H-Imidazole-2-propanoic acid, 1-[4-(4-chlorophenyl)-5-[3-(2-methylphenoxy)propyl]-2-oxazolyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 327189-10-6 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-(3,4,5-trimethoxyphenoxy)propyl]- (9CI) (CA INDEX NAME)





RN 327189-11-7 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-(2,4,6-trimethoxyphenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 327189-06-0 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-propyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327189-07-1 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-5-[3-(2-methoxyphenoxy)propyl]-2-(2-undecyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327189-12-8 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-5-[3-(2,3-dimethoxyphenoxy)propyl]-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327189-13-9 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-(3,4,5-trimethoxyphenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 327189-14-0 CAPLUS
CN Oxazole,
4-(4-chlorophenyl)-5-[3-(2,6-dimethoxyphenoxy)propyl]-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327189-15-1 CAPLUS
CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-(2-methylthiophenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 327189-16-2 CAPLUS
CN Benzenepropanoic acid,
2-[3-[4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-oxazolyl]propoxy]-, methyl ester (9CI) (CA INDEX NAME)




RN 327189-17-3 CAPLUS
CN Benzenepropanol,
2-[3-[4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-oxazolyl]propoxy]- (9CI) (CA INDEX NAME)



RN 327189-18-4 CAPLUS
CN Benzenepropanoic acid,
2-[3-[4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-oxazolyl]propoxy]- (9CI) (CA INDEX NAME)




RN 327189-27-5 CAPLUS
CN 5-Oxazolebutanoic acid,
4-(4-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-, ethyl ester, hydrochloride (9CI) (CA INDEX NAME)




● X HCl


RN 327189-29-7 CAPLUS
CN Oxazole,
2-(2-methyl-1H-imidazol-1-yl)-5-[3-(2-methylphenoxy)propyl]-4-[4-(trifluoromethyl)phenyl]- (9CI) (CA INDEX NAME)




RN 327189-31-1 CAPLUS
CN Oxazole, 4-(3,4-dichlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-(2-methylphenoxy)propyl]- (9CI) (CA INDEX NAME)




RN 327189-32-2 CAPLUS
CN Benzonitrile, 3-[3-[4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-oxazolyl]propoxy]- (9CI) (CA INDEX NAME)



L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 327189-33-3 CAPLUS
 CN Benzonitrile, 4-[3-[4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-oxazolyl]propoxy]-3-methoxy- (9CI) (CA INDEX NAME)




RN 327189-34-4 CAPLUS
 CN Oxazole, 4-(4-chlorophenyl)-5-[3-(4-fluoro-2-methylphenoxy)propyl]-2-(2-methyl-1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327189-35-5 CAPLUS
 CN Phosphonic acid, [[4-[3-[4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-oxazolyl]propoxy]phenyl]methyl]-, diethyl ester (9CI) (CA INDEX NAME)

L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 327189-37-7 CAPLUS
 CN Benzenecetonitrile, 4-[3-[4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-oxazolyl]propoxy]- (9CI) (CA INDEX NAME)




RN 327189-38-8 CAPLUS
 CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)oxy]propyl]- (9CI) (CA INDEX NAME)


L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)



RN 327189-40-2 CAPLUS
 CN Phenol, 4-[3-[4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-oxazolyl]propoxy]-3-methyl- (9CI) (CA INDEX NAME)




RN 327189-42-4 CAPLUS
 CN 5-Oxazolepropanoic acid, 2-chloro-4-[4-(trifluoromethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 327189-44-6 CAPLUS
 CN 5-Oxazolepropanoic acid, 2-chloro-4-[3,4-dichlorophenyl]-, methyl ester (9CI) (CA INDEX NAME)


L5 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




RN 327189-45-7 CAPLUS
 CN 5-Oxazolepropanoic acid, 2-(2-methyl-1H-imidazol-1-yl)-4-[4-(trifluoromethyl)phenyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 327189-46-8 CAPLUS
 CN 5-Oxazolepropanoic acid, 4-(3,4-dichlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-, methyl ester (9CI) (CA INDEX NAME)




RN 327189-47-9 CAPLUS
 CN Oxazole, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-5-[3-(2-methylphenoxy)propyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl



IT 198063-87-5, Methyl 2-chloro-4-(4-chlorophenyl)-5-oxazolepropanoate 198064-23-2, 4-(4-Chlorophenyl)-2-(1-pyrazolyl)-5-oxazolepropanol 198064-43-6, 4-(4-Chlorophenyl)-2-(1-imidazolyl)-5-oxazolepropanol 198064-44-7, 4-(4-Chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)-5-oxazolepropanol 198064-45-8, 4-(4-Chlorophenyl)-2-(2-pyridinylthio)-5-oxazolepropanol 198064-57-2, 3-[4-(4-Chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-oxazolyl]propyl methanesulfonate 327188-50-1, Ethyl 2-chloro-4-(4-chlorophenyl)-5-oxazolepropanoate
 RL: RCT (Reactant); RACT (Reactant or reagent)
 (reactant; preparation of oxazoles and thiazoles useful as neurotrophin production/secretion promoting agents)
 RN 198063-87-5 CAPLUS
 CN 5-Oxazolepropanoic acid, 2-chloro-4-(4-chlorophenyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 198064-23-2 CAPLUS
 CN 5-Oxazolepropanol, 4-(4-chlorophenyl)-2-(1H-pyrazol-1-yl)- (9CI) (CA INDEX NAME)




RN 327188-50-1 CAPLUS
 CN 5-Oxazolepropanoic acid, 2-chloro-4-(4-chlorophenyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 198064-43-6 CAPLUS
 CN 5-Oxazolepropanol, 4-(4-chlorophenyl)-2-(1H-imidazol-1-yl)- (9CI) (CA INDEX NAME)



RN 198064-44-7 CAPLUS
 CN 5-Oxazolepropanol, 4-(4-chlorophenyl)-2-(1H-1,2,4-triazol-1-yl)- (9CI) (CA INDEX NAME)



RN 198064-45-8 CAPLUS
 CN 5-Oxazolepropanol, 4-(4-chlorophenyl)-2-(2-pyridinylthio)- (9CI) (CA INDEX NAME)




RN 198064-57-2 CAPLUS
 CN 5-Oxazolepropanol, 4-(4-chlorophenyl)-2-(2-methyl-1H-imidazol-1-yl)-, methanesulfonate (ester) (9CI) (CA INDEX NAME)


ACCESSION NUMBER: 2001:63981 CAPLUS
 DOCUMENT NUMBER: 134:115970
 TITLE: Preparation and effect of pyrazinones against caspase-3
 INVENTOR(S): Han, Yongxin; Giroux, Andre; Zamboni, Robert; McKay, Daniel J.; Bayly, Christopher I.; Grimm, Erich L.; Colucci, John
 PATENT ASSIGNEE(S): Merck Frosst Canada and Co., Can.
 SOURCE: PCT Int. Appl., 92 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001005772	A1	20010125	WO 2000-CA833	20000717
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, T2, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
CA 2378834	AA	20010125	CA 2000-2378834	20000717
EP 1202976	A1	20020508	EP 2000-947711	20000717
EP 1202976	B1	20061102		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
JP 2003505378	T2	20030212	JP 2001-511433	20000717
AU 773317	B2	20040520	AU 2000-61432	20000717
US 6444811	B1	20020903	US 2000-618875	20000719
US 2003236402	A1	20031225	US 2002-202817	20020725
US 6699856	B2	20040302		
PRIORITY APPLN. INFO.:			US 1999-14466P	P 19990719
			US 1999-170614P	P 19991214
			WO 2000-CA833	W 20000717
			US 2000-618875	A3 20000719

OTHER SOURCE(S): MARPAT 134:115970
 GI



I



II

AB Title compds. [I; R1 = H; R2 = CH3CH2, CH3OCH2, C6H5, CH3SCH2, C6H5CH2OCH2, H, CH3(CH2)2; R1R2 = (CH2)4, CH3N(CH2)2(CH2)2; R3 = C6H5CH2SCH2, 2-F-6-ClC6H3CH2SCH2, C6H5CH2NHCH2, H, C6H5CH2N(CH3)CH2, C6H5CH2N(CH2CH3)CH2, CH3(CH2)N(CH2)CH2, C6H5(CH2)3, CH3; R4 = H, CH3CH2, (CH3)3C, (CH3)2CH; Q = heterocyclalkyl, heterocyclyl, heterocyclphenyl, heterocyclphenylalkyl, CH3OCH2CH2], enantiomers, pharmaceutically acceptable salts, esters, N-oxides and hydrates are disclosed. Pharmaceutical compns. and methods of use are also included. The compds. are active against the caspase-3 enzyme, and thus are useful to treat caspase-3 mediated diseases and conditions. Thus, the title compound II was prepared and tested.

IT 321436-51-5P


RL: BAC (Biological activity or effector, except adverse); BSU

(Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation and effect of pyrazinones against caspase-3 enzyme)

RN 321436-51-5 CAPLUS

CN 2-Oxazolebutanoic acid, β-[[2-[3-[[4-methyl-1,2,5-oxadiazol-3-yl)methyl]amino]-2-oxo-1(2H)-pyrazinyl]-1-oxobutyl]amino]-γ-oxo-5-phenyl-, (BS)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

ACCESSION NUMBER: 1998:338114 CAPLUS
DOCUMENT NUMBER: 129:12755
TITLE: Use of selected nonsteroidal antiinflammatory compounds for the prevention and the treatment of neurodegenerative diseases
INVENTOR(S): Grilli, Mariagrazia; Pizzi, Marina; Memo, Maurizio; Spano, Pierfranco
PATENT ASSIGNEE(S): Universita' Degli Studi di Brescia - Dipartimento di Scienze Biomediche, Italy
SOURCE: PCT Int. Appl., 24 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9820864	A2	19980522	WO 1997-EP6323	19971113
WO 9820864	A3	19981015		

W: JP, US

SE RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,

PRIORITY APPLN. INFO.: IT 1996-MI2356 A 19961113

OTHER SOURCE(S): MARPAT 129:12755

AB Nonsteroidal antiinflammatory compds. are used for the prevention and the treatment of neurodegenerative diseases, e.g. Alzheimer's disease and Parkinson's disease.

IT 21256-18-8, Oxaprozol 21256-18-8D, Oxaprozol, metabolites

RL: BAC (Biological activity or effector, except adverse); BSU


(Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES

(Uses)

(nonsteroidal antiinflammatory compds. for prevention and treatment of neurodegenerative diseases)


RN 21256-18-8 CAPLUS

CN 2-Oxazolepropanoic acid, 4,5-diphenyl- (9CI) (CA INDEX NAME)



RN 21256-18-8 CAPLUS

CN 2-Oxazolepropanoic acid, 4,5-diphenyl- (9CI) (CA INDEX NAME)




L5 ANSWER 49 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN
 ANSWER NUMBER: 127:109198
 DOCUMENT NUMBER: 127:109198
 TITLE: Inhibitors of interleukin-1 β converting enzyme
 INVENTOR(S): Bemis, Guy W.; Duffy, John P.; Friedman, Wolf Herman;
 Golec, Julian M. C.; Livingston, David J.; Mullican,
 Michael D.; Murcko, Mark A.; Zelle, Robert E.
 PATENT ASSIGNEE(S): Vertex Pharmaceuticals Incorporated, USA
 SOURCE: PCT Int. Appl., 103 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9722618	A1	19970626	WO 1996-US20370	19961220
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LA, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5843904	A	19981201	US 1995-575648	19951220
CA 2240489	AA	19970626	CA 1996-2240489	19961220
ZA 9610797	A	19970626	ZA 1996-10797	19961220
AU 9714658	A1	19970714	AU 1997-14658	19961220
AU 722936	B2	20000817		
EP 876395	A1	19981111	EP 1996-945237	19961220
EP 876395	B1	20051116		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, RO				
CN 1207743	A	19990210	CN 1996-199733	19961220
CN 1127511	B	20031112		
BR 9612191	A	19990713	BR 1996-12191	19961220
HU 9902254	A2	19990928	HU 1999-2254	19961220
NZ 326555	A	20000327	NZ 1996-326555	19961220
JP 2000503635	T2	20000328	JP 1997-523008	19961220
RU 2213096	C2	20030927	RU 1998-113932	19961220
CZ 292633	B6	20031112	CZ 1998-1905	19961220
CN 1500781	A	20040602	CN 2003-2003158992	19961220
PL 188813	B1	20050429	PL 1996-327333	19961220
IL 124954	A1	20051120	IL 1996-124954	19961220
AT 310013	E	20051215	AT 1996-945237	19961220
US 6162790	A	20001219	US 1998-24537	19980217
NO 9802774	A	19980819	NO 1998-2774	19980616
HK 1016611	A1	20060929	HK 1999-101441	19990409
JP 2004143182	A2	20040520	JP 2003-408331	20031205
PRIORITY APPLN. INFO.:			US 1995-575648	A 19951220
			JP 1997-523008	A3 19961220
			WO 1996-US20370	W 19961220

OTHER SOURCE(S): MARPAT 127:109198
 AB Compds. R5(NHCHR4CO)nNR3CH2CONHCH(CH(OR2)(OR1))(CH2)mCO2R [R = H, (un)substituted alkyl; R1, R2 = R6, COR6, CONHR6 (R6 = aryl, alkyl, aralkyl, etc.); R1 and R2 may form a saturated cyclic group; or corresponding

L5 ANSWER 49 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)
 anhydrides for the case of R = R1 = H; R3 = arylmethyl, non-arom. cyclic group; R4 = (un)substituted alkyl; R5 = COR6, CO2H or ester or amide deriva., SO2R6, COCOR6, R6, H; m = 1, 2; n = 0-21 were prepd. as inhibitors of interleukin-1 β converting enzyme (ICE). Thus, (S)-Br-L-Val-N(Bzl)CH2CONHCH(CH2CO2CO2H)CHO was prepd. via peptide coupling in soln. and found to have an ICE inhibition const. (Ki) of 69 nM.
 IT 192582-96-0P 192583-11-2P 192583-13-4P
 192583-15-6P 192583-17-8P
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (inhibitors of interleukin-1 β converting enzyme)
 RN 192582-96-0 CAPLUS
 CN Glycinamide, N-benzoyl-L-valyl-N-[(1S)-1-(carboxymethyl)-2-[5-(2,6-dichlorophenyl)-2-oxazolyl]-2-oxoethyl]-N2-(phenylmethyl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192583-11-2 CAPLUS
 CN Glycinamide, N-benzoyl-L-valyl-N-[(1S)-1-(carboxymethyl)-2-[5-(2,6-dichlorophenyl)-2-oxazolyl]-2-oxoethyl]-N2-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 49 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 192583-13-4 CAPLUS
 CN Glycinamide, N-(1,3-benzodioxol-5-ylcarbonyl)-L-valyl-N-[(1S)-1-(carboxymethyl)-2-[5-(2,6-dichlorophenyl)-2-oxazolyl]-2-oxoethyl]-N2-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 192583-15-6 CAPLUS
 CN Glycinamide, N-(3,4,5-trimethoxybenzoyl)-L-valyl-N-[(1S)-1-(carboxymethyl)-2-[5-(2,6-dichlorophenyl)-2-oxazolyl]-2-oxoethyl]-N2-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.

L5 ANSWER 49 OF 50 CAPLUS COPYRIGHT 2006 ACS ON STN (Continued)



RN 192583-17-8 CAPLUS
 CN Glycinamide, N-(4-chlorobenzoyl)-L-valyl-N-[(1S)-1-(carboxymethyl)-2-[5-(2,6-dichlorophenyl)-2-oxazolyl]-2-oxoethyl]-N2-(2,3-dihydro-1H-inden-2-yl)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



IT 192582-94-8P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent) (inhibitors of interleukin-1 β converting enzyme)


L5 ANSWER 49 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 192582-94-8 CAPLUS
 CN Glycinamide, N-benzoyl-L-valyl-N-[(1S)-1-[[5-(2,6-dichlorophenyl)-2-oxazolyl]hydroxymethyl]-3-(1,1-dimethylethoxy)-3-oxopropyl]-N2-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 192582-93-7P 192582-95-9P
 RL: RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use);
 BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent);
 USES (Uses)
 (inhibitors of interleukin-1 β converting enzyme)
 RN 192582-93-7 CAPLUS
 CN 2-Oxazolidinebutanoic acid, 5-(2,6-dichlorophenyl)- γ -hydroxy- β -[[2-propenyloxy]carbonylamino]-, 1,1-dimethylethyl ester, (BS)- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 192582-95-9 CAPLUS
 CN Glycinamide, N-benzoyl-L-valyl-N-[(1S)-1-[[5-(2,6-dichlorophenyl)-2-oxazolyl]carbonyl]-3-(1,1-dimethylethoxy)-3-oxopropyl]-N2-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 50 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN
 ACCESSION NUMBER: 1996:688823 CAPLUS
 DOCUMENT NUMBER: 125:328702
 TITLE: Preparation of 3-(3,4-dihydroxyphenyl)serine via oxazolidones
 INVENTOR(S): Oda, Yoshiaki; Iwakura, Kazunori
 PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 5 pp.
 CODEN: JKOXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08231518	A2	19960910	JP 1995-119863	19950518
PRIORITY APPLN. INFO.:			JP 1995-119863	A 19950518
			JP 1994-322838	19941226

OTHER SOURCE(S): CASREACT 125:328702; MARPAT. 125:328702
 GI




AB L-Threo-3-(3,4-dihydroxyphenyl)serine (I), which is known to be useful for treatment of hypotension, depression, Parkinson disease, etc., is prepared by treatment of (2S)-amino acids II (R1-R3 = protecting group; X = halo; n = 0-3) with Ce(II) salts, followed by ring-cleavage reaction and deprotection of the resulting (4S,5R)-oxazolidones III (R1-R3, X, n = same as above). Racemic 3-(3,4-dihydroxyphenyl)serine is similarly prepared from the corresponding racemic amino acids. II (R1 = R2 = R3 = PhCH2, Xn = H) was treated with Cu acetate and ceric ammonium nitrate in aqueous acetone for 8 h to give 66% III (R1 = R2 = R3 = PhCH2, Xn = H). Treatment of the product with NaOH/EtOH and successive catalytic hydrogenation gave 48% I.
 IT 183236-73-9P 183236-74-OP 183236-75-1P
 RL: IMF (Industrial manufacture); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (preparation of 3-(3,4-dihydroxyphenyl)serine from dihydroxyphenylalanine derivs. via oxazolidones)

L5 ANSWER 49 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)




L5 ANSWER 50 OF 50 CAPLUS COPYRIGHT 2006 ACS on STN (Continued)
 RN 183236-73-9 CAPLUS
 CN 4-Oxazolidinecarboxylic acid, 5-[3,4-bis(phenylmethoxy)phenyl]-2-oxo-, methyl ester, (4S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 183236-74-0 CAPLUS
 CN 4-Oxazolidinecarboxylic acid, 5-(2-chloro-3,4-dimethoxyphenyl)-2-oxo-, methyl ester, (4S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 183236-75-1 CAPLUS
 CN 4-Oxazolidinecarboxylic acid, 5-[3,4-bis(phenylmethoxy)phenyl]-2-oxo-, methyl ester, (4S-trans)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 183236-76-2 CAPLUS

CN 4-Oxazolidinecarboxylic acid, 5-(3,4-dihydroxyphenyl)-2-oxo-, methyl ester, (4S-trans)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

259.29

426.65

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-37.50

-37.50

STN INTERNATIONAL LOGOFF AT 12:44:35 ON 29 NOV 2006